Novel peptides as selective IL-23 receptor antagonists

Abstract

The present disclosure relates to peptide IL23 receptor antagonists, pharmaceutical compositions thereof, and medical uses thereof, e.g., for the treatment of inflammatory bowel disease, such as Crohn's disease.

Description

[0001] The present disclosure relates to peptide IL-23 receptor antagonists and their medical uses, for example, for the treatment of inflammatory bowel diseases such as Crohn's disease. The compounds disclosed herein are macrolide peptides and show high solubility and stability under neutral conditions and in simulated intestinal and gastric fluids. The macrolide peptides show high in vitro potency against the interleukin 23 receptor (IL-23R) and have favorable physicochemical properties. [Background Technology]

[0002] There is increasing evidence that the interleukin-23 (IL-23) cytokine plays a key role in the pathogenesis of autoimmune inflammation and related diseases and disorders such as asthma, rheumatoid arthritis, psoriasis, multiple sclerosis, and inflammatory bowel disease (IBD) (e.g., ulcerative colitis and Crohn's disease). The major role of IL-23R can be revealed by acute and chronic IBD mouse models and downstream effector cytokines in disease pathogenesis. Th17 cells, y8 T cells, natural killer (NK) cells, dendritic cells, macrophages, and innate lymphoid cells found in large numbers in the intestine are adaptive and innate immune cells that express IL-23R. IBD patients have increased gene expression and levels of IL-23R on the intestinal mucosal surface. There is evidence that IL-23 contributes to this effect by promoting the development of pathogenic CD4+ T cell populations that produce IL-6, IL-17, and tumor necrosis factor (TNF).

[0003] Increased concentrations of IL-23 in the intestine are thought to play a key role in regulating the balance between tolerance and immunity through both T cell-dependent and T cell-independent pathways of intestinal inflammation. This regulation has an effect on helper T cell 1 (Th1) and Th17-related cytokines and inhibits regulatory T cell responses in the intestine, thereby promoting inflammation. In addition, IL-23R polymorphisms are associated with susceptibility to intestinal inflammation, further confirming the importance of the IL-23 pathway in intestinal homeostasis.

[0004] Psoriasis is a chronic skin disease with an incidence of approximately 2%-3% in the Caucasian population, which has been shown to be mediated by the body's T-cell inflammatory response mechanism. IL-23 is one of several interleukins that are thought to play a key role in the pathogenesis of psoriasis by maintaining chronic autoimmune inflammation, via the induction of interleukin-17, activation of macrophages, and regulation of T memory cells. In animal models of psoriasis, neutralizing antibodies against IL-23 showed IL-23-dependent inhibition of psoriasis development, and in tissues from psoriasis patients, increased high expression of IL-23 and IL-23R has been demonstrated.

[0005] IL-23 is part of the IL-12 cytokine family and consists of a p19 subunit specific for IL-23 and a p40 subunit for IL-12. It is a cytokine involved in the development of helper T-1 (TH1) cells that produce interferon-γ (IFN-γ). Although both IL-23 and IL-12 contain a p40 subunit, they have different phenotypic properties. While IL-12-deficient animals are susceptible to inflammatory autoimmune diseases, IL-23-deficient animals are resistant, most likely due to a reduction in the number of CD4+ T cells that produce IL-6, IL-17, and TNF in the CNS. IL-23 binds to IL-23R, a heterodimeric receptor composed of IL-12Rβ1 and IL-23R subunits. Binding of IL-23 to IL-23R activates Jak-Stat signaling molecules Jak2, Tyk2, Stat1, Stat3, Stat4, and Stat 5, although Stat4 activation is significantly weaker and a distinct DNA-bound Stat complex is formed in response to IL-23 compared with IL-12. IL-23R associates constitutively with Jak2 and with Stat3 in a ligand-dependent manner. Unlike IL-12, which acts primarily on naive CD4(+) T cells, IL-23 acts preferentially on memory CD4(+) T cells.

[0006] Based on the biological importance, inhibition of the IL-23 pathway is an attractive option for treating IL-23-related diseases and disorders. Many antibodies that bind to IL-23 or IL-23R have been identified, including ustekinumab, a humanized antibody that binds to IL-23, which has been approved for the treatment of psoriasis. Recently, polypeptide inhibitors that bind to IL-23R and inhibit the binding of IL-23 to IL-23R have been identified (see, e.g., U.S. Patent Application Publication No. US2013 / 0029907). Clinical trials in Crohn's disease or psoriasis using ustekinumab and briakinumab (which target the common p40 subunit) and tildrakizumab, guselkumab, brazikumab, and risankizumab (which target the unique p19 subunit of IL-23) highlight the potential of IL-23 signaling blockade in treating human inflammatory diseases. Although these findings are promising, challenges remain in identifying stable and selective agents that preferentially target the IL-23 pathway in the intestine, which can be used to treat intestinal inflammation, such as intestinal diseases including Crohn's disease, ulcerative colitis, and related disorders.

[0007] Irritable bowel disease (IBD) patients with autoimmune inflammation of the intestine may benefit from oral to topical treatments where compounds specifically target the IL-23 pathway on the luminal side of the intestine. The present disclosure addresses these needs by providing novel peptide compounds that bind to IL-23R to inhibit IL-23 binding and signaling and are suitable for oral administration. [Specific implementation method]

[0008] A problem associated with the use of peptide compounds as orally administered therapeutic agents in the treatment of inflammatory diseases and other indications is the limited stability of these peptide compounds in the intestinal environment. Therefore, the peptide sequence can be stabilized by the introduction of non-genetically encoded amino acids and / or cyclized to enhance stability against proteases to allow interaction with targets located on the luminal side of the intestine.

[0009] Therefore, when developing new therapeutic molecules, there is a need for variants with improved pharmaceutical properties, in particular increased stability against proteases present in the intestine and / or increased chemical or physical stability and / or prolonged in vivo half-life and / or increased in vivo potency / efficacy.

[0010] Furthermore, there remains a need for anti-inflammatory therapies that avoid or even mitigate common systemic side effects of IL-23R-based therapies (e.g., protection against infection), thereby achieving a strong anti-inflammatory effect with improved tolerability.

[0011] The leading authors' WO 2016011208 A1, WO 2017011820 A2, WO 2018022937A1, WO2018136646 A1, WO 2020014646, WO 2021007433, WO 2021146454, WO 2021146458 and WO2021146441 and Sayago et al., ACS Med. Chem. Lett. [American Chemical Society Medicinal Chemistry Communications] 2018, 9, 912-916 disclose peptide antagonists of IL-23 receptor for oral administration. WO 2022109328 discloses a composition of a cyclic peptide having the sequence Ac-Pen-Asn-Thr-Wim-Lys(Ac)-Pen-Yae-Nal-Thp-Glu-Asn-Pal-Sar-NH2, wherein a disulfide bond is formed between Pen-Pen. The common structural feature of the disclosed compounds is a ring formed by 6 amino acids as ring members.

[0012] WO 2013063468 discloses cyclic peptides that are modified with long chain hydrocarbon groups to produce amphiphilic molecules that can be used as drug delivery systems, including nucleotide delivery to cells.

[0013] WO 2015179438 also discloses a cyclic peptide having a 2- to 10-membered ring formed by amino acids as an inhibitor of Rac or Rho in cells or tissues, wherein at least two of the amino acids are arginine.

[0014] The compounds of the present disclosure show high affinity for the IL-23 receptor.

[0015] The characteristic structural motifs of the disclosed compounds include a macrocyclic lactam ring with 34-40 atoms, which is formed by: 9, 10 or 11 amino acids as structural units, and thioether, disulfide or ester bridges between the side chains of the amino acids to form a second bicyclic structure with 5 or 6 amino acids as structural units.

[0016] Therefore, novel bicyclic peptides with high affinity for IL-23 receptor are provided. The medical uses of these bicyclic peptides are further provided.

[0017] Disclosed herein are compounds having formula (I):

[0018] in

[0019] -X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Pipa, Pipb, Pipp, Dab, Dad and Dap, and is linked to X11 via an amide bond,

[0020] or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond,

[0021] - R1 is absent or, if X1 is selected from the residues of Ahx, Aoa, Apt, Lys, Dab and Dap, R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[0022] -X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu and their corresponding d-form residues. In some embodiments, X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr and their corresponding d-form residues,

[0023] -X7 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Thr and Abu and their corresponding d-form residues,

[0024] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond,

[0025] -X3 is an amino acid residue selected from the group consisting of Sar, His, Lys, Ala, Ahx, Apt, Arg, Asn, Gab, Gln, Trp, Thr, Ndmk, Nmn, Ntmk and Lys(αAc),

[0026] -X4 is absent or is an amino acid residue selected from the group consisting of His, Lys, Ahx, Apt, Arg, Asn, Gab, Gln, Trp and Thr residues,

[0027] -X5 is an amino acid residue selected from the group consisting of Trp, Wme, Nak, Wcl, Wim, Wdm and Wfl,

[0028] -X6 is an amino acid residue selected from the group consisting of a residue of Gln, Aib, Glu, Phe, Ile, Iva, Lys, Lys(Ac), Leu, Mle, Mly, Mva, Thr, Val, Trp and Phe,

[0029] -X8 is an amino acid residue selected from the group consisting of: Yme, Tyr, Trp, Yde and Yae. In some embodiments, X8 is an amino acid residue selected from the group consisting of: Yme, Tyr, Trp and Yde,

[0030] -X9 is an amino acid residue selected from the group consisting of a residue of Nal, Nak and Trp,

[0031] -X10 is an amino acid residue selected from the group consisting of: Aib, Cba, Cit, d-Trp, d-Tza, Lys, Lys(Ac), Leu, Mle, Mly, Gln, Mkdm and Thp,

[0032] -X11 is an amino acid residue selected from the group consisting of Asp, Bal, Gab, Glu, Kme, Lys and Orn residues, and is linked to X1 via an amide bond,

[0033] -X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues,

[0034] -X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, Leu, Ile, Iva, Hol, Hph, Pal, Pyal, PyEA, His, Hme, Val and their corresponding d-form residues,

[0035] - X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile, Dnmy and Hme residues,

[0036] -X15 is absent or is a Lys amino acid residue,

[0037] -R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[0038] and

[0039] wherein the amide bonds between X1 and X2, X2 and X3, X3 and X4, X4 and X5, and X11 and X1 are optionally methylated,

[0040] or a salt or solvate thereof.

[0041] The compounds of formula (I) inhibit the binding of interleukin-23 to the interleukin-23 receptor.

[0042] In another aspect of any of the peptides described herein, the compounds may comprise one or more half-life extending moieties and / or one or more linker moieties attached to the peptide.

[0043] In another aspect, the compounds of the present disclosure may have formula (I) as described in detail below.

[0044] In another aspect, compositions are disclosed that include a compound of formula (I) or (Ia) as described herein, or a salt or solvate thereof, mixed with a carrier.

[0045] The disclosure also relates to the use of a compound of formula (I) or formula (Ia) as described herein for use as a medicament, for example for the treatment of a condition as described in the description.

[0046] The present disclosure also relates to compositions, wherein the composition is a pharmaceutically acceptable composition and the carrier is a pharmaceutically acceptable carrier.

[0047] The present disclosure also relates to pharmaceutical compositions comprising a compound of Formula (I) or Formula (Ia) as described herein and at least a pharmaceutically acceptable carrier.

[0048] The present disclosure also relates to a pharmaceutical composition for use as a medicament, comprising at least one compound of the present disclosure or a physiologically acceptable salt or solvate thereof, and at least a pharmaceutically acceptable carrier. definition

[0049] Amino Acids. Amino acids are referred to herein by either their names, their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Terminology Commission. Thus, the amino acid sequences disclosed herein comprise the conventional one-letter and three-letter codes for naturally occurring amino acids, as well as the commonly accepted three-letter codes for other amino acids, e.g., Aib for alpha-aminoisobutyric acid, Orn for ornithine, or Ahx for 6-aminohexanoic acid.

[0050] As used herein, the term "amino acid" or "any amino acid" refers to any and all amino acids, including naturally occurring amino acids (e.g., α-amino acids), unnatural amino acids, modified amino acids, and non-natural amino acids. It includes both D-amino acids and L-amino acids. Natural amino acids include those found in nature, for example, the 22 amino acids that combine into peptide chains to form the building blocks of a large number of proteins. These are primarily L stereoisomers, although some D-amino acids are found in bacterial envelopes and some antibiotics.

[0051] Non-natural. "Non-natural" amino acids are naturally occurring or chemically synthesized non-protein amino acids (i.e., those that are not naturally encoded or found in the genetic code). More than 140 non-natural amino acids are known, and there may be more than thousands of combinations. Examples of "non-natural" amino acids include β-amino acids (β and β2), homoamino acids, proline and pyruvate derivatives, 3-substituted alanine derivatives, glycine derivatives, ring-substituted phenylalanine and tyrosine derivatives, linear core amino acids, diamino acids, D-amino acids, α-methyl amino acids, and N-methyl amino acids. Non-natural amino acids also include modified amino acids. "Modified" amino acids include amino acids (e.g., natural amino acids) that have been chemically modified to include one or more groups or chemical moieties that are not naturally present on amino acids.

[0052] Residue. Within the present disclosure, the term "residue" is intended to refer to a structural unit within a peptide compound, which results from the combination of natural amino acids, or unnatural amino acids, or compounds such as Buty or Butyl.

[0053] "Inhibits the binding of interleukin-23 to the interleukin-23 receptor". The expression "inhibits the binding of interleukin-23 to the interleukin-23 receptor" is intended to refer to the property of the peptide compounds of the present disclosure that prevents the binding of the IL-23 receptor to its ligand IL-23. This property is measured as binding affinity and can be expressed as "IC 50The "value" is the effective concentration of the compound that induces a half-maximal decrease in the binding of IL-2.3 to its receptor in a dose-response experiment. The compounds disclosed herein have a binding affinity for the interleukin 23 receptor of 100 nM or less (i.e., IC 50 ≤100nM).

[0054] In addition, Table 1 shows the codes used for amino acids and other compounds. Table 1: Natural and unnatural amino acids and other compounds Detailed description Peptide compounds Compounds having formula (I)

[0055] Disclosed herein are compounds having formula (I):

[0056] in

[0057] -X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Pipa, Pipb, Pipp, Dab, Dad and Dap, and is linked to X11 via an amide bond,

[0058] or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond,

[0059] - R1 is absent or, if X1 is selected from the residues of Ahx, Aoa, Apt, Lys, Dab and Dap, R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[0060] -X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu and their corresponding d-form residues. In some embodiments, X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr and their corresponding d-form residues,

[0061] -X7 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Thr and Abu and their corresponding d-form residues,

[0062] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond,

[0063] -X3 is an amino acid residue selected from the group consisting of Sar, His, Lys, Ala, Ahx, Apt, Arg, Asn, Gab, Gln, Trp, Thr, Ndmk, Nmn, Ntmk and Lys(αAc),

[0064] -X4 is absent or is an amino acid residue selected from the group consisting of His, Lys, Ahx, Apt, Arg, Asn, Gab, Gln, Trp and Thr residues,

[0065] -X5 is an amino acid residue selected from the group consisting of Trp, Wme, Nak, Wcl, Wim, Wdm and Wfl,

[0066] -X6 is an amino acid residue selected from the group consisting of a residue of Gln, Aib, Glu, Phe, Ile, Iva, Lys, Lys(Ac), Leu, Mle, Mly, Mva, Thr, Val, Trp and Phe,

[0067] -X8 is an amino acid residue selected from the group consisting of: Yme, Tyr, Trp, Yde and Yae. In some embodiments, X8 is an amino acid residue selected from the group consisting of: Yme, Tyr, Trp and Yde,

[0068] -X9 is an amino acid residue selected from the group consisting of a residue of Nal, Nak and Trp,

[0069] -X10 is an amino acid residue selected from the group consisting of: Aib, Cba, Cit, d-Trp, d-Tza, Lys, Lys(Ac), Leu, Mle, Mly, Gln, Mkdm and Thp,

[0070] -X11 is an amino acid residue selected from the group consisting of Asp, Bal, Gab, Glu, Kme, Lys and Orn residues, and is linked to X1 via an amide bond,

[0071] -X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues,

[0072] -X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, Leu, Ile, Iva, Hol, Hph, Pal, Pyal, PyEA, His, Hme, Val and their corresponding d-form residues,

[0073] - X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile, Dnmy and Hme residues,

[0074] -X15 is absent or is a Lys amino acid residue,

[0075] -R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[0076] and

[0077] wherein the amide bonds between X1 and X2, X2 and X3, X3 and X4, X4 and X5, and X11 and X1 are optionally methylated,

[0078] or a salt or solvate thereof.

[0079] The compounds of formula (I) inhibit the binding of interleukin-23 to the interleukin-23 receptor.

[0080] In some embodiments, the compound having formula (I) can be a compound where X2 is:

[0081] An amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu and their corresponding d-form amino acid residues, and X8 is an amino acid residue selected from the group consisting of Yme, Tyr, Trp and Yde,

[0082] Or an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr and their corresponding d-type amino acid residues, and X8 is an amino acid residue selected from the group consisting of Yme, Tyr, Trp, Yde and Yae.

[0083] In some embodiments, the compound of formula (I) may be a compound where when X2 is Abu or its corresponding d-form, then X8 is not an amino acid residue of Yae.

[0084] In some embodiments, the compound of formula (I) may be such a compound: when X8 is Yae, then X2 is not Abu or its corresponding d-form amino acid residue.

[0085] In a first group of embodiments, the compound having formula (I) is a compound:

[0086] -X1 is the residue of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Pipa, Pipb, Pipp, Dab, Dad or Dap and is linked to X11 via an amide bond,

[0087] or is a Buty or Butyl residue and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond,

[0088] -R1 does not exist, or

[0089] If X1 is the residue of Ahx, Aoa, Apt, Lys, Dab or Dap, then R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[0090] -X2 is Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr or Abu and their corresponding d-type amino acid residues,

[0091] -X7 is Cys, Glu, Asp, Thr or Abu and their corresponding d-type amino acid residues,

[0092] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond,

[0093] -X3 is an amino acid residue of Sar, His, Lys, Ala, Ahx, Apt, Arg, Asn, Gab, Gln, Trp, Thr, Ndmk, Nmn, Ntmk or Lys(αAc),

[0094] -X4 is absent or is an amino acid residue of His, Lys, Ahx, Apt, Arg, Asn, Gab, Gln, Trp or Thr,

[0095] -X5 is an amino acid residue of Trp, Wme, Nak, Wcl, Wim, Wdm or Wfl,

[0096] -X6 is an amino acid residue of Gln, Aib, Glu, Phe, Ile, Iva, Lys, Lys(Ac), Leu, Mle, Mly, Mva, Thr, Val, Trp or Phe,

[0097] -X8 is an amino acid residue of Yme, Tyr, Trp or Yde,

[0098] -X9 is an amino acid residue of Nal, Nak or Trp,

[0099] -X10 is an amino acid residue of Aib, Cba, Cit, d-Trp, d-Tza, Lys, Lys(Ac), Leu, Mle, Mly, Gln, Mkdm or Thp,

[0100] -X11 is an amino acid residue of Asp, Bal, Gab, Glu, Kme, Lys or Orn, and is linked to X1 via an amide bond,

[0101] -X12 is absent or is an amino acid residue of Asn, Gly, Ser or Ala,

[0102] -X13 is absent or is Asn, Ala, Bal, Gly, Leu, Ile, Iva, Hol, Hph, Pal, Pyal, PyEA, His, Hme or Val and their corresponding d-type amino acid residues,

[0103] -X14 is absent or is an amino acid residue of Mep, Sar, Bal, Ile, Dnmy or Hme,

[0104] -X15 is absent or is a Lys amino acid residue,

[0105] -R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[0106] and

[0107] wherein the amide bonds between X1 and X2, X2 and X3, X3 and X4, X4 and X5, and X11 and X1 are optionally methylated,

[0108] or a salt or solvate thereof.

[0109] In one such group of embodiments, the compound having formula (I) inhibits the binding of interleukin-23 to the interleukin-23 receptor.

[0110] In some embodiments of the first group of embodiments, the compound having formula (I) can be a compound:

[0111] -X1 is a residue selected from the group consisting of Ahx, Apt, Nmha, Nmapt, Lys and Dad, and is linked to X11 via an amide bond,

[0112] or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond,

[0113] -R1 does not exist, or

[0114] If X1 is a residue selected from the group consisting of Ahx, Apt and Lys, then R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[0115] -X2 is an amino acid residue selected from the group consisting of a Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu residue,

[0116] -X7 is an amino acid residue selected from the group consisting of a Cys, Glu, Asp, Thr and Abu residue,

[0117] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond,

[0118] -X3 is an amino acid residue selected from the group consisting of Apt, Asn, Ndmk, Nmn and Lys(αAc),

[0119] -X4 does not exist or is a Thr amino acid residue,

[0120] -X5 is an amino acid residue selected from the group consisting of a residue of Trp, Wme and Wim,

[0121] -X6 is an amino acid residue selected from the group consisting of a Gln, Lys(Ac) and Leu residue,

[0122] -X8 is an amino acid residue selected from the group consisting of a residue of Yme, Trp and Yde,

[0123] -X9 is the amino acid residue of Nal,

[0124] - X10 is an amino acid residue selected from the group consisting of Aib, Lys, Lys(Ac), Mle, Mly, Mkdm and Thp,

[0125] -X11 is an amino acid residue selected from the group consisting of Asp, Glu, Kme, Lys and Orn residues, and is linked to X1 via an amide bond,

[0126] -X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues,

[0127] -X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, d-Leu, Ile, Pal, Pyal, PyEA, His and Hme residues,

[0128] - X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile and Hme residues,

[0129] -X15 is absent or is a Lys amino acid residue,

[0130] -R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[0131] or a salt or solvate thereof.

[0132] In a second group of embodiments, the compound having formula (I) is a compound:

[0133] -X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Pipa, Pipb, Pipp, Dab, Dad and Dap, and is linked to X11 via an amide bond,

[0134] or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond,

[0135] -R1 does not exist, or

[0136] If X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Lys, Dab and Dap, then R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[0137] -X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr and their corresponding d-form residues,

[0138] -X7 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Thr and Abu and their corresponding d-form residues,

[0139] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond,

[0140] -X3 is an amino acid residue selected from the group consisting of Sar, His, Lys, Ala, Ahx, Apt, Arg, Asn, Gab, Gln, Trp, Thr, Ndmk, Nmn, Ntmk and Lys(αAc),

[0141] - X4 is absent or is an amino acid residue selected from the group consisting of His, Lys, Ahx, Apt, Arg, Asn, Gab, Gln, Trp and Thr residues,

[0142] -X5 is an amino acid residue selected from the group consisting of Trp, Wme, Nak, Wcl, Wim, Wdm and Wfl,

[0143] -X6 is an amino acid residue selected from the group consisting of a residue of Gln, Aib, Glu, Phe, Ile, Iva, Lys, Lys(Ac), Leu, Mle, Mly, Mva, Thr, Val, Trp and Phe,

[0144] -X8 is an amino acid residue selected from the group consisting of a residue of Yme, Tyr, Trp, Yde and Yae,

[0145] -X9 is an amino acid residue selected from the group consisting of a residue of Nal, Nak and Trp,

[0146] -X10 is an amino acid residue selected from the group consisting of: Aib, Cba, Cit, d-Trp, d-Tza, Lys, Lys(Ac), Leu, Mle, Mly, Gln, Mkdm and Thp,

[0147] -X11 is an amino acid residue selected from the group consisting of Asp, Bal, Gab, Glu, Kme, Lys and Orn residues, and is linked to X1 via an amide bond,

[0148] -X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues,

[0149] -X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, Leu, Ile, Iva, Hol, Hph, Pal, Pyal, PyEA, His, Hme, Val and their corresponding d-form residues,

[0150] - X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile, Dnmy and Hme residues,

[0151] -X15 is absent or is a Lys amino acid residue,

[0152] -R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[0153] and

[0154] wherein the amide bonds between X1 and X2, X2 and X3, X3 and X4, X4 and X5, and X11 and X1 are optionally methylated,

[0155] or a salt or solvate thereof.

[0156] In one such group of embodiments, the compound having formula (I) inhibits the binding of interleukin-23 to the interleukin-23 receptor.

[0157] In some embodiments of the second group of embodiments, the compound having formula (I) can be a compound:

[0158] -X1 is a residue selected from the group consisting of Ahx, Apt, Nmha, Nmapt, Lys and Dad, and is linked to X11 via an amide bond,

[0159] or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond,

[0160] -R1 does not exist, or

[0161] If X1 is a residue selected from the group consisting of Ahx, Apt and Lys, then R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[0162] -X2 is an amino acid residue selected from the group consisting of a Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr residue,

[0163] -X7 is an amino acid residue selected from the group consisting of a Cys, Glu, Asp, Thr and Abu residue,

[0164] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond,

[0165] -X3 is an amino acid residue selected from the group consisting of Apt, Asn, Ndmk, Nmn and Lys(αAc),

[0166] -X4 does not exist or is a Thr amino acid residue,

[0167] -X5 is an amino acid residue selected from the group consisting of a residue of Trp, Wme and Wim,

[0168] -X6 is an amino acid residue selected from the group consisting of a Gln, Lys(Ac) and Leu residue,

[0169] -X8 is an amino acid residue selected from the group consisting of a residue of Yme, Trp, Yde and Yae,

[0170] -X9 is the amino acid residue of Nal,

[0171] - X10 is an amino acid residue selected from the group consisting of Aib, Lys, Lys(Ac), Mle, Mly, Mkdm and Thp,

[0172] -X11 is an amino acid residue selected from the group consisting of Asp, Glu, Kme, Lys and Orn residues, and is linked to X1 via an amide bond,

[0173] -X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues,

[0174] -X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, d-Leu, Ile, Pal, Pyal, PyEA, His and Hme residues,

[0175] - X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile and Hme residues,

[0176] -X15 does not exist or is a Lys amino acid residue,

[0177] -R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[0178] or a salt or solvate thereof.

[0179] Examples of compounds of formula (I) are those compounds wherein R1 is absent.

[0180] Examples of compounds of formula (I) are those wherein R1 is H.

[0181] Examples of compounds of formula (I) are those compounds, in which R1 is C1-C4-alkyl.

[0182] Examples of compounds of formula (I) are those wherein R1 is acetyl.

[0183] Examples of compounds of formula (I) are those compounds wherein R2 is absent.

[0184] Examples of compounds of formula (I) are those wherein R2 is -NH2.

[0185] Examples of compounds of formula (I) are those wherein R2 is -OH.

[0186] Examples of compounds of formula (I) are those wherein R2 is -N(C2H5)2.

[0187] Examples of compounds of formula (I) are those wherein:

[0188] X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Pipa, Pipb, Pipp, Dab and Dap, and X11 is an amino acid residue selected from the group consisting of Asp and Glu,

[0189] or

[0190] X1 is a residue of Dad and X11 is an amino acid residue selected from the group consisting of residues of Lys and Kme,

[0191] or

[0192] X1 is a residue selected from the group consisting of Buty and Butyl residues and X11 is an amino acid residue of Kme.

[0193] Examples of compounds of formula (I) are those compounds, wherein X1 is the residue of Ahx and X11 is an amino acid residue selected from the residues of Glu or Asp.

[0194] Examples of compounds of formula (I) are those compounds, wherein X1 is the residue of Apt and X11 is an amino acid residue selected from the residue of Glu or Asp.

[0195] Examples of compounds of formula (I) are those wherein X1 is the residue of Apt and X11 is the amino acid residue of Glu.

[0196] Examples of compounds of formula (I) are those compounds, wherein X1 is the residue of Nmapt and X11 is an amino acid residue selected from the residues of Glu or Asp.

[0197] Examples of compounds of formula (I) are those wherein X1 is the residue of Nmapt and X11 is the amino acid residue of Glu.

[0198] Examples of compounds of formula (I) are those compounds wherein X1 is the residue of Nmapt and X11 is the amino acid residue of Asp.

[0199] Examples of compounds of formula (I) are those compounds, wherein X1 is the residue of Nmha and X11 is an amino acid residue selected from the residue of Glu or Asp.

[0200] Examples of compounds of formula (I) are those wherein X1 is the residue of Nmha and X11 is the amino acid residue of Glu.

[0201] Examples of compounds of formula (I) are those compounds wherein X1 is the residue of Nmha and X11 is the amino acid residue of Asp.

[0202] Examples of compounds of formula (I) are those compounds, wherein X1 is a Lys residue and X11 is an amino acid residue selected from the residues of Glu or Asp.

[0203] Examples of compounds of formula (I) are those compounds wherein X1 is a Lys residue and X11 is a Glu amino acid residue.

[0204] Examples of compounds of formula (I) are those compounds, wherein X1 is a Lys residue and X11 is an amino acid residue of Asp.

[0205] Examples of compounds of formula (I) are those compounds, wherein X1 is the residue of Dad and X11 is an amino acid residue selected from the residues of Lys or Kme.

[0206] Examples of compounds of formula (I) are those compounds wherein X1 is the residue of Dad and X11 is the amino acid residue of Lys.

[0207] Examples of compounds of formula (I) are those wherein X1 is the residue of Dad and X11 is the amino acid residue of Kme.

[0208] Examples of compounds of formula (I) are those compounds, wherein X1 is the residue of Buty and X11 is an amino acid residue selected from the residues of Lys or Kme.

[0209] Examples of compounds of formula (I) are those compounds wherein X1 is the residue of Buty and X11 is the amino acid residue of Lys.

[0210] Examples of compounds of formula (I) are those compounds wherein X1 is the residue of Buty and X11 is the amino acid residue of Kme.

[0211] Examples of compounds of formula (I) are those compounds, wherein X1 is the residue of Butyl and X11 is an amino acid residue selected from the residues of Lys or Kme.

[0212] Examples of compounds of formula (I) are those compounds wherein X1 is a Butyl residue and X11 is a Lys amino acid residue.

[0213] Examples of compounds of formula (I) are those compounds wherein X1 is the residue of Butyl and X11 is the amino acid residue of Kme.

[0214] In some embodiments of the first group of embodiments, X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu and their corresponding d-form residues.

[0215] In some embodiments of the second group of embodiments, X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr and their corresponding d-form residues.

[0216] Examples of compounds of formula (I) are those compounds wherein X2 is an amino acid residue selected from Cys and Nmc and their corresponding d-form residues,

[0217] X7 is an amino acid residue selected from Cys and its corresponding d-form residues,

[0218] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond,

[0219] or

[0220] X2 is an amino acid residue selected from the group consisting of Cys, Nmc, Thr and Abu and their corresponding d-form residues,

[0221] X7 is an amino acid residue selected from the group consisting of Cys, Thr and Abu and their corresponding d-form residues,

[0222] wherein X2 and X7 are linked to each other via Q, wherein Q is a thioether bond,

[0223] or

[0224] X2 is an amino acid residue selected from the group consisting of Glu, Asp, Nmd, Nme, Nmt and Thr and their corresponding d-type residues,

[0225] X7 is an amino acid residue selected from the group consisting of Glu, Asp, Thr and their corresponding d-type residues,

[0226] wherein X2 and X7 are linked to each other via Q, wherein Q is an ester bond.

[0227] Embodiments of compounds of formula (I) are those compounds, wherein X2 is an amino acid residue selected from Cys and its corresponding d-form residues,

[0228] X7 is an amino acid residue selected from Cys and its corresponding d-form residues,

[0229] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond,

[0230] or

[0231] X2 is an amino acid residue selected from the group consisting of Cys, Glu, Thr and Abu and their corresponding d-form residues,

[0232] X7 is an amino acid residue selected from the group consisting of Cys, Thr and Abu and their corresponding d-form residues,

[0233] wherein X2 and X7 are linked to each other via Q, wherein Q is a thioether bond,

[0234] or

[0235] X2 is an amino acid residue selected from the group consisting of Glu and Thr and their corresponding d-form residues,

[0236] X7 is an amino acid residue selected from the group consisting of Glu, Asp and Thr and their corresponding d-form residues,

[0237] wherein X2 and X7 are linked to each other via Q, wherein Q is an ester bond.

[0238] Embodiments of compounds of formula (I) are those compounds, wherein X2-Q-X7 is selected from the group consisting of:

[0239] Cys-Q-Cys, Nmc-Q-Cys and Cys-Q-Nmc, wherein Q is a disulfide bond, or

[0240] Abu-Q-Cys, Cys-Q-Abu, wherein Q is a thioether bond, or

[0241] Thr-Q-Asp, Thr-Q-Glu, Glu-Q-Thr, wherein Q is an ester bond.

[0242] In some embodiments of the first group of embodiments, compounds of formula (I) are those compounds, wherein X2-Q-X7 is selected from the group consisting of:

[0243] -Cys-Q-Cys, Nmc-Q-Cys and Cys-Q-Nmc, wherein Q is a disulfide bond, or

[0244] -Abu-Q-Cys, Cys-Q-Abu, wherein Q is a thioether bond, or

[0245] -Thr-Q-Asp, Thr-Q-Glu, Glu-Q-Thr, wherein Q is an ester bond.

[0246] In some embodiments of the second group of embodiments, compounds of formula (I) are those compounds, wherein X2-Q-X7 is selected from the group consisting of:

[0247] -Cys-Q-Cys, Nmc-Q-Cys and Cys-Q-Nmc, wherein Q is a disulfide bond, or

[0248] -Cys-Q-Abu, wherein Q is a thioether bond, or

[0249] -Thr-Q-Asp, Thr-Q-Glu, Glu-Q-Thr, wherein Q is an ester bond.

[0250] Embodiments of compounds of formula (I) are those compounds wherein X2-Q-X7 is selected from the group consisting of Cys-Q-Cys and Nmc-Q-Cys, wherein Q is a disulfide bond, or Abu-Q-Cys, wherein Q is a thioether bond, or Glu-Q-Thr, wherein Q is an ester bond.

[0251] Embodiments of compounds of formula (I) are those compounds, wherein X2-Q-X7 is selected from the group consisting of Cys-Q-Cys and Nmc-Q-Cys, wherein Q is a disulfide bond.

[0252] Embodiments of compounds of formula (I) are those wherein X2-Q-X7 is Abu-Q-Cys, wherein Q is a thioether bond.

[0253] Embodiments of compounds of formula (I) are those wherein X2-Q-X7 is Glu-Q-Thr, wherein Q is an ester bond.

[0254] Examples of compounds of formula (I) are those compounds wherein X3 is an amino acid residue selected from the group consisting of: Apt, Ndmk, Nmn and Lys(αAc).

[0255] Examples of compounds of formula (I) are those wherein X3 is an amino acid residue of Sar.

[0256] Examples of compounds of formula (I) are those wherein X3 is an amino acid residue of His.

[0257] Examples of compounds of formula (I) are those compounds wherein X3 is an amino acid residue of Lys.

[0258] Examples of compounds of formula (I) are those wherein X3 is the amino acid residue of Ala.

[0259] Examples of compounds of formula (I) are those wherein X3 is an amino acid residue of Ahx.

[0260] Examples of compounds of formula (I) are those wherein X3 is the amino acid residue of Apt.

[0261] Examples of compounds of formula (I) are those wherein X3 is the amino acid residue of Arg.

[0262] Examples of compounds of formula (I) are those wherein X3 is an amino acid residue of Asn.

[0263] Examples of compounds of formula (I) are those wherein X3 is an amino acid residue of Gab.

[0264] Examples of compounds of formula (I) are those wherein X3 is the amino acid residue of GIn.

[0265] Examples of compounds of formula (I) are those wherein X3 is an amino acid residue of Trp.

[0266] Examples of compounds of formula (I) are those compounds, wherein X3 is an amino acid residue of Thr.

[0267] Examples of compounds of formula (I) are those compounds wherein X3 is an amino acid residue of Ndmk,

[0268] Examples of compounds of formula (I) are those wherein X3 is an amino acid residue of Nmn.

[0269] Examples of compounds of formula (I) are those wherein X3 is an amino acid residue of Ntmk.

[0270] Examples of compounds of formula (I) are those compounds wherein X3 is an amino acid residue of Lys(αAc).

[0271] Examples of compounds of formula (I) are those compounds wherein X4 is absent.

[0272] Embodiments of compounds of formula (I) are those compounds wherein X3 is an amino acid residue selected from the group consisting of Lys, Ahx, Apt, Thr, Ndmk, Nmn, Ntmk and Lys(αAc), and X4 is absent.

[0273] Examples of compounds of formula (I) are those compounds wherein X3 is an amino acid residue selected from the group consisting of: Apt, Ndmk, Nmn and Lys(αAc), and X4 is absent.

[0274] Examples of compounds of formula (I) are those compounds wherein X3 is an amino acid residue selected from the group consisting of: Apt, Ndmk and Lys(αAc), and X4 is absent.

[0275] Examples of compounds of formula (I) are those compounds wherein X3 is an amino acid residue of Lys(αAc) and X4 is absent.

[0276] Examples of compounds of formula (I) are those wherein X4 is an amino acid residue selected from the group consisting of His, Lys, Arg, Asn, Gab, Gln, Trp and Thr residues.

[0277] Examples of compounds of formula (I) are those wherein X4 is an amino acid residue selected from the group consisting of His, Lys, Arg, Asn, Gln, Trp and Thr residues.

[0278] Examples of compounds of formula (I) are those wherein X4 is an amino acid residue of His.

[0279] Examples of compounds of formula (I) are those wherein X4 is an amino acid residue of Lys.

[0280] Examples of compounds of formula (I) are those wherein X4 is an amino acid residue of Ahx.

[0281] Examples of compounds of formula (I) are those wherein X4 is the amino acid residue of Apt.

[0282] Examples of compounds of formula (I) are those wherein X4 is the amino acid residue of Arg.

[0283] Examples of compounds of formula (I) are those wherein X4 is an amino acid residue of Asn.

[0284] Examples of compounds of formula (I) are those wherein X4 is an amino acid residue of Gab.

[0285] Examples of compounds of formula (I) are those wherein X4 is the amino acid residue of GIn.

[0286] Examples of compounds of formula (I) are those wherein X4 is an amino acid residue of Trp.

[0287] Examples of compounds of formula (I) are those wherein X4 is an amino acid residue of Thr.

[0288] Examples of compounds of formula (I) are those wherein X5 is an amino acid residue selected from the group consisting of Trp, Wme, Nak, Wcl, Wim, Wdm and Wfl.

[0289] Examples of compounds of formula (I) are those wherein X5 is an amino acid residue selected from the group consisting of Trp, Wme, Wcl, Wim, Wdm and Wfl residues.

[0290] Examples of compounds of formula (I) are those compounds, wherein X5 is an amino acid residue selected from the group consisting of Trp and Wim residues.

[0291] Examples of compounds of formula (I) are those wherein X5 is the amino acid residue of Trp.

[0292] Examples of compounds of formula (I) are those wherein X5 is an amino acid residue of Wme.

[0293] Examples of compounds of formula (I) are those wherein X5 is an amino acid residue of Nak.

[0294] Examples of compounds of formula (I) are those wherein X5 is an amino acid residue of Wcl.

[0295] Examples of compounds of formula (I) are those wherein X5 is the amino acid residue of Wim.

[0296] Examples of compounds of formula (I) are those wherein X5 is an amino acid residue of Wdm.

[0297] Examples of compounds of formula (I) are those wherein X5 is the amino acid residue of Wfl.

[0298] Examples of compounds of formula (I) are those wherein X6 is an amino acid residue selected from the group consisting of Gln, Aib, Glu, Phe, Ile, Iva, Lys, Lys(Ac), Leu, Mle, Mly, Mva, Thr, Val, Trp and Phe residues.

[0299] Examples of compounds of formula (I) are those wherein X6 is an amino acid residue selected from the group consisting of Gln, Aib, Glu, Ile, Iva, Lys, Lys(Ac), Leu, Mle, Mly, Mva and Val residues.

[0300] Examples of compounds of formula (I) are those compounds wherein X6 is an amino acid residue selected from the group consisting of the residues of Gln, Lys (Ac) and Leu.

[0301] Examples of compounds of formula (I) are those wherein X6 is the amino acid residue of GIn.

[0302] Examples of compounds of formula (I) are those wherein X6 is an amino acid residue of Aib.

[0303] Examples of compounds of formula (I) are those wherein X6 is an amino acid residue of Glu.

[0304] Examples of compounds of formula (I) are those wherein X6 is an amino acid residue of Phe.

[0305] Examples of compounds of formula (I) are those wherein X6 is an amino acid residue of Ile.

[0306] Examples of compounds of formula (I) are those wherein X6 is an amino acid residue of Iva.

[0307] Examples of compounds of formula (I) are those wherein X6 is an amino acid residue of Lys.

[0308] Examples of compounds of formula (I) are those wherein X6 is an amino acid residue of Lys(Ac).

[0309] Examples of compounds of formula (I) are those wherein X6 is an amino acid residue of Leu.

[0310] Examples of compounds of formula (I) are those wherein X6 is the amino acid residue of Mle.

[0311] Examples of compounds of formula (I) are those wherein X6 is the amino acid residue of Mly.

[0312] Examples of compounds of formula (I) are those wherein X6 is the amino acid residue of Mva.

[0313] Examples of compounds of formula (I) are those wherein X6 is an amino acid residue of Thr.

[0314] Examples of compounds of formula (I) are those wherein X6 is the amino acid residue of Val.

[0315] Examples of compounds of formula (I) are those wherein X6 is an amino acid residue of Trp.

[0316] Examples of compounds of formula (I) are those wherein X6 is an amino acid residue of Phe.

[0317] Examples of compounds of formula (I) are those wherein X8 is an amino acid residue selected from the group consisting of: Yme, Tyr, Trp, Yde and Yae residues.

[0318] In some embodiments of the first group of embodiments, X8 is an amino acid residue selected from the group consisting of: Yme, Tyr, Trp and Yde.

[0319] In some embodiments of the second group of embodiments, X8 is an amino acid residue selected from the group consisting of: Yme, Tyr, Trp, Yde and Yae.

[0320] Examples of compounds of formula (I) are those compounds wherein X8 is an amino acid residue selected from the group consisting of the residues of Yme, Yde and Yae,

[0321] Examples of compounds of formula (I) are those wherein X8 is the amino acid residue of Yme.

[0322] Examples of compounds of formula (I) are those wherein X8 is the amino acid residue of Tyr.

[0323] Examples of compounds of formula (I) are those wherein X8 is an amino acid residue of Trp.

[0324] Examples of compounds of formula (I) are those wherein X8 is the amino acid residue of Yde.

[0325] Examples of compounds of formula (I) are those wherein X8 is the amino acid residue of Yae.

[0326] Examples of compounds of formula (I) are those wherein X9 is the amino acid residue of Nal.

[0327] Examples of compounds of formula (I) are those wherein X9 is a Nak amino acid.

[0328] Examples of compounds of formula (I) are those wherein X9 is the amino acid residue of Trp.

[0329] Examples of compounds of formula (I) are those wherein X10 is an amino acid residue selected from the group consisting of Aib, Cba, Cit, d-Trp, d-Tza, Lys, Lys(Ac), Leu, Mle, Mly, Gln, Mkdm and Thp residues.

[0330] Examples of compounds of formula (I) are those wherein X10 is an amino acid residue selected from the group consisting of the residues of Aib, Lys, Lys(Ac), Mle, Mly, Mkdm and Thp.

[0331] Examples of compounds of formula (I) are those wherein X10 is an amino acid residue selected from the group consisting of the residues of Aib, Mle, Mly, Mkdm and Thp.

[0332] Examples of compounds of formula (I) are those wherein X10 is an amino acid residue of Aib.

[0333] Examples of compounds of formula (I) are those wherein X10 is the amino acid residue of Cba.

[0334] Examples of compounds of formula (I) are those wherein X10 is an amino acid residue of Cit.

[0335] Examples of compounds of formula (I) are those wherein X10 is an amino acid residue of d-Trp.

[0336] Examples of compounds of formula (I) are those wherein X10 is the amino acid residue of d-Tza.

[0337] Examples of compounds of formula (I) are those wherein X10 is an amino acid residue of Lys.

[0338] Examples of compounds of formula (I) are those wherein X10 is an amino acid residue of Lys(Ac).

[0339] Examples of compounds of formula (I) are those compounds, wherein X10 is an amino acid residue selected from Leu.

[0340] Examples of compounds of formula (I) are those wherein X10 is the amino acid residue of Mle.

[0341] Examples of compounds of formula (I) are those wherein X10 is the amino acid residue of Mly.

[0342] Examples of compounds of formula (I) are those wherein X10 is the amino acid residue of Gln.

[0343] Examples of compounds of formula (I) are those wherein X10 is the amino acid residue of Mkdm.

[0344] Examples of compounds of formula (I) are those wherein X10 is an amino acid residue of Thp.

[0345] Examples of compounds of formula (I) are those wherein X12 is absent or is an amino acid residue selected from the group consisting of Asn, Ser and Ala residues.

[0346] Examples of compounds of formula (I) are those compounds wherein X12 is absent.

[0347] Examples of compounds of formula (I) are those wherein X12 is an amino acid residue of Asn.

[0348] Examples of compounds of formula (I) are those wherein X12 is an amino acid residue of Ser.

[0349] Examples of compounds of formula (I) are those wherein X12 is the amino acid residue of Ala.

[0350] Embodiments of compounds of formula (I) are those compounds wherein X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, Leu, Ile, Iva, Hol, Hph, Pal, Pyal, His, Mhis, Val and their corresponding d-form residues.

[0351] Embodiments of compounds of formula (I) are those wherein X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, Leu, d-Leu, Ile, Iva, Hol, Hph, Pal, Pyal, His, Hme and Val residues.

[0352] Examples of compounds of formula (I) are those wherein X13 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, d-Leu, Pal and His residues.

[0353] Examples of compounds of formula (I) are those wherein X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile, Dnmy and Hme residues.

[0354] Examples of compounds of formula (I) are those compounds wherein X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal and He.

[0355] Examples of compounds of formula (I) are those compounds wherein X14 is absent.

[0356] Examples of compounds of formula (I) are those wherein X14 is an amino acid residue selected from the group consisting of Mep, Sar, Bal and He.

[0357] Examples of compounds of formula (I) are those wherein X14 is an amino acid residue of Sar.

[0358] Examples of compounds of formula (I) are those wherein X15 is absent or is an amino acid residue of Lys.

[0359] Examples of compounds of formula (I) are those compounds, wherein X15 is absent.

[0360] Examples of compounds of formula (I) are those wherein X15 is an amino acid residue of Lys.

[0361] In a third group of embodiments, compounds of formula (I) are those compounds wherein:

[0362] X1 is a residue selected from the group consisting of Ahx, Apt, Nmha, Nmapt, Lys and Dad, and is linked to X11 via an amide bond,

[0363] or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond,

[0364] R1 is absent or, if X1 is selected from the group consisting of the residues of Ahx, Apt and Lys, R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[0365] X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu residues,

[0366] X7 is an amino acid residue selected from the group consisting of a Cys, Glu, Asp, Thr and Abu residue,

[0367] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond,

[0368] X3 is an amino acid residue selected from the group consisting of Apt, Asn, Ndmk, Nmn and Lys(αAc),

[0369] X4 does not exist or is a Thr amino acid residue,

[0370] X5 is an amino acid residue selected from the group consisting of a residue of Trp, Wme and Wim,

[0371] X6 is an amino acid residue selected from the group consisting of a residue of Gln, Lys(Ac) and Leu,

[0372] X8 is an amino acid residue selected from the group consisting of a residue of Yme, Trp, Yde and Yae,

[0373] X9 is the amino acid residue of Nal,

[0374] X10 is an amino acid residue selected from the group consisting of Aib, Lys, Lys(Ac), Mle, Mly, Mkdm and Thp,

[0375] X11 is an amino acid residue selected from the group consisting of Asp, Glu, Kme, Lys and Orn, and is linked to X1 via an amide bond,

[0376] X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues,

[0377] X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, d-Leu, Ile, Pal, Pyal, PyEA, His and Hme residues,

[0378] X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile and Hme residues,

[0379] X15 does not exist or is a Lys amino acid residue.

[0380] R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[0381] or a salt or solvate thereof,

[0382] and

[0383] The compound of formula (I) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[0384] In a third group of embodiments, the compound having formula (I) may be a compound where X2 is:

[0385] an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu, and X8 is an amino acid residue selected from the group consisting of Yme, Trp and Yde,

[0386] or an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr residues, and X8 is an amino acid residue selected from the group consisting of Yme, Trp, Yde and Yae residues.

[0387] In a fourth group of embodiments, compounds of formula (I) are those compounds wherein:

[0388] X1 is a residue selected from the group consisting of Ahx, Apt, Nmha, Nmapt, Lys and Dad, and is linked to X11 via an amide bond,

[0389] or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond,

[0390] R1 is absent or, if X1 is selected from the group consisting of the residues of Ahx, Apt and Lys, R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[0391] X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu residues,

[0392] X7 is an amino acid residue selected from the group consisting of a Cys, Glu, Asp, Thr and Abu residue,

[0393] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond,

[0394] X3 is an amino acid residue selected from the group consisting of Asn and Nmn residues,

[0395] X4 is the amino acid residue of Thr,

[0396] X5 is an amino acid residue selected from the group consisting of a residue of Trp, Wme and Wim,

[0397] X6 is an amino acid residue selected from the group consisting of a residue of Gln, Lys(Ac) and Leu,

[0398] X8 is an amino acid residue selected from the group consisting of a residue of Yme, Trp, Yde and Yae,

[0399] X9 is the amino acid residue of Nal,

[0400] X10 is an amino acid residue selected from the group consisting of Aib, Lys, Lys(Ac), Mle, Mly, Mkdm and Thp,

[0401] X11 is an amino acid residue selected from the group consisting of Asp, Glu, Kme, Lys and Orn, and is linked to X1 via an amide bond,

[0402] X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues,

[0403] X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, d-Leu, Ile, Pal, Pyal, PyEA, His and Hme residues,

[0404] X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile and Hme residues,

[0405] X15 does not exist or is a Lys amino acid residue.

[0406] R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[0407] or a salt or solvate thereof,

[0408] and

[0409] The compound of formula (I) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[0410] In a fourth group of embodiments, the compound having formula (I) may be a compound where X2 is:

[0411] an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu, and X8 is an amino acid residue selected from the group consisting of Yme, Trp and Yde,

[0412] or an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr residues, and X8 is an amino acid residue selected from the group consisting of Yme, Trp, Yde and Yae residues.

[0413] In a fifth group of embodiments, compounds of formula (I) are those compounds wherein:

[0414] X1 is a residue selected from the group consisting of Ahx, Apt, Nmha, Nmapt, Lys and Dad, and is linked to X11 via an amide bond,

[0415] or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond,

[0416] R1 is absent or, if X1 is selected from the group consisting of the residues of Ahx, Apt and Lys, R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[0417] X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu residues,

[0418] X7 is an amino acid residue selected from the group consisting of a Cys, Glu, Asp, Thr and Abu residue,

[0419] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond,

[0420] X3 is an amino acid residue selected from the group consisting of Apt, Ndmk and Lys(αAc),

[0421] X4 does not exist,

[0422] X5 is an amino acid residue selected from the group consisting of a residue of Trp, Wme and Wim,

[0423] X6 is an amino acid residue selected from the group consisting of a residue of Gln, Lys(Ac) and Leu,

[0424] X8 is an amino acid residue selected from the group consisting of a residue of Yme, Trp, Yde and Yae,

[0425] X9 is the amino acid residue of Nal,

[0426] X10 is an amino acid residue selected from the group consisting of Aib, Lys, Lys(Ac), Mle, Mly, Mkdm and Thp,

[0427] X11 is an amino acid residue selected from the group consisting of Asp, Glu, Kme, Lys and Orn, and is linked to X1 via an amide bond,

[0428] X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues,

[0429] X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, d-Leu, Ile, Pal, Pyal, PyEA, His and Hme residues,

[0430] X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile and Hme residues,

[0431] X15 does not exist or is a Lys amino acid residue.

[0432] R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[0433] or a salt or solvate thereof,

[0434] and

[0435] The compound of formula (I) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[0436] In a fifth group of embodiments, the compound having formula (I) may be a compound where X2 is:

[0437] an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu, and X8 is an amino acid residue selected from the group consisting of Yme, Trp and Yde,

[0438] or an amino acid residue selected from the group consisting of Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr Abu, and X8 is an amino acid residue selected from the group consisting of Yme, Trp, Yde and Yae.

[0439] In a sixth group of embodiments, compounds of formula (I) are those compounds wherein:

[0440] R 1 is absent or is H, C1-C4-alkyl or acetyl, and is attached to the amino function of X1,

[0441] X1 is the residue of Apt and is linked to X11 via an amide bond,

[0442] X2 is the amino acid residue of Cys,

[0443] X7 is the amino acid residue of Cys,

[0444] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond,

[0445] X3 is an amino acid residue selected from the group consisting of Asn and Lys(αAc),

[0446] X4 does not exist or is a Thr amino acid residue,

[0447] X5 is the amino acid residue of Wim,

[0448] X6 is an amino acid residue of Lys(Ac),

[0449] X8 is the amino acid residue of Yde,

[0450] X9 is the amino acid residue of Nal,

[0451] X10 is an amino acid residue selected from the group consisting of residues of Mkdm and Thp,

[0452] X11 is an amino acid residue of Glu and is linked to X1 via an amide bond,

[0453] X12 is an amino acid residue of Asn,

[0454] X13 is the amino acid residue of Pal,

[0455] X14 is the amino acid residue of Sar,

[0456] X15 does not exist.

[0457] R2 is -NH2,

[0458] or a salt or solvate thereof,

[0459] and

[0460] The compound of formula (I) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[0461] In a seventh group of embodiments, compounds of formula (I) are those compounds wherein:

[0462] R1 is absent or is H, C1-C4-alkyl or acetyl and is linked to the amino function of X1,

[0463] X1 is the residue of Apt and is linked to X11 via an amide bond,

[0464] X2 is the amino acid residue of Cys,

[0465] X7 is the amino acid residue of Cys,

[0466] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond,

[0467] X3 is an amino acid residue of Asn,

[0468] X4 is the amino acid residue of Thr,

[0469] X5 is the amino acid residue of Wim,

[0470] X6 is an amino acid residue of Lys(Ac),

[0471] X8 is the amino acid residue of Yde,

[0472] X9 is the amino acid residue of Nal,

[0473] X10 is an amino acid residue selected from the group consisting of residues of Mkdm and Thp,

[0474] X11 is an amino acid residue of Glu and is linked to X1 via an amide bond,

[0475] X12 is an amino acid residue of Asn,

[0476] X13 is the amino acid residue of Pal,

[0477] X14 is the amino acid residue of Sar,

[0478] X15 does not exist.

[0479] R2 is -NH2,

[0480] or a salt or solvate thereof,

[0481] and

[0482] The compound of formula (I) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[0483] In an eighth group of embodiments, compounds of formula (I) are those compounds wherein:

[0484] R1 is absent or is H, C1-C4-alkyl or acetyl and is attached to one of the following amino functional groups,

[0485] X1 is the residue of Apt and is linked to X11 via an amide bond,

[0486] X2 is the amino acid residue of Cys,

[0487] X7 is the amino acid residue of Cys,

[0488] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond,

[0489] X3 is an amino acid residue of Lys(αAc),

[0490] X4 does not exist,

[0491] X5 is the amino acid residue of Wim,

[0492] X6 is an amino acid residue of Lys(Ac),

[0493] X8 is the amino acid residue of Yde,

[0494] X9 is the amino acid residue of Nal,

[0495] X10 is an amino acid residue selected from the group consisting of residues of Mkdm and Thp,

[0496] X11 is an amino acid residue of Glu and is linked to X1 via an amide bond,

[0497] X12 is an amino acid residue of Asn,

[0498] X13 is the amino acid residue of Pal,

[0499] X14 is the amino acid residue of Sar,

[0500] X15 does not exist.

[0501] R2 is -NH2,

[0502] or a salt or solvate thereof,

[0503] and

[0504] The compound of formula (I) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[0505] In a ninth group of embodiments, compounds of formula (I) are those compounds wherein:

[0506] R1 is absent or, if X1 is selected from Ahx, Apt and Lys, R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[0507] X1 is a residue selected from the group consisting of Ahx, Apt, Nmha, Nmapt, Lys and Dad, and is linked to X11 via an amide bond,

[0508] or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond,

[0509] X2 is an amino acid residue selected from the group consisting of a Cys, Nmc and Abu residue,

[0510] X7 is an amino acid residue selected from the group consisting of a Cys, Glu, Asp and Thr residue,

[0511] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond,

[0512] X3 is an amino acid residue of Lys(αAc),

[0513] X4 does not exist,

[0514] X5 is an amino acid residue selected from the group consisting of Trp and Wim residues,

[0515] X6 is an amino acid residue of Lys(Ac),

[0516] X8 is the amino acid residue of Yde,

[0517] X9 is the amino acid residue of Nal,

[0518] X10 is an amino acid residue selected from the group consisting of residues of Mkdm and Thp,

[0519] X11 is an amino acid residue selected from the group consisting of Asp, Glu, Kme and Lys residues, and is linked to X1 via an amide bond,

[0520] X12 is the amino acid residue of Gly,

[0521] X13 is the amino acid residue of PyEA,

[0522] X14 does not exist,

[0523] X15 does not exist.

[0524] R2 does not exist,

[0525] or a salt or solvate thereof,

[0526] and

[0527] The compound of formula (I) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[0528] In a tenth group of embodiments, compounds of formula (I) are those compounds wherein:

[0529] X1 is a residue selected from the group consisting of Ahx, Apt, Nmha, Nmapt, Lys, Dad, and is linked to X11 via an amide bond,

[0530] R1 is absent or, if X1 is selected from the residues of Ahx, Aoa, Apt, Lys, Dab and Dap, R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[0531] X2-Q-X7 is selected from Cys-Q-Cys and Nmc-Q-Cys, wherein Q is a disulfide bond, or Abu-Q-Cys, wherein Q is a thioether bond, or Glu-Q-Thr, wherein Q is an ester bond,

[0532] X3 is an amino acid residue of Lys(αAc) and X4 is absent,

[0533] or X3 is an amino acid residue of Asn, and X4 is an amino acid residue of Thr,

[0534] X5 is an amino acid residue selected from the group consisting of Trp and Wim residues,

[0535] X6 is an amino acid residue selected from the group consisting of Gln and Lys(Ac),

[0536] X8 is an amino acid residue selected from the group consisting of a residue of Yme, Yde and Yae,

[0537] X9 is the amino acid residue of Nal,

[0538] X10 is an amino acid residue selected from the group consisting of Aib, Mle, Mly, Mkdm and Thp,

[0539] X11 is an amino acid residue selected from the group consisting of Asp, Glu, Kme and Lys, and is linked to X1 via an amide bond,

[0540] X12 is an amino acid residue selected from the group consisting of Asn, Ser and Ala residues,

[0541] X13 is an amino acid residue selected from the group consisting of Asn, Gly, d-Leu, Pal and His,

[0542] X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal and Ile residues,

[0543] X15 does not exist.

[0544] R2 is -NH2,

[0545] or a salt or solvate thereof,

[0546] and

[0547] The compound of formula (I) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[0548] In some embodiments of the tenth group of embodiments, the compound having formula (I) can be a compound:

[0549] X2-Q-X7 is selected from Cys-Q-Cys and Nmc-Q-Cys, wherein Q is a disulfide bond, or Abu-Q-Cys, wherein Q is a thioether bond, or Glu-Q-Thr, wherein Q is an ester bond, and X8 is an amino acid residue selected from the group consisting of residues of Yme and Yde, or

[0550] X7 is selected from Cys-Q-Cys and Nmc-Q-Cys, wherein Q is a disulfide bond, or Glu-Q-Thr, wherein Q is an ester bond, and X8 is an amino acid residue selected from the group consisting of: Yme, Yde and Yae residues.

[0551] In an eleventh group of embodiments, compounds of formula (I) are those compounds wherein X2-X3-X4-X5-X6-X7 are selected from the following:

[0552] Cys-Asn-Thr-Trp-Gln-Cys,

[0553] Cys-Asn-Thr-Wim-Gln-Cys,

[0554] Cys-Asn-Thr-Trp-Lys(Ac)-Cys,

[0555] Cys-Asn-Thr-Wim-Lys(Ac)-Cys、

[0556] Cys-Nmn-Thr-Trp-Gln-Cys,

[0557] Abu-Asn-Thr-Trp-Lys(Ac)-Cys,

[0558] Abu-Asn-Thr-Wim-Lys(Ac)-Cys and

[0559] Abu-Asn-Thr-Wme-Leu-Cys.

[0560] In a twelfth group of embodiments, compounds of formula (I) are those compounds wherein X2-X3-X4-X5-X6-X7 are selected from the following:

[0561] Cys-Asn-Thr-Trp-Lys(Ac)-Cys,

[0562] Cys-Asn-Thr-Wim-Lys(Ac)-Cys、

[0563] Cys-Nmn-Thr-Trp-Gln-Cys,

[0564] Abu-Asn-Thr-Trp-Lys(Ac)-Cys and

[0565] Abu-Asn-Thr-Wim-Lys(Ac)-Cys.

[0566] In a thirteenth group of embodiments, compounds of formula (I) are those compounds wherein X2-X3-X4-X5-X6-X7 are selected from the following:

[0567] Cys-Asn-Thr-Trp-Lys(Ac)-Cys and

[0568] Cys-Asn-Thr-Wim-Lys(Ac)-Cys.

[0569] In a fourteenth group of embodiments, compounds of formula (I) are those compounds wherein X2-X3-X5-X6-X7 are selected from the following:

[0570] Cys-Lys(αAc)-Trp-Gln-Cys,

[0571] Cys-Lys(αAc)-Wim-Gln-Cys,

[0572] Cys-Lys(αAc)-Trp-Lys(Ac)-Cys,

[0573] Cys-Lys(αAc)-Wim-Lys(Ac)-Cys,

[0574] Cys-Ndmk-Trp-Lys(Ac)-Cys,

[0575] Cys-Ndmk-Wim-Lys(Ac)-Cys,

[0576] Cys-Lys(αAc)-Wim-Leu-Cys,

[0577] Nmc-Lys(αAc)-Wim-Leu-Cys,

[0578] Cys-Apt-Trp-Gln-Cys,

[0579] Abu-Lys(αAc)-Trp-Lys(Ac)-Cys,

[0580] Abu-Lys(αAc)-Wim-Lys(Ac)-Cys and

[0581] Glu-Apt-Trp-Gln-Thr,

[0582] And X4 does not exist.

[0583] In a fifteenth group of embodiments, compounds of formula (I) are those compounds wherein X2-X3-X5-X6-X7 are selected from the following:

[0584] Cys-Lys(αAc)-Trp-Gln-Cys,

[0585] Cys-Lys(αAc)-Wim-Gln-Cys,

[0586] Cys-Lys(αAc)-Trp-Lys(Ac)-Cys,

[0587] Cys-Lys(αAc)-Wim-Lys(Ac)-Cys,

[0588] Cys-Ndmk-Trp-Lys(Ac)-Cys,

[0589] Cys-Ndmk-Wim-Lys(Ac)-Cys,

[0590] Cys-Lys(αAc)-Wim-Leu-Cys,

[0591] Nmc-Lys(αAc)-Wim-Leu-Cys and

[0592] Cys-Apt-Trp-Gln-Cys,

[0593] And X4 does not exist.

[0594] In a sixteenth group of embodiments, compounds of formula (I) are those compounds wherein X2-X3-X5-X6-X7 are selected from the following:

[0595] Cys-Lys(αAc)-Trp-Lys(Ac)-Cys,

[0596] Cys-Lys(αAc)-Wim-Lys(Ac)-Cys,

[0597] Cys-Ndmk-Trp-Lys(Ac)-Cys and

[0598] Cys-Ndmk-Wim-Lys(Ac)-Cys,

[0599] And X4 does not exist.

[0600] In a seventeenth group of embodiments, compounds of formula (I) are those compounds wherein X8-X9-X10 is X8-Nal-X10, wherein X8 is selected from the residues of Yae, Yde and Yme and X10 is selected from the residues of Aib, Mle, Thp, Mkdm and Mly.

[0601] In an eighteenth group of embodiments, compounds having formula (I) are those compounds wherein X8-X9-X10 is Yde-Nal-X10, wherein X10 is selected from the residues of Aib, Mle, Thp, Mkdm and Mly.

[0602] In a nineteenth group of embodiments, compounds of formula (I) are those compounds wherein X8-X9-X10 are selected from the group consisting of:

[0603] Yde-Nal-Aib,

[0604] Yde-Nal-Mle,

[0605] Yde-Nal-Thp,

[0606] Yde-Nal-Mkdm,

[0607] Yde-Nal-Mly,

[0608] Yme-Nal-Aib,

[0609] Yae-Nal-Mle,

[0610] Yae-Nal-Thp,

[0611] Yme-Nal and

[0612] Yde-Nal-Aib.

[0613] In the twentieth group of embodiments, compounds having formula (I) are those compounds wherein X12-X13- is selected from the group consisting of sn-Asn-, Asn-Gly, Asn-d-Leu-, Ala-Gly-, Ala-d-Leu-, Asn-His-, Ser-His-, Asn-Pal-, Asn-Pyal- and Gly-PyEA-.

[0614] In a twenty-first group of embodiments, compounds having formula (I) are those compounds wherein X12-X13- is Gly-PyEA, X14 is absent, X15 is absent, and R2 is absent.

[0615] In the twenty-second group of embodiments, compounds having formula (I) are those compounds wherein X12-X13- is selected from: Asn-Asn-, Asn-Gly-, Asn-d-Leu-, Ala-Gly-, Ala-d-Leu-, Asn-His-, Ser-His-, Asn-Pal- and Asn-Pyal-, X14 is absent, X15 is absent, and R2 is NH2 is absent.

[0616] In the twenty-third group of embodiments, compounds having formula (I) are those compounds, wherein X12-X13-X14- is selected from: Asn-Pal-Sar-, Asn-Pal-Ile-, Asn-Asn-Ile-, Asn-His-Sar, Asn-His-Bal-, Asn-His-Mep-, Ser-Pal-Sar- and Ala-Pal-Sar-.

[0617] In the twenty-fourth group of embodiments, compounds of formula (I) are those compounds wherein X12-X13-X14- is selected from the group consisting of: Asn-Pal-Sar-, Asn-Pal-Ile-, Asn-Asn-Ile-, Asn-His-Sar, Asn-His-Bal-, Asn-His-Mep-, Ser-Pal-Sar-, Ala-Pal-Sar-, Asn-Asn--, Asn-Gly-absent-, Asn-d-Leu-absent-, Ala-Gly-absent-, Ala-d-Leu-absent-, Asn-His-absent-, Ser-His-absent-, Asn-Pal-absent-, Asn-Pal-absent-, Asn-absent-absent-, Asn-Pyal-absent-, and Gly-PyEA-absent-.

[0618] In a twenty-fifth group of embodiments, compounds of formula (I) are those compounds wherein X12-X13-X14-X15 is selected from the group consisting of Asn-Asn--absent-, Asn-Gly-absent-absent-, Asn-d-Leu-absent-absent-, Ala-Gly-absent-absent-, Ala-d-Leu-absent-absent-, Asn-His-absent-absent-, Ser-His-absent-absent-, Asn-Pal-absent-absent-, Asn-Pal-Sar-absent-absent-. absent-, Asn-Pal-Sar-Lys, Asn-Pal-Ile-absent-, Asn-Asn-Ile-absent-, Asn-His-Sar-absent-, Asn-His-Bal-absent-, Asn-His-Mep-absent, Ser-Pal-Sar-absent-, Ala-Pal-Sar-absent-, Asn-Pal-absent-Lys-, Asn-absent-absent-Lys, Asn-Pyal-absent-absent, and Gly-PyEA-absent-absent.

[0619] In a twenty-sixth group of embodiments, compounds of formula (I) are those compounds wherein:

[0620] R1 is H or acetyl and is connected to the amino functional group of X1,

[0621] X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Dab, Dad, Dap, and is linked to X11 via an amide bond,

[0622] X2-X3-X4-X5-X6-X7 is selected from:

[0623] Cys-Asn-Thr-Trp-Gln-Cys,

[0624] Cys-Asn-Thr-Wim-Gln-Cys,

[0625] Cys-Asn-Thr-Trp-Lys(Ac)-Cys,

[0626] Cys-Asn-Thr-Wim-Lys(Ac)-Cys、

[0627] Cys-Nmn-Thr-Trp-Gln-Cys,

[0628] Abu-Asn-Thr-Trp-Lys(Ac)-Cys,

[0629] Abu-Asn-Thr-Wim-Lys(Ac)-Cys and

[0630] Abu-Asn-Thr-Wme-Leu-Cys,

[0631] X2-Q-X7 is selected from the group consisting of Cys-Q-Cys and Nmc-Q-Cys, wherein Q is a disulfide bond, or Abu-Q-Cys, wherein Q is a thioether bond, or

[0632] Glu-Q-Thr, where Q is an ester bond,

[0633] X8-X9-X10 is selected from the group consisting of:

[0634] Yde-Nal-Aib,

[0635] Yde-Nal-Mle,

[0636] Yde-Nal-Thp,

[0637] Yde-Nal-Mkdm,

[0638] Yde-Nal-Mly,

[0639] Yme-Nal-Aib,

[0640] Yae-Nal-Mle,

[0641] Yae-Nal-Thp,

[0642] Yme-Nal and

[0643] Yde-Nal-Aib,

[0644] X11 is an amino acid residue selected from the group consisting of Asp, Glu, Kme and Lys residues, and is linked to X1 via an amide bond,

[0645] X12-X13-X14-X15 is selected from the group consisting of Asn-Asn-absent-absent-, Asn-Gly-absent-absent-, Asn-d-Leu-absent-absent-, Ala-Gly-absent-absent-, Ala-d-Leu-absent-absent-, Asn-His-absent-absent-, Ser-His-absent-absent-, Asn-Pal-absent-absent-, Asn-Pal-Sar-absent-, Asn-Pal-Sa r-Lys, Asn-Pal-Ile-absent-, Asn-Asn-Ile-absent-, Asn-His-Sar-absent-, Asn-His-Bal-absent-, Asn-His-Mep-absent, Ser-Pal-Sar-absent-, Ala-Pal-Sar-absent-, Asn-Pal-absent-Lys-, Asn-absent-absent-Lys, Asn-Pyal-absent-absent-, and Gly-PyEA-absent-absent-,

[0646] R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[0647] or a salt or solvate thereof,

[0648] and

[0649] The compound of formula (I) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[0650] In a twenty-seventh group of embodiments, compounds of formula (I) are those compounds wherein:

[0651] R1 is H or acetyl and is connected to the amino functional group of X1,

[0652] X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Dab, Dad, Dap, and is linked to X11 via an amide bond,

[0653] X2-X3-X4-X5-X6-X7 is selected from:

[0654] Cys-Asn-Thr-Trp-Gln-Cys,

[0655] Cys-Asn-Thr-Wim-Gln-Cys,

[0656] Cys-Asn-Thr-Trp-Lys(Ac)-Cys,

[0657] Cys-Asn-Thr-Wim-Lys(Ac)-Cys、

[0658] Cys-Nmn-Thr-Trp-Gln-Cys,

[0659] Abu-Asn-Thr-Trp-Lys(Ac)-Cys、

[0660] Abu-Asn-Thr-Wim-Lys(Ac)-Cys and

[0661] Abu-Asn-Thr-Wme-Leu-Cys,

[0662] X2-Q-X7 is selected from the group consisting of Cys-Q-Cys and Nmc-Q-Cys, wherein Q is a disulfide bond, or Abu-Q-Cys, wherein Q is a thioether bond, or

[0663] Glu-Q-Thr, where Q is an ester bond,

[0664] X8-X9-X10 is selected from the group consisting of:

[0665] Yde-Nal-Aib,

[0666] Yde-Nal-Mle,

[0667] Yde-Nal-Thp,

[0668] Yde-Nal-Mkdm,

[0669] Yde-Nal-Mly,

[0670] Yme-Nal-Aib,

[0671] Yae-Nal-Mle,

[0672] Yme-Nal and

[0673] Yde-Nal-Aib,

[0674] X11 is an amino acid residue selected from the group consisting of Asp, Glu, Kme and Lys residues, and is linked to X1 via an amide bond,

[0675] X12-X13-X14-X15 is selected from the group consisting of Asn-Asn-absent-absent-, Asn-Gly-absent-absent-, Asn-d-Leu-absent-absent-, Ala-Gly-absent-absent-, Ala-d-Leu-absent-absent-, Asn-His-absent-absent-, Ser-His-absent-absent-, Asn-Pal-absent-absent-, Asn-Pal-Sar-absent-, Asn-Pal-Sa r-Lys, Asn-Pal-Ile-absent-, Asn-Asn-Ile-absent-, Asn-His-Sar-absent-, Asn-His-Bal-absent-, Asn-His-Mep-absent, Ser-Pal-Sar-absent-, Ala-Pal-Sar-absent-, Asn-Pal-absent-Lys-, Asn-absent-absent-Lys, Asn-Pyal-absent-absent-, and Gly-PyEA-absent-absent-,

[0676] R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[0677] or a salt or solvate thereof,

[0678] and

[0679] The compound of formula (I) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[0680] In a twenty-eighth group of embodiments, compounds of formula (I) are those compounds wherein:

[0681] R1 is H or acetyl and is connected to the amino functional group of X1,

[0682] X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Dab, Dad, Dap, and is linked to X11 via an amide bond,

[0683] X2-X3-X4-X5-X6-X7 is selected from:

[0684] Cys-Asn-Thr-Trp-Gln-Cys,

[0685] Cys-Asn-Thr-Wim-Gln-Cys,

[0686] Cys-Asn-Thr-Trp-Lys(Ac)-Cys,

[0687] Cys-Asn-Thr-Wim-Lys(Ac)-Cys、

[0688] Cys-Nmn-Thr-Trp-Gln-Cys,

[0689] Abu-Asn-Thr-Trp-Lys(Ac)-Cys,

[0690] Abu-Asn-Thr-Wme-Leu-Cys,

[0691] X2-Q-X7 is selected from the group consisting of Cys-Q-Cys and Nmc-Q-Cys, wherein Q is a disulfide bond, or Abu-Q-Cys, wherein Q is a thioether bond, or

[0692] Glu-Q-Thr, where Q is an ester bond,

[0693] X8-X9-X10 is selected from the group consisting of:

[0694] Yde-Nal-Aib,

[0695] Yde-Nal-Mle,

[0696] Yde-Nal-Thp,

[0697] Yde-Nal-Mkdm,

[0698] Yde-Nal-Mly,

[0699] Yme-Nal-Aib,

[0700] Yae-Nal-Mle,

[0701] Yae-Nal-Thp,

[0702] Yme-Nal and

[0703] Yde-Nal-Aib,

[0704] X11 is an amino acid residue selected from the group consisting of Asp, Glu, Kme and Lys residues, and is linked to X1 via an amide bond,

[0705] X12-X13-X14-X15 is selected from the group consisting of Asn-Asn-absent-absent-, Asn-Gly-absent-absent-, Asn-d-Leu-absent-absent-, Ala-Gly-absent-absent-, Ala-d-Leu-absent-absent-, Asn-His-absent-absent-, Ser-His-absent-absent-, Asn-Pal-absent-absent-, Asn-Pal-Sar-absent-, Asn-Pal-Sa r-Lys, Asn-Pal-Ile-absent-, Asn-Asn-Ile-absent-, Asn-His-Sar-absent-, Asn-His-Bal-absent-, Asn-His-Mep-absent, Ser-Pal-Sar-absent-, Ala-Pal-Sar-absent-, Asn-Pal-absent-Lys-, Asn-absent-absent-Lys, Asn-Pyal-absent-absent-, and Gly-PyEA-absent-absent-,

[0706] R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[0707] or a salt or solvate thereof,

[0708] and

[0709] The compound of formula (I) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[0710] In a twenty-ninth group of embodiments, compounds of formula (I) are those compounds wherein:

[0711] R1 is H or acetyl and is connected to the amino functional group of X1,

[0712] X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Dab, Dad, Dap, and is linked to X11 via an amide bond,

[0713] X2-X3-X5-X6-X7 is selected from:

[0714] Cys-Lys(αAc)-Trp-Gln-Cys,

[0715] Cys-Lys(αAc)-Wim-Gln-Cys,

[0716] Cys-Lys(αAc)-Trp-Lys(Ac)-Cys,

[0717] Cys-Lys(αAc)-Wim-Lys(Ac)-Cys,

[0718] Cys-Ndmk-Trp-Lys(Ac)-Cys,

[0719] Cys-Ndmk-Wim-Lys(Ac)-Cys,

[0720] Cys-Lys(αAc)-Wim-Leu-Cys,

[0721] Nmc-Lys(αAc)-Wim-Leu-Cys,

[0722] Cys-Apt-Trp-Gln-Cys,

[0723] Abu-Lys(αAc)-Trp-Lys(Ac)-Cys,

[0724] Abu-Lys(αAc)-Wim-Lys(Ac)-Cys and

[0725] Glu-Apt-Trp-Gln-Thr,

[0726] X4 does not exist,

[0727] X2-Q-X7 is selected from Cys-Q-Cys and Nmc-Q-Cys, wherein Q is a disulfide bond, or Abu-Q-Cys, wherein Q is a thioether bond, or

[0728] Glu-Q-Thr, where Q is an ester bond,

[0729] X8-X9-X10 is selected from the group consisting of:

[0730] Yde-Nal-Aib, Yde-Nal-Mle, Yde-Nal-Thp, Yde-Nal-Mkdm, Yde-Nal-Mly, Yme-Nal-Aib, Yae-Nal-Mle, Yae-Nal-Thp, Yme-Nal and Yde-Nal-Aib,

[0731] X11 is an amino acid residue selected from the group consisting of Asp, Glu, Kme and Lys residues, and is linked to X1 via an amide bond,

[0732] X12-X13-X14-X15 is selected from the group consisting of:

[0733] Asn-Asn-absent-absent-, Asn-Gly-absent-absent-, Asn-d-Leu-absent-absent-, Ala-Gly-absent-absent-, Ala-d-Leu-absent-absent-, Asn-His-absent-absent-, Ser-His-absent-absent-, Asn-Pal-absent-absent-, Asn-Pal-Sar-absent-, Asn-Pal-Sar-Lys, Asn-Pal-Ile-absent-, Asn-Asn-Ile-absent-, Asn-His-Sar-absent-, Asn-His-Bal-absent-, Asn-His-Mep-absent, Ser-Pal-Sar-absent-, Ala-Pal-Sar-absent-, Asn-Pal-absent-Lys-, Asn-Absent-Absent-, and Gly-PyEA-absent-absent-,

[0734] R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[0735] or a salt or solvate thereof,

[0736] and

[0737] The compound of formula (I) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[0738] In a thirtieth group of embodiments, compounds of formula (I) are those compounds wherein:

[0739] R1 is H or acetyl and is connected to the amino functional group of X1,

[0740] X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Dab, Dad, Dap, and is linked to X11 via an amide bond,

[0741] X2-X3-X5-X6-X7 is selected from

[0742] Cys-Lys(αAc)-Trp-Gln-Cys,

[0743] Cys-Lys(αAc)-Wim-Gln-Cys,

[0744] Cys-Lys(αAc)-Trp-Lys(Ac)-Cys,

[0745] Cys-Lys(αAc)-Wim-Lys(Ac)-Cys,

[0746] Cys-Ndmk-Trp-Lys(Ac)-Cys,

[0747] Cys-Ndmk-Wim-Lys(Ac)-Cys,

[0748] Cys-Lys(αAc)-Wim-Leu-Cys,

[0749] Nmc-Lys(αAc)-Wim-Leu-Cys,

[0750] Cys-Apt-Trp-Gln-Cys,

[0751] Abu-Lys(αAc)-Trp-Lys(Ac)-Cys,

[0752] Abu-Lys(αAc)-Wim-Lys(Ac)-Cys and

[0753] Glu-Apt-Trp-Gln-Thr,

[0754] X4 does not exist,

[0755] X2-Q-X7 is selected from Cys-Q-Cys and Nmc-Q-Cys, wherein Q is a disulfide bond, or Abu-Q-Cys, wherein Q is a thioether bond, or

[0756] Glu-Q-Thr, where Q is an ester bond,

[0757] X8-X9-X10 is selected from the group consisting of:

[0758] Yde-Nal-Aib, Yde-Nal-Mle, Yde-Nal-Mkdm, Yde-Nal-Mly, Yme-Nal-Aib, Yae-Nal-Mle, Yae-Nal-Thp, Yme-Nal and Yde-Nal-Aib,

[0759] X11 is an amino acid residue selected from the group consisting of Asp, Glu, Kme and Lys residues, and is linked to X1 via an amide bond,

[0760] X12-X13-X14-X15 is selected from the group consisting of:

[0761] Asn-Asn-absent-absent-, Asn-Gly-absent-absent-, Asn-d-Leu-absent-absent-, Ala-Gly-absent-absent-, Ala-d-Leu-absent-absent-, Asn-His-absent-absent-, Ser-His-absent-absent-, Asn-Pal-absent-absent-, Asn-Pal-Sar-absent-, Asn-Pal-Sar-Lys, Asn-Pal-Ile-absent-, Asn-Asn-Ile-absent-, Asn-His-Sar-absent-, Asn-His-Bal-absent-, Asn-His-Mep-absent, Ser-Pal-Sar-absent-, Ala-Pal-Sar-absent-, Asn-Pal-absent-Lys-, Asn-Absent-Absent-, and Gly-PyEA-absent-absent-,

[0762] R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[0763] or a salt or solvate thereof,

[0764] and

[0765] The compound of formula (I) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[0766] In a thirty-first group of embodiments, compounds of formula (I) are those compounds wherein:

[0767] R1 is H or acetyl and is connected to the amino functional group of X1,

[0768] X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Dab, Dad, Dap, and is linked to X11 via an amide bond,

[0769] X2-X3-X5-X6-X7 is selected from

[0770] Cys-Lys(αAc)-Trp-Gln-Cys,

[0771] Cys-Lys(αAc)-Wim-Gln-Cys,

[0772] Cys-Lys(αAc)-Trp-Lys(Ac)-Cys,

[0773] Cys-Lys(αAc)-Wim-Lys(Ac)-Cys,

[0774] Cys-Ndmk-Trp-Lys(Ac)-Cys,

[0775] Cys-Ndmk-Wim-Lys(Ac)-Cys,

[0776] Cys-Lys(αAc)-Wim-Leu-Cys,

[0777] Nmc-Lys(αAc)-Wim-Leu-Cys,

[0778] Cys-Apt-Trp-Gln-Cys,

[0779] Abu-Lys(αAc)-Trp-Lys(Ac)-Cys,

[0780] Glu-Apt-Trp-Gln-Thr,

[0781] X4 does not exist,

[0782] X2-Q-X7 is selected from Cys-Q-Cys and Nmc-Q-Cys, wherein Q is a disulfide bond, or Abu-Q-Cys, wherein Q is a thioether bond, or

[0783] Glu-Q-Thr, where Q is an ester bond,

[0784] X8-X9-X10 is selected from the group consisting of:

[0785] Yde-Nal-Aib, Yde-Nal-Mle, Yde-Nal-Thp, Yde-Nal-Mkdm, Yde-Nal-Mly, Yme-Nal-Aib, Yae-Nal-Mle, Yae-Nal-Thp, Yme-Nal and Yde-Nal-Aib,

[0786] X11 is an amino acid residue selected from the group consisting of Asp, Glu, Kme and Lys residues, and is linked to X1 via an amide bond,

[0787] X12-X13-X14-X15 is selected from the group consisting of:

[0788] Asn-Asn-absent-absent-, Asn-Gly-absent-absent-, Asn-d-Leu-absent-absent-, Ala-Gly-absent-absent-, Ala-d-Leu-absent-absent-, Asn-His-absent-absent-, Ser-His-absent-absent-, Asn-Pal-absent-absent-, Asn-Pal-Sar-absent-, Asn-Pal-Sar-Lys, Asn-Pal-Ile-absent-, Asn-Asn-Ile-absent-, Asn-His-Sar-absent-, Asn-His-Bal-absent-, Asn-His-Mep-absent, Ser-Pal-Sar-absent-, Ala-Pal-Sar-absent-, Asn-Pal-absent-Lys-, Asn-Absent-Absent-, and Gly-PyEA-absent-absent-,

[0789] R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[0790] or a salt or solvate thereof,

[0791] and

[0792] The compound of formula (I) inhibits the binding of interleukin-23 to interleukin-23 receptor. Compounds having formula (Ia)

[0793] In some embodiments, the peptide compounds described herein comprise one or more half-life extending moieties and / or multiple linker moieties attached to the peptide.

[0794] Disclosed herein are compounds having formula (Ia)

[0795] in

[0796] X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Pipa, Pipb, Pipp, Dab, Dad and Dap, and is linked to X11 via an amide bond,

[0797] or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond,

[0798] R1 is absent or, if X1 is selected from the residues of Ahx, Aoa, Apt, Lys, Dab and Dap, R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[0799] X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu and their corresponding d-form residues,

[0800] X7 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Thr and Abu and their corresponding d-form residues,

[0801] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond,

[0802] X3 is an amino acid residue selected from the group consisting of Sar, His, Lys, Ala, Ahx, Apt, Arg, Asn, Gab, Gln, Trp, Thr, Ndmk, Nmn, Ntmk and Lys(αAc),

[0803] X4 is absent or is an amino acid residue selected from the group consisting of His, Lys, Ahx, Apt, Arg, Asn, Gab, Gln, Trp and Thr residues,

[0804] X5 is an amino acid residue selected from the group consisting of Trp, Wme, Nak, Wcl, Wim, Wdm and Wfl,

[0805] X6 is an amino acid residue selected from the group consisting of: a residue of Gln, Aib, Glu, Phe, Ile, Iva, Lys, Lys(Ac), Leu, Mle, Mly, Mva, Thr, Val, Trp and Phe,

[0806] X8 is an amino acid residue selected from the group consisting of a residue of Yme, Tyr, Trp, Yde and Yae,

[0807] X9 is an amino acid residue selected from the group consisting of a residue of Nal, Nak and Trp,

[0808] X10 is an amino acid residue selected from the group consisting of Aib, Cba, Cit, d-Trp, d-Tza, Lys, Lys(Ac), Leu, Mle, Mly, Gln, Mkdm and Thp,

[0809] X11 is an amino acid residue selected from the group consisting of Asp, Bal, Gab, Glu, Kme, Lys and Orn residues, and is linked to X1 via an amide bond,

[0810] X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues,

[0811] X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, Leu, Ile, Iva, Hol, Hph, Pal, Pyal, PyEA, His, Hme, Val and their corresponding d-form residues,

[0812] X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile, Dnmy and Hme residues,

[0813] X15 does not exist or is a Lys amino acid residue.

[0814] And among them

[0815] The amide bonds between X1 and X2, X2 and X3, X3 and X4, X4 and X5, and X11 and X1 are optionally methylated,

[0816] R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[0817] or a salt or solvate thereof,

[0818] and

[0819] At least one of X10 and X15

[0820] It is an amino acid residue having a -NH2 group in the side chain, wherein the -NH2 side chain group is functionalized by -C(O)-R5, -C(O)O-R5, -C(O)NH-R5, -S(O)2-R5 or R5, for example by -C(O)-R5, wherein R5 can be a moiety containing up to 50 or up to 100 carbon atoms and optionally heteroatoms selected from halogen, N, O, S and P.

[0821] In some embodiments, compounds having Formula (Ia) inhibit the binding of interleukin-23 to the interleukin-23 receptor.

[0822] The embodiments described for R1, X1 to X15 and R2 of formula (I) also apply to compounds having formula (Ia), wherein at least one of X10 and X15 is functionalized as disclosed herein.

[0823] In some embodiments, the compound having formula (Ia) can be a compound where X2 is:

[0824] An amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu and their corresponding d-form amino acid residues, and X8 is an amino acid residue selected from the group consisting of Yme, Tyr, Trp and Yde,

[0825] Or an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr and their corresponding d-type amino acid residues, and X8 is an amino acid residue selected from the group consisting of Yme, Tyr, Trp, Yde and Yae.

[0826] In some embodiments, the compound having formula (Ia) may be a compound where when X2 is Abu or its corresponding d-form, then X8 is not an amino acid residue of Yae.

[0827] In some embodiments, the compound having formula (Ia) may be a compound where when X8 is Yae, then X2 is not Abu or its corresponding d-form amino acid residue.

[0828] A first group of examples of compounds having formula (Ia) may be compounds:

[0829] -X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Pipa, Pipb, Pipp, Dab, Dad and Dap, and is linked to X11 via an amide bond,

[0830] or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond,

[0831] -R1 does not exist, or

[0832] If X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Lys, Dab and Dap, then R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[0833] -X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu and their corresponding d-form residues,

[0834] -X7 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Thr and Abu and their corresponding d-form residues,

[0835] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond,

[0836] -X3 is an amino acid residue selected from the group consisting of Sar, His, Lys, Ala, Ahx, Apt, Arg, Asn, Gab, Gln, Trp, Thr, Ndmk, Nmn, Ntmk and Lys(αAc),

[0837] -X4 is absent or is an amino acid residue selected from the group consisting of His, Lys, Ahx, Apt, Arg, Asn, Gab, Gln, Trp and Thr residues,

[0838] -X5 is an amino acid residue selected from the group consisting of Trp, Wme, Nak, Wcl, Wim, Wdm and Wfl,

[0839] -X6 is an amino acid residue selected from the group consisting of a residue of Gln, Aib, Glu, Phe, Ile, Iva, Lys, Lys(Ac), Leu, Mle, Mly, Mva, Thr, Val, Trp and Phe,

[0840] -X8 is an amino acid residue selected from the group consisting of a residue of Yme, Tyr, Trp and Yde,

[0841] -X9 is an amino acid residue selected from the group consisting of a residue of Nal, Nak and Trp,

[0842] -X10 is an amino acid residue selected from the group consisting of: Aib, Cba, Cit, d-Trp, d-Tza, Lys, Lys(Ac), Leu, Mle, Mly, Gln, Mkdm and Thp,

[0843] -X11 is an amino acid residue selected from the group consisting of Asp, Bal, Gab, Glu, Kme, Lys and Orn residues and is linked to X1 via an amide bond,

[0844] -X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues,

[0845] -X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, Leu, Ile, Iva, Hol, Hph, Pal, Pyal, PyEA, His, Hme, Val and their corresponding d-form residues,

[0846] - X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile, Dnmy and Hme residues,

[0847] -X15 is absent or is a Lys amino acid residue,

[0848] -R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[0849] and

[0850] wherein the amide bonds between X1 and X2, X2 and X3, X3 and X4, X4 and X5, and X11 and X1 are optionally methylated,

[0851] and

[0852] wherein at least one of X10 and X15 is an amino acid residue having a -NH2 group in the side chain, wherein the -NH2 side chain group is functionalized by -C(O)-R5, -C(O)O-R5, -C(O)NH-R5, -S(O)2-R5 or R5, wherein R5 can be a moiety comprising up to 50 or up to 100 carbon atoms and heteroatoms optionally selected from halogen, N, O, S and P,

[0853] or a salt or solvate thereof,

[0854] The compound of formula (Ia) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[0855] A second group of embodiments of compounds having formula (Ia) may be compounds:

[0856] -X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Pipa, Pipb, Pipp, Dab, Dad and Dap, and is linked to X11 via an amide bond,

[0857] or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond,

[0858] -R1 does not exist, or

[0859] If X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Lys, Dab and Dap, then R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[0860] -X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr and their corresponding d-form residues,

[0861] -X7 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Thr and Abu and their corresponding d-form residues,

[0862] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond,

[0863] -X3 is an amino acid residue selected from the group consisting of Sar, His, Lys, Ala, Ahx, Apt, Arg, Asn, Gab, Gln, Trp, Thr, Ndmk, Nmn, Ntmk and Lys(αAc),

[0864] - X4 is absent or is an amino acid residue selected from the group consisting of His, Lys, Ahx, Apt, Arg, Asn, Gab, Gln, Trp and Thr residues,

[0865] -X5 is an amino acid residue selected from the group consisting of Trp, Wme, Nak, Wcl, Wim, Wdm and Wfl,

[0866] -X6 is an amino acid residue selected from the group consisting of a residue of Gln, Aib, Glu, Phe, Ile, Iva, Lys, Lys(Ac), Leu, Mle, Mly, Mva, Thr, Val, Trp and Phe,

[0867] -X8 is an amino acid residue selected from the group consisting of a residue of Yme, Tyr, Trp, Yde and Yae,

[0868] -X9 is an amino acid residue selected from the group consisting of a residue of Nal, Nak and Trp,

[0869] -X10 is an amino acid residue selected from the group consisting of: Aib, Cba, Cit, d-Trp, d-Tza, Lys, Lys(Ac), Leu, Mle, Mly, Gln, Mkdm and Thp,

[0870] -X11 is an amino acid residue selected from the group consisting of Asp, Bal, Gab, Glu, Kme, Lys and Orn residues and is linked to -X1 via an amide bond,

[0871] -X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues,

[0872] -X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, Leu,

[0873] Ile, Iva, Hol, Hph, Pal, Pyal, PyEA, His, Hme, Val and their corresponding d-type residues,

[0874] - X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile, Dnmy and Hme residues,

[0875] -X15 is absent or is a Lys amino acid residue,

[0876] -R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[0877] and

[0878] wherein the amide bonds between X1 and X2, X2 and X3, X3 and X4, X4 and X5, and X11 and X1 are optionally methylated,

[0879] and

[0880] wherein at least one of X10 and X15 is an amino acid residue having a -NH2 group in the side chain, wherein the -NH2 side chain group is functionalized by -C(O)-R5, -C(O)O-R5, -C(O)NH-R5, -S(O)2-R5 or R5, wherein R5 can be a moiety comprising up to 50 or up to 100 carbon atoms and heteroatoms optionally selected from halogen, N, O, S and P,

[0881] or a salt or solvate thereof,

[0882] The compound of formula (Ia) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[0883] In some embodiments, at least one of X10 and X15 is an amino acid residue having a -NH2 group in the side chain, wherein the -NH2 side chain group is functionalized by -C(O)-R5, wherein R5 can be a moiety containing up to 50 or up to 100 carbon atoms and optionally heteroatoms selected from halogen, N, O, S and P.

[0884] In one embodiment, X10 or X15 is an amino acid residue having a functionalized -NH2 side chain group, such as a functionalized Lys, Orn, Mly, Dab or Dap, or a functionalized Lys or Mly.

[0885] Amino acid residues having an -NH2 side chain group, such as Lys, Orn, Mly, Dab or Dap, can be functionalized in that at least one H atom of the -NH2 side chain group is replaced by -C(O)-R5, -C(O)O-R5, -C(O)NH-R5, -S(O)2-R5 or R5, for example, by -C(O)-R5, wherein R5 can be a moiety containing up to 50 or up to 100 carbon atoms and optionally heteroatoms selected from halogen, N, O, S and P.

[0886] In certain embodiments, R5 may comprise a lipophilic moiety, for example, an acyclic straight chain or branched saturated hydrocarbon group, wherein R5, for example, comprises an acyclic straight chain or branched (C4-C 30 ) saturated or unsaturated hydrocarbon radicals, and / or cyclic saturated, unsaturated or aromatic radicals, for example monocyclic, bicyclic or tricyclic radicals containing 4 to 14 carbon atoms and 0, 1 or 2 heteroatoms selected from N, O and S, for example cyclohexyl, phenyl, biphenyl, chromanyl, phenanthrenyl or naphthyl, wherein the acyclic or cyclic radicals may be unsubstituted or substituted, for example, by halogen, -OH and / or CO2H.

[0887] In some embodiments, R5 may comprise a lipophilic moiety, for example, an acyclic linear or branched chain (C 12 -C 22 ) saturated or unsaturated hydrocarbon group. In all stereoisomeric forms, the lipophilic moiety can be attached to the -NH2 side chain group via a linker, for example, a linker comprising one or more (e.g., 2) amino acid linker groups (e.g., γ-aminobutyric acid (GABA), ε-aminocaproic acid (ε-Ahx), γ-Glu and / or β-Ala). In one embodiment, the lipophilic moiety is attached to the -NH2 side chain group via a linker. In another embodiment, the lipophilic moiety is directly attached to the -NH2 side chain group. A specific example of an amino acid linker group is (β-Ala) 1-4 , (γ-Glu) 1-4 、(ε-Ahx) 1-4 or (GABA) 1-4 Examples of amino acid linker groups are β-Ala, γ-Glu, β-Ala-β-Ala and γ-Glu-γ-Glu.

[0888] Specific examples of the -C(O)-R5 group are listed in Table 2 below, which are selected from the group consisting of: (S)-4-carboxy-4-hexadecanoylamino-butyryl-, (S)-4-carboxy-4-octadecanoylamino-butyryl-, 4-hexadecanoylamino-butyryl-, 4-{3-[(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino}-butyryl-, 4-octadecanoylamino-butyryl-, 4-((Z)-octadec-9-enoylamino)-butyryl-, 6-[(4,4-diphenyl-cyclohexyloxy)-hydroxy-phosphoryloxy]-hexanoyl-, hexadecanoyl-, (S)-4-carboxy-4-octadecanoylamino-butyryl-, 4-{3-[(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino}-butyryl-, 4-octadecanoylamino-butyryl-, 4-((Z)-octadec-9-enoylamino)-butyryl-, 6-[(4,4-diphenyl-cyclohexyloxy)-hydroxy-phosphoryloxy]-hexanoyl-, -4-carboxy-4-(15-carboxy-pentadecanoylamino)-butyryl-, (S)-4-carboxy-4-{3-[3-((2S,3R,4S,5R)-5-carboxy-2,3,4,5-tetrahydroxy-pentanoylamino)-propionylamino]-propionylamino}-butyryl-, (S)-4-carboxy-4-{3-[(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino}-butyryl-, (S)-4-carboxy-4-((9Z,12Z)-octadecane-9,12-dienoylamino)-butyryl-, (S)-4-carboxy-4-[6-((2S,3R (S)-4-carboxy-4-((2S,3R,4S,5R)-5-carboxy-2,3,4,5-tetrahydroxy-pentanoylamino)-hexanoylamino]-butyryl-, (S)-4-carboxy-4-tetradecanoylamino-butyryl-, (S)-4-(11-benzyloxycarbonyl-undecanoylamino)-4-carboxy-butyryl-, (S)-4-carboxy-4-[11-((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxy-hexylcarbamoyl)-undecanoylamino]-butyryl-, (S)-4-carboxy-4-((Z)-octadec-9-enoylamino )-butyryl-, (S)-4-carboxy-4-(4-p-dodecyloxy-benzoylamino)-butyryl-, (S)-4-carboxy-4-eicosylamino-butyryl-, (S)-4-carboxy-4-behenoylamino-butyryl-, (S)-4-carboxy-4-((Z)-19-10-enoylamino)-butyryl-, (S)-4-carboxy-4-(4-decyloxy-benzoylamino)-butyryl-, (S)-4-carboxy-4-[(4'-octyloxy-diphenyl-4-carbonyl)-amino]-butyryl-, (S)-4-carboxy-4-(12-phenyl-dodecylamino)-butyryl-, (S)-4-carboxy-4-eicosylamino-butyryl-,(S)-4-carboxy-4-((S)-4-carboxy-4-hexadecanoylamino-butyrylamino)-butyryl-, (S)-4-carboxy-4-((S)-4-carboxy-4-octadecanoylamino-butyrylamino)-butyryl-, 3-(3-octadecanoylamino-propionylamino)-propionyl-, 3-(3-hexadecanoylamino-propionylamino)-propionyl-, 3-hexadecanoylamino-propionyl-, (S)-4-carboxy-4-[(R)-4-((3R,5S,7R,8R,9R,10S,12S,13R,14R,17R)-3,7,12-trihydroxy-8,10,13-trimethyl-hexahydro-cyclopentyl] 17-phenanthren-17-yl)-pentanoylamino]-butyryl-, (S)-4-carboxy-4-[(R)-4-((3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-hexahydro-cyclopenta[a]phenanthren-17-yl)-pentanoylamino]-butyryl-, (S)-4-carboxy-4-((9S,10R)-9,10,16-trihydroxy-hexadecanoylamino)-butyryl-, tetradecanoyl-, 11-carboxy-undecanoyl-, 11-benzyloxycarbonyl-undecanoyl-, (S)-4-carboxy-4-((S)-4-carboxy-4-tetradecanoylamino- butyrylamino)-butyryl-, 6-[hydroxy-(naphthalen-2-yloxy)-phosphoryloxy]-hexanoyl-, 6-[hydroxy-(5-phenyl-pentyloxy)-phosphoryloxy]-hexanoyl-, 4-(naphthalene-2-sulfonylamino)-4-oxo-butyryl-, 4-(diphenyl-4-sulfonylamino)-4-oxo-butyryl-, (S)-4-carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyryl amino}-butyryl-, (S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyryl-, (S)-4-carboxy-2-{(S)-4-carboxy-2-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-,(S)-4-carboxy-2-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyryl-, (S)-4-carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-, (S)-4-carboxy-4-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl- -(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-butyryl-, (S)-4-carboxy-2-{(S)-4-carboxy-2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-, (S)-4-carboxy-2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-butyryl-, 2-(2-{2-[2-( 2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl-, 2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetyl, (S)-4-carboxy-4-((S)-4-carboxy-4-{(S)-4-carboxy-4-[(S)-4-carboxy-4-(19-carboxy-nonadecanoylamino)-butyrylamino]-butyrylamino}-butyrylamino)-butyryl, 2-(2-{2-[2-(2- {2-[(S)-4-carboxy-4-(16-1H-tetrazol-5-yl-hexadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl-, 2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(16-carboxy-hexadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl-, (S)-4-carboxy-4-{(S)-4-carboxy-4-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-butyrylamino}-butyryl-,(S)-4-carboxy-4-((S)-4-carboxy-4-{2-[2-(2-{2-[2-(2-{(S)-4-carboxy-4-[10-(4-carboxy-phenoxy)-decanoylamino]-butyrylamino}-ethoxy)-ethoxy]-acetylamino}-ethoxy)-ethoxy]-acetylamino}-butyryl-, (S)-4-carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-[7-carboxy-phenoxy)-decanoylamino]-butyrylamino}-ethoxy)-ethoxy]-acetylamino}-ethoxy)-acetylamino}-butyryl- butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-, (S)-4-carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(11-carboxy-undecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-, ( (S)-4-carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(13-carboxy-tridecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-, (S)-4-carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(15-carboxy-tridecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl- butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl- and (S)-4-carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(19-carboxy-nonadecaylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-. ,

[0889] Other specific examples of the -C(O)-R5 group are tetradecanoyl, hexadecanoyl and 2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl-.

[0890] Other specific examples of -C(O)-R5 groups are listed in Table 2 as Myri, Palm and Sema.

[0891] Further examples are stereoisomers of these groups, such as enantiomers (S- or R-enantiomers). The term "R" in Table 2 is intended to refer to the attachment site of -C(O)-R5 on the peptide backbone, ie, the epsilon-amino group of, for example, Lys or Mly. Table 2: -C(O)R5 functional groups

[0892] According to one embodiment, R5 is selected from the group consisting of: (S)-4-carboxy-4-hexadecanoylamino-butyryl (γE-x53), (S)-4-carboxy-4-octadecanoylamino-butyryl (γE-x70), 4-hexadecanoylamino-butyryl (GABA-x53), 4-{3-[(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino}-butyryl-(GABA-x60), 4-octadecanoylamino-butyryl (GABA-x70), 4-hexadecanoylamino-butyryl (GABA-x73), 4-{3-[(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino}-butyryl-(GABA-x60), 4-octadecanoylamino-butyryl (GABA-x74), 4-octadecanoylamino-butyryl (GABA-x75), 4-octadecanoylamino-butyryl (GABA-x76). ABA-x70), 4-((Z)-octadec-9-enoylamino)-butyryl (GABA-x74), 6-[(4,4-diphenyl-cyclohexyloxy)-hydroxy-phosphoryloxy]-hexanoyl (Phospho1), hexadecanoyl (x53), tetradecanoyl (x69), (S)-4-carboxy-4-(15-carboxy-pentadecanoylamino)-butyryl (x52), (S)-4-carboxy-4-{3-[3-((2S,3R,4S,5R)-5-carboxy-2,3,4,5-tetrahydroxy-pentanoylamino)-propionylamino] -propionylamino}-butyryl (γE-x59), (S)-4-carboxy-4-{3-[(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino}-butyryl (γE-x60), (S)-4-carboxy-4-((9Z,12Z)-octadec-9,12-dienoylamino)-butyryl (γE-x61), (S)-4-carboxy-4-[6-((2S,3R,4S,5R)-5-carboxy-2,3,4,5-tetramethyl-2-((4R,8R)-4,8,12-trimethyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino}-butyryl (γE-x6 (γE-x64), (S)-4-carboxy-4-((2S,3R,4S,5R)-5-carboxy-2,3,4,5-tetrahydroxy-pentanoylamino)-butyryl (γE-x65), (S)-4-carboxy-4-tetradecanoylamino-butyryl (γE-x69), (S)-4-(11-benzyloxycarbonyl-undecanoylamino)-4-carboxy-butyryl (γE-x72), (S)-4-carboxy-4-[11-((2S,3R,4R,5R)-2,3,4,5,(S)-4-carboxy-4-((Z)-octadec-9-enoylamino)-butyryl (γE-x74), (S)-4-carboxy-4-(4-p-dodecyloxy-benzoylamino)-butyryl (γE-x75), (S)-4-carboxy-4-eicosylamino-butyryl (γE-x76), (S)-4-carboxy-4-behenosylamino-butyryl (γE-x77), (S)-4-carboxy-4-((Z)-19-10-enoylamino)-butyryl (γE-x79), (S)-4-carboxy-4-(4-decyloxy-benzoylamino)-butyryl (γE-x80), ( S)-4-carboxy-4-[(4'-octyloxy-diphenyl-4-carbonyl)-amino]-butyryl (γE-x81), (S)-4-carboxy-4-(12-phenyl-dodecanoylamino)-butyryl (γE-x82), (S)-4-carboxy-4-eicosanoylamino-butyryl (γE-x95), (S)-4-carboxy-4-((S)-4-carboxy-4-hexadecanoylamino-butyrylamino)-butyryl (γE-γE-x53), (S)-4-carboxy-4-((S)-4-carboxy-4-octadecanoylamino-butyrylamino)-butyryl (γE-γE-x70) and 3-(3-octadecanoylamino-propionylamino)-propionyl (β-Ala-β-Ala-x70). ,

[0893] According to another embodiment, R5 is selected from the group consisting of: (S)-4-carboxy-4-octadecanoylamino-butyryl (γE-x70), (S)-4-carboxy-4-hexadecanoylamino-butyryl (γE-x53) and hexadecanoyl (x53).

[0894] According to yet another embodiment, R5 is (S)-4-carboxy-4-hexadecanoylamino-butyryl (γE-x53).

[0895] In some embodiments, position X10 or X15 represents Lys or Mly. According to some embodiments, Lys or Mly at position X10, Lys at position X15 is functionalized with a group -C(O)R5, for example as described above.

[0896] In other embodiments, X15 is absent and X10 is Mly functionalized with -C(O)-R5, -C(O)O-R5, -C(O)NH-R5, -S(O)2-R5 or R5, e.g., via -C(O)-R5, wherein R5 is as defined above.

[0897] In other embodiments, X10 is not functionalized and X15 is Lys functionalized with C(O)-R5, -C(O)O-R5, -C(O)NH-R5, -S(O)2-R5 or R5, for example through -C(O)-R5, wherein R5 is as defined above.

[0898] In other embodiments, X10 is not functionalized, X14 is absent and X15 is Lys functionalized with -C(O)-R5, -C(O)O-R5, -C(O)NH-R5, -S(O)2-R5 or R5, e.g., via -C(O)-R5, wherein R5 is as defined above.

[0899] In some embodiments, X15 is absent and X10 is Mly functionalized with C(O)-R5, wherein R5 is selected from the group consisting of: (S)-4-carboxy-4-hexadecanoylamino-butyryl (γE-x53), (S)-4-carboxy-4-octadecanoylamino-butyryl (γE-x70), 4-hexadecanoylamino-butyryl (GABA-x53), 4-{3-[(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino}-butyryl- (GABA-x60), 4-octadecanoylamino-butyryl (GABA-x70), 4-((Z)-octadec-9-enoylamino)-butyryl (GABA-x74), 6-[(4,4-diphenyl-cyclohexyloxy)-hydroxy-phosphoryloxy]-hexanoyl (Phospho1), hexadecanoyl (x53), (S)-4-carboxy-4-(15-carboxy-pentadecanoylamino)-butyryl (x52), (S)-4-carboxy-4-{3-[3-((2S,3R,4S,5R)-5-carboxy-2,3,4,5-tetrahydroxy-pentanoyl (γE-x59), (S)-4-carboxy-4-{3-[(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino}-butyryl (γE-x60), (S)-4-carboxy-4-((9Z,12Z)-octadecane-9,12-dienoylamino)-butyryl (γE-x61), (S)-4-carboxy-4-[6-((2S,3R,4S,5R)-5-carboxy-2,3, (S)-4-carboxy-4-((2S,3R,4S,5R)-5-carboxy-2,3,4,5-tetrahydroxy-pentanoylamino)-butyryl (γE-x65), (S)-4-carboxy-4-tetradecanoylamino-butyryl (γE-x69), (S)-4-(11-benzyloxycarbonyl-undecanoylamino)-4-carboxy-butyryl (γE-x72), (S)-4-carboxy-4-[11-((2S,3R,4R,5R)-2,3,4,5,(S)-4-carboxy-4-((Z)-octadec-9-enoylamino)-butyryl (γE-x74), (S)-4-carboxy-4-(4-p-dodecyloxy-benzoylamino)-butyryl (γE-x75), (S)-4-carboxy-4-eicosylamino-butyryl (γE-x76), (S)-4-carboxy-4-behenosylamino-butyryl (γE-x77), (S)-4-carboxy-4-((Z)-19-10-enoylamino)-butyryl (γE-x79), (S)-4-carboxy-4-(4-decyloxy-benzoylamino)-butyryl (γE-x80), ( S)-4-carboxy-4-[(4'-octyloxy-diphenyl-4-carbonyl)-amino]-butyryl (γE-x81), (S)-4-carboxy-4-(12-phenyl-dodecanoylamino)-butyryl (γE-x82), (S)-4-carboxy-4-eicosanoylamino-butyryl (γE-x95), (S)-4-carboxy-4-((S)-4-carboxy-4-hexadecanoylamino-butyrylamino)-butyryl (γE-γE-x53), (S)-4-carboxy-4-((S)-4-carboxy-4-octadecanoylamino-butyrylamino)-butyryl (γE-γE-x70) and 3-(3-octadecanoylamino-propionylamino)-propionyl (β-Ala-β-Ala-x70). ,

[0900] In some embodiments, X10 is not functionalized and X15 is Lys functionalized with C(O)-R5, wherein R5 is selected from the group consisting of: (S)-4-carboxy-4-hexadecanoylamino-butyryl (γE-x53), (S)-4-carboxy-4-octadecanoylamino-butyryl (γE-x70), 4-hexadecanoylamino-butyryl (GABA-x53), 4-{3-[(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino}-butyryl yl-(GABA-x60), 4-octadecanoylamino-butyryl (GABA-x70), 4-((Z)-octadec-9-enoylamino)-butyryl (GABA-x74), 6-[(4,4-diphenyl-cyclohexyloxy)-hydroxy-phosphoryloxy]-hexanoyl (Phospho1), hexadecanoyl (x53), (S)-4-carboxy-4-(15-carboxy-pentadecanoylamino)-butyryl (x52), (S)-4-carboxy-4-{3-[3-((2S,3R,4S,5R)-5-carboxy-2,3,4,5-tetrahydroxy-pentanoyl (γE-x59), (S)-4-carboxy-4-{3-[(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino}-butyryl (γE-x60), (S)-4-carboxy-4-((9Z,12Z)-octadecane-9,12-dienoylamino)-butyryl (γE-x61), (S)-4-carboxy-4-[6-((2S,3R,4S,5R)-5-carboxy-2,3 ,4,5-tetrahydroxy-pentanoylamino)-hexanoylamino]-butyryl (γE-x64), (S)-4-carboxy-4-((2S,3R,4S,5R)-5-carboxy-2,3,4,5-tetrahydroxy-pentanoylamino)-butyryl (γE-x65), (S)-4-carboxy-4-tetradecanoylamino-butyryl (γE-x69), (S)-4-(11-benzyloxycarbonyl-undecanoylamino)-4-carboxy-butyryl (γE-x72), (S)-4-carboxy-4-[11-((2S,3R,4R,5R)-2,3,4,5,(S)-4-carboxy-4-((Z)-octadec-9-enoylamino)-butyryl (γE-x74), (S)-4-carboxy-4-(4-p-dodecyloxy-benzoylamino)-butyryl (γE-x75), (S)-4-carboxy-4-eicosylamino-butyryl (γE-x76), (S)-4-carboxy-4-behenosylamino-butyryl (γE-x77), (S)-4-carboxy-4-((Z)-19-10-enoylamino)-butyryl (γE-x79), (S)-4-carboxy-4-(4-decyloxy-benzoylamino)-butyryl (γE-x80), ( S)-4-carboxy-4-[(4'-octyloxy-diphenyl-4-carbonyl)-amino]-butyryl (γE-x81), (S)-4-carboxy-4-(12-phenyl-dodecanoylamino)-butyryl (γE-x82), (S)-4-carboxy-4-eicosanoylamino-butyryl (γE-x95), (S)-4-carboxy-4-((S)-4-carboxy-4-hexadecanoylamino-butyrylamino)-butyryl (γE-γE-x53), (S)-4-carboxy-4-((S)-4-carboxy-4-octadecanoylamino-butyrylamino)-butyryl (γE-γE-x70) and 3-(3-octadecanoylamino-propionylamino)-propionyl (β-Ala-β-Ala-x70). ,

[0901] Specific examples of the peptide compounds having formula (I) and formula (Ia) are compounds of SEQ ID NOs: 1-158, or salts or solvates thereof.

[0902] Specific examples of the peptide compound having formula (I) are compounds of SEQ ID NOs: 1-66, 68-70, 72-74, 76-82, 84-95, 98, 102-106, 108-158, or salts or solvates thereof.

[0903] Specific examples of the peptide compound having formula (Ia) are compounds of SEQ ID NOs: 67, 71, 75, 83, 96, 97, 99, 100, 101, 107 and 108, or a salt or solvate thereof.

[0904] In some embodiments, the compounds of the present disclosure are selected from compounds of SEQ ID NOs: 1-158, or a salt or solvate thereof.

[0905] In some embodiments, the compounds of the present disclosure are selected from compounds of any one of SEQ ID NOs: 1 to 74, 101 to 106, 115, 116, 122, 126, 127, and 149 to 158, or a salt or solvate thereof.

[0906] In some embodiments, the compounds of the present disclosure are selected from compounds of SEQ ID NOs: 75 to 100, 107 to 114, 117 to 121, 123 to 125, and 128 to 148, or a salt or solvate thereof.

[0907] In some embodiments, the compounds of the present disclosure are selected from compounds of SEQ ID NOs: 1 to 70, 72 to 74, 101 to 106, 115, 116, 122, 126, 127, and 149 to 158, or a salt or solvate thereof.

[0908] In some embodiments, the compounds of the present disclosure are selected from compounds of SEQ ID NOs: 71, 75 to 100, 107 to 114, 117 to 121, 123 to 125, and 128 to 148, or a salt or solvate thereof.

[0909] In some embodiments, the compounds of the present disclosure are selected from compounds of SEQ ID NOs: 1 to 74, 102 to 106, 122, 126, 127, and 149 to 158, or a salt or solvate thereof.

[0910] In some embodiments, the compounds of the present disclosure are selected from compounds of SEQ ID NOs: 75 to 101, 107 to 121, 123 to 125, and 128 to 148, or a salt or solvate thereof.

[0911] In some embodiments, the compounds of the present disclosure are selected from compounds of SEQ ID NOs: 1 to 74, 102 to 106, 122, 126, and 149 to 158, or a salt or solvate thereof.

[0912] In some embodiments, the compounds of the present disclosure are selected from compounds of SEQ ID NOs: 75 to 101, 107 to 121, 123 to 127, and 128 to 148, or a salt or solvate thereof.

[0913] In some embodiments, the compounds of the present disclosure are selected from compounds of SEQ ID NOs: 1 to 38, 40 to 74, 108-106, 126, 127, 149, 151, 152, and 154-158, or a salt or solvate thereof.

[0914] In some embodiments, the compounds of the present disclosure are compounds of SEQ ID NOs: 67, 71, 75, 83, 96, 97, 99, 100, 101, and 107 to 108, or salts or solvates thereof.

[0915] In some embodiments, the compounds of the present disclosure are compounds of SEQ ID NOs: 35, 66, 113, 128, 144, 146, 147, 147, 148, and 149, or salts or solvates thereof.

[0916] Table 3 shows the structures of the compounds of SEQ ID NOs: 1 to 158. Table 3: Compounds of SEQ ID NO: 1 to 158

[0917] (@2) indicates that an ester bond, a thioether bond or a disulfide bond is formed between the amino acid residues.

[0918] (§1) indicates that a lactam bond is formed between amino acid residues.

[0919] C(§3), Nmc(§3) or Abu(§3) and K[aAc](@3) indicates that a peptide bond is formed between the ε-NH2 group of K[aAc] and the C-terminus of C, Nmc or Abu.

[0920] [Ac] represents acetylation in R1 of the X1 amino acid residue or acetylation of the amino acid side chain.

[0921] The compounds disclosed herein have a binding affinity of 100 nM or less (i.e., IC 50 ≤100 nM), or 50 nM or less (i.e., IC 50 ≤50.0 nM), or 10 nM or less (i.e., IC 50 ≤10.0 nM) and even 5 nM or less (i.e., IC 50 ≤5.0nM).

[0922] As used herein, the term "activity" refers to the ability of a compound to inhibit the human interleukin-23 receptor. For example, as used herein, the term "activity" refers to the ability of a compound to stimulate STAT3 phosphorylation in cells. Sometimes, the term "potency" or "in vitro potency" may also be mentioned instead of "activity". Thus, "potency" is a measure of the ability of a compound to inhibit the interleukin-23 receptor in a cell-based assay. Numerically, it is expressed as "IC 50 The "value" is the effective concentration of the compound that inhibits the half-maximal increase in response (e.g., the formation of phosphorylation of STAT3) in a dose-response experiment.

[0923] The compounds disclosed herein have interleukin-23 receptor affinity. The term refers to the ability to bind to the interleukin-23 receptor and inhibit signal transduction pathways, leading to Th17 cell activation or other physiological effects as known in the art. For example, the interleukin-23 receptor affinity or activity of the compounds disclosed herein can be tested using the assays described in the methods, and the results are shown in Table 10 herein.

[0924] In further embodiments, the compounds disclosed herein are sufficiently chemically stable in solution at varying pH.

[0925] The compounds disclosed herein are chemically stable in solution at less than 30% loss of relative purity or in solution at less than 25% loss of relative purity at 37°C for 24 h.

[0926] The compounds disclosed herein are chemically stable in solution at less than 5% loss of relative purity or in solution at less than 2% loss of relative purity at 37°C for 24 h.

[0927] The compounds disclosed herein are chemically stable in solution at less than 5% loss of relative purity or in solution at less than 3% loss of relative purity at pH 7.4 at 37°C for 24 h.

[0928] In further embodiments, the compounds disclosed herein are sufficiently stable in the intestinal environment to exert a pharmacological effect. Peptide synthesis

[0929] The skilled person knows a variety of different methods for preparing peptides. These methods include, but are not limited to, synthetic methods and recombinant gene expression. Therefore, one method for preparing peptides is to synthesize in solution or on a solid support and then separate and purify.

[0930] A method for preparing the compounds disclosed herein is solid phase synthesis on a suitable resin. Solid phase peptide synthesis is a well-established method (see, e.g., Stewart and Young, Solid Phase Peptide Synthesis, Pierce Chemical Co., Rockford, Ill., 1984; E. Atherton and RC Sheppard, Solid Phase Peptide Synthesis. A Practical Approach, Oxford-IRL Press, New York, 1989). Solid phase synthesis is initiated by attaching the carboxyl terminus of an N-terminally protected amino acid to an inert solid support with a cleavable linker. This solid support can be any polymer that allows the coupling of the starting amino acid, for example, trityl resin, chlorotrityl resin, Wang resin or Rink resin, wherein the carboxyl group (or carboxamide for Rink resin) attached to the resin is acid-sensitive (when using the Fmoc strategy). The polymer support must remain stable under the conditions used to deprotect the α-amino group during peptide synthesis.

[0931] After the first amino acid protected at the N-terminus is coupled to the solid support, the α-amino protecting group of the amino acid is removed. The remaining protected amino acids are then coupled one by one in the order represented by the peptide sequence using a suitable amide coupling agent (e.g., BOP, HBTU, HATU or DIC (N,N'-diisopropylcarbodiimide) / HOBt (1-hydroxybenzotriazole), where BOP, HBTU and HATU are used with a tertiary amine base) or with a preformed dipeptide, tripeptide or tetrapeptide or with an amino acid building block having a modified side chain such as N-α-(9-fluorenylmethoxycarbonyl)-N-ε-(N -α'-octadecanoyl-tert-butyl ester-L-glutamic acid α'-tert-butyl ester-2-[2-[2-[[2-[2-(2-aminoethoxy)ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl)-L-lysine, (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-2-methyl-6-(tetradecanoylamino)hexanoic acid or (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-6-(hexadecanoylamino)-2-methyl-hexanoic acid. Alternatively, the released N-terminus can be functionalized with a group other than an amino acid, such as a carboxylic acid.

[0932] Typically, the reactive side chain groups of amino acids are protected with suitable blocking groups. These blocking groups are removed after the desired peptide has completed assembly. They are removed under the same conditions as the desired product is cut from the resin. Blocking groups and the procedures for introducing blocking groups can be found in Protective Groups in Organic Synthesis, 3rd edition, Greene, TW and Wuts, PGM, Wiley & Sons (New York: 1999).

[0933] In some cases, it may be necessary to have a side chain protecting group that can be selectively removed, while other side chain protecting groups remain intact. In this case, the released functional group can be selectively functionalized. For example, lysine can be protected with ivDde ([1-(4,4-dimethyl-2,6-dioxocyclohexane-1-yl subunit)-3-methylbutyl) protecting group (SRChhabra et al., Tetrahedron Lett. [Tetrahedron Express] 39, (1998), 1603), which is unstable to a base with a strong nucleophilicity, such as 4% hydrazine in DMF (dimethylformamide). Therefore, if the N-terminal amino group and all side chain functional groups are protected with acid-labile protecting groups, the ivDde group can be selectively removed using 4% hydrazine in DMF, and then the corresponding free amino group can be further modified, such as by acylation. Alternatively, lysine can be coupled to a protected amino acid, the amino group of which can then be deprotected, resulting in another free amino group that can be acylated or attached to another amino acid.

[0934] Finally, the peptide is cleaved from the resin. This can be accomplished using King's cocktail (DS King, CG Fields, GB Fields, Int. J. Peptide Protein Res. 36, 1990, 255-266) or similar cleavage mixtures known to those skilled in the art. For example, EDT can be replaced by DODT, or a mixture of TIS, water and TFA can be used. The raw material can then be purified by chromatography (e.g., preparative RP-HPLC) if necessary.

[0935] All starting materials, such as amino acids and chemicals, have been ordered from suppliers. For example, (2S)-6-(tert-butoxycarbonylamino)-2-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid was purchased from Fisher Scientific (eKat). Other suppliers are Bachem AG (Hauptstrasse 144, 4416 Bubendorf, Switzerland); Iris Biotech GmbH (Adalbert-Zoellner-Str. 1, 95615 Marktredwitz); Gyros Protein Technologies (Uppsala Science Park, Dag Hammarskjold Str. 54, SE-751 83 Uppsala, Sweden). 54, SE-751 83 Uppsala, Sweden); Thermo Fisher Scientific (168 Third Avenue, Waltham, MA USA 02451). Cyclization / lactam formation

[0936] Methods for lactam bond formation are known to those skilled in the art. Exemplary methods are given in the examples. When participating in intramolecular bonds according to the present disclosure, the amino acid residue homoserine (hSer or Br) in unbonded form can take the form of 2-aminobutyric acid (Abu).

[0937] The synthesis of Sema is described in WO 2011080102, which is incorporated by reference. Effectiveness

[0938] As used herein, the term "potency" or "in vitro potency" is a measure of the ability of a compound to inactivate the interleukin-23 receptor in a cell-based assay. Numerically, it is expressed as "IC 50 The value is the effective concentration of the compound that induces a half-maximal decrease in the response (e.g., the state of intracellular STAT3) in a dose-response experiment. Therapeutic Uses

[0939] The term "disease or disorder" refers to any pathological or unhealthy state, particularly diseases related to the immune system, such as ulcerative colitis, Crohn's disease, and psoriasis.

[0940] "Treat" or "treating" means administering a compound or composition or a combination of compounds or compositions to a subject in order to: eliminate a disease or disorder; prevent or slow a disease or disorder in a subject; inhibit or slow the development of a new disease or disorder in a subject; reduce the frequency or severity of symptoms and / or recurrences in a subject currently suffering from or previously suffering from a disease or disorder; and / or prolong, i.e., increase, the life span of a subject. For example, the term "treating" or "treatment" of a disease or disorder includes curing, shortening the duration, ameliorating, slowing or inhibiting the progression or worsening of a disease or disorder or its symptoms.

[0941] "Prevent" or "preventing" means administering a compound or composition, or a combination of compounds or compositions, to a subject to inhibit or delay the onset of a disease or disorder in the subject.

[0942] According to the present disclosure, the term "subject" means a subject to be treated, particularly a diseased subject (also referred to as a "patient"), including humans, non-human primates or other animals, particularly mammals, such as cows, horses, pigs, sheep, goats, dogs, cats, rabbits or rodents (e.g., mice, rats, guinea pigs and hamsters). In one embodiment, the subject / patient is a human.

[0943] In certain embodiments, the disclosure includes methods of inhibiting IL-23 signaling of cells, which methods include contacting IL-23 with a peptide compound disclosed herein. In certain embodiments, the cell is a mammalian cell. In a specific embodiment, the method is performed in vitro or in vivo. In some embodiments, the inhibition of IL-23 signaling can be determined by measuring changes in the level of phospho-STAT3 in the cell.

[0944] In some embodiments, inhibition of IL-23 binding to IL-23R occurs in a specific organ or tissue of the subject, such as the stomach, small intestine, large intestine / colon, intestinal mucosa, lamina propria, Peyer's patches, mesenteric lymph nodes, or lymphatic ducts.

[0945] Further provided is the use of a compound of formula (I) or (Ia) or a composition comprising a compound of formula (I) or (Ia) disclosed herein in the preparation of a pharmaceutical composition, for example, for the treatment of an autoimmune disease or an inflammatory disease.

[0946] The autoimmune or inflammatory disease may be, for example, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, psoriasis, psoriatic arthritis and hidradenitis suppurativa.

[0947] In certain embodiments, the disease or disorder is autoimmune inflammatory and related diseases and disorders, such as multiple sclerosis, asthma, rheumatoid arthritis, inflammatory bowel disease (IBD), juvenile IBD, juvenile IBD, Crohn's disease, sarcoidosis, systemic lupus erythematosus, ankylosing spondylitis (axial spondyloarthritis), psoriatic arthritis, or psoriasis. In some embodiments, the disease or disorder is psoriasis (e.g., plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, palmoplantar pustulosis, psoriasis vulgaris, or erythrodermic psoriasis), atopic dermatitis, atopic acne, ulcerative colitis, Crohn's disease, celiac disease (non-tropical sprue), enteropathy associated with seronegative arthropathy, microscopic colitis, collagenous colitis, eosinophilic gastroenteritis / esophagitis, colitis associated with radiation therapy or chemotherapy, colitis associated with innate immune diseases Colitis (such as leukocyte adhesion deficiency-1), chronic granulomatous disease, glycogen storage disease type lb, Hermansky-Pudlak syndrome, congenital leukocyte granuloma syndrome, Wiskott-Aldrich syndrome, pouchitis after proctocolectomy and ileoanal anastomosis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, primary biliary cirrhosis, virus-related enteropathy, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, uveitis, or graft-versus-host disease.

[0948] In further related embodiments, the disclosure includes methods of inhibiting gastrointestinal (GI) inflammation and / or neutrophil infiltration into the GI, the method comprising providing a peptide compound disclosed herein to a subject in need thereof. Pharmaceutical composition

[0949] The term "pharmaceutical composition" means a mixture containing ingredients that are compatible and can be administered when mixed. A pharmaceutical composition may contain one or more drugs. In addition, a pharmaceutical composition may contain carriers, buffers, acidifiers, alkalizers, solvents, adjuvants, tonicity regulators, emollients, bulking agents, preservatives, physical and chemical stabilizers, e.g., surfactants, antioxidants and other components, whether these ingredients are considered active ingredients or inactive ingredients. Examples of preservatives are benzyl alcohol or phenolic compounds, such as phenol or m-cresol.

[0950] Pharmaceutical compositions may include one or more compounds of the present disclosure and at least one pharmaceutically acceptable carrier.

[0951] A "pharmaceutically acceptable carrier" is a carrier that is physiologically acceptable (e.g., physiologically acceptable pH) while retaining the therapeutic properties of the substance with which it is administered. A pharmaceutically acceptable carrier, diluent, or excipient refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material, or formulation auxiliary of any type.

[0952] Standard acceptable pharmaceutical carriers and their formulations are known to those skilled in the art and are described, for example, in Remington: The Science and Practice of Pharmacy, (20th ed.) ed. ARGennaro AR, 2000, Lippencott Williams & Wilkins and RC Rowe et al. (eds.), Handbook of Pharmaceutical Excipients, PhP, updated May 2013. An exemplary pharmaceutically acceptable carrier is a physiological saline solution.

[0953] The term "pharmaceutically acceptable salt" means a salt of a compound disclosed herein that is safe and effective for use in mammals, for example, an acetate salt, a chloride salt, or a sodium salt.

[0954] The term "solvate" means a complex of a compound disclosed herein or a salt thereof and solvent molecules (eg, organic solvent molecules and / or water).

[0955] Acceptable pharmaceutical carriers or diluents include those used in formulations suitable for oral, rectal, nasal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal and transdermal) administration.

[0956] In certain embodiments, the compositions are administered orally, parenterally, intracisternal, intravaginal, intraperitoneal, rectally, topically (e.g., by powders, ointments, drops, suppositories, or transdermal patches), by inhalation (e.g., intranasal sprays), ocularly (e.g., intraocularly), or buccally. As used herein, the term "parenteral" refers to modes of administration, including intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous, intradermal, and intraarticular injection and infusion. Thus, in certain embodiments, the compositions are formulated for delivery by any of these routes of administration.

[0957] In certain embodiments, the pharmaceutical composition for parenteral injection comprises a pharmaceutically acceptable sterile aqueous solution or non-aqueous solution, dispersion, suspension or emulsion or sterile powder for reconstructing in a sterile injectable solution or dispersion immediately before use. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.), carboxymethyl cellulose and suitable mixtures thereof, beta cyclodextrin, vegetable oils (e.g., olive oil) and injectable organic esters (e.g., ethyl oleate). Appropriate fluidity can be maintained, for example, in the following manner: by using a coating material (e.g., lecithin), by maintaining the desired particle size in the case of a dispersion, and by using a surfactant. These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifiers and dispersants. Extended absorption of injectable drug forms can be achieved by including agents (e.g., aluminum monostearate and gelatin) that delay absorption.

[0958] In certain embodiments, the compound of the present disclosure or the pharmaceutical composition comprising the compound of the present disclosure is suspended in a sustained release matrix. As used herein, the sustained release matrix is ​​a matrix made by enzymatic or acid-base hydrolysis or by dissolving a degradable material (usually a polymer). Once entering the body, the matrix is ​​acted upon by enzymes and body fluids. The sustained release matrix is ​​desirably selected from biocompatible materials, such as liposomes, polylactide (polylactic acid), polyglycolide (glycolic acid polymer), polylactide-co-glycolide (copolymer of lactic acid and glycolic acid) polyanhydrides, poly (ortho) esters, polypeptides, hyaluronic acid, collagen, chondroitin sulfate, carboxylic acid, fatty acid, phospholipids, polysaccharides, nucleic acids, polyamino acids, amino acids (such as phenylalanine, tyrosine, isoleucine), polynucleotides, polyethylene propylene, polyvinyl pyrrolidone and silicone. An embodiment of a biodegradable matrix is ​​a matrix of one of polylactide, polyglycolide or polylactide-co-glycolide (copolymer of lactic acid and glycolic acid).

[0959] Injectable depot forms include those made by forming microencapsule matrices of the peptide compound in one or more biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters), poly(anhydrides) and (poly) glycols such as PEG. Depending on the ratio of peptide to polymer, and the nature of the particular polymer employed, the rate of release of the peptide compound can be controlled. Injectable depot formulations are also prepared by entrapping the peptide compound in liposomes or microemulsions that are compatible with body tissues.

[0960] The injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium immediately before use.

[0961] Topical administration includes administration to the skin or mucous membranes (including the surface of the lungs and eyes). Compositions for topical pulmonary administration (including those for inhalation and intranasal) can relate to solutions and suspensions in aqueous and non-aqueous preparations, and can be prepared as dry powders that can be pressurized or non-pressurized. In non-pressurized powder compositions, the active ingredient can be in finely dispersed form, and can be mixed with a pharmaceutically acceptable inert carrier of larger size, which includes, for example, particles having a size of up to 100 microns in diameter. Suitable inert carriers include sugars, such as lactose.

[0962] Alternatively, the composition can be pressurized and contain compressed gas (such as nitrogen or liquefied gas propellant). The liquefied propellant medium and indeed the total composition can be such that the active ingredient does not dissolve therein to any substantial degree. The pressurized composition can also contain a surfactant (such as a liquid or solid nonionic surfactant), or can be a solid anionic surfactant. In certain embodiments, a solid anionic surfactant in the form of a sodium salt can be used.

[0963] Another form of topical administration is administration to the eye. The peptide compounds disclosed herein can be delivered in a pharmaceutically acceptable ophthalmic vehicle so that the peptide compounds maintain contact with the ocular surface for a sufficient period of time to allow the peptide compounds to penetrate the cornea and internal areas of the eye, such as the anterior chamber, posterior chamber, vitreous body, aqueous humor, vitreous humour, cornea, iris / ciliary body, lens, choroid / retina and sclera. Pharmaceutically acceptable ophthalmic vehicles can be, for example, ointments, vegetable oils or encapsulating materials. Alternatively, the peptide compounds disclosed herein can be injected directly into the vitreous body and aqueous humor.

[0964] Compositions for rectal or vaginal administration include suppositories, which can be prepared by mixing the peptides of the disclosure with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

[0965] The peptide compounds disclosed herein can also be administered in liposomes or other lipid-based carriers. As known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by monolayer or multilayer hydrated liquid crystals dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipids capable of forming liposomes can be used. In addition to the peptide compounds disclosed herein, the compositions of the present invention in the form of liposomes can also contain stabilizers, preservatives, excipients, etc. In certain embodiments, lipids include phospholipids, including natural and synthetic phosphatidylcholine (lecithin) and serine. Methods for forming liposomes are known in the art.

[0966] Pharmaceutical compositions suitable for parenteral administration used in the present disclosure may comprise sterile aqueous solutions and / or suspensions of the peptide compounds isotonic with the blood of the recipient, typically using sodium chloride, glycerol, glucose, mannitol, sorbitol, or the like. Oral administration

[0967] One example of a mode of administration of the compounds disclosed herein or pharmaceutical compositions thereof is oral administration.

[0968] The present disclosure provides pharmaceutical compositions for oral delivery. The compositions and peptides disclosed herein can be prepared for oral administration according to any method, technique and / or delivery vehicle described herein. In addition, it will be appreciated by those skilled in the art that the peptides disclosed herein can be modified or incorporated into systems or delivery vehicles not disclosed herein, but are well known in the art and compatible with oral delivery for peptides.

[0969] In certain embodiments, the preparation for oral administration may contain an adjuvant that artificially increases the permeability of the intestinal wall (e.g., resorcinol and / or nonionic surfactants such as polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether), and / or an enzyme inhibitor that inhibits enzymatic degradation (e.g., trypsin inhibitors, diisopropyl fluorophosphate (DFF) or trasylol). In certain embodiments, the peptide compound in a solid dosage form for oral administration may be mixed with at least one additive such as sucrose, lactose, cellulose, mannitol, trehalose, raffinose, maltitol, dextran, starch, agar, alginate, chitin, chitosan, pectin, tragacanth, gum arabic, gelatin, collagen, casein, albumin, synthetic or semi-synthetic polymers or glycerides. These dosage forms

[0970] It may also contain one or more other types of additives, for example, inactive diluents, lubricants (such as magnesium stearate), parabens, preservatives (such as sorbic acid, ascorbic acid, α-tocopherol), antioxidants (such as cysteine), disintegrators, binders, thickeners, buffers, pH adjusters, sweeteners, flavoring agents or fragrances.

[0971] In some embodiments, oral dosage forms or unit doses compatible with the peptide compounds disclosed herein may include a mixture of the peptide compound and a non-drug component or excipient, as well as other non-reusable materials that may be considered as ingredients or packaging. Oral compositions may include at least one of liquid, solid, and semisolid dosage forms. In some embodiments, an oral dosage form comprising an effective amount of a peptide compound is provided, wherein the dosage form comprises at least one of a pill, tablet, capsule, gel, paste, drink, syrup, ointment, and suppository. In some cases, an oral dosage form is provided that is designed and configured to achieve delayed release of the peptide compound in the small intestine and / or colon of a subject.

[0972] In one embodiment, the oral pharmaceutical composition comprising the peptide compound disclosed herein comprises an enteric coating, which is designed to delay the release of the peptide compound in the small intestine. In at least some embodiments, a pharmaceutical composition is provided, which is included in the peptide compound disclosed herein and a protease inhibitor (such as aprotinin) in a delayed release pharmaceutical preparation. In some cases, the pharmaceutical composition of the present disclosure is included in an enteric coating soluble in gastric juice at a pH of about 5.0 or higher. In at least one embodiment, a pharmaceutical composition comprising an enteric coating is provided, which comprises a polymer with a dissociable carboxyl group, such as a cellulose derivative, including hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate and cellulose acetate trimellitate and similar derivatives of cellulose and other carbohydrate polymers.

[0973] In one embodiment, the pharmaceutical composition comprising the peptide compound disclosed herein is provided in an enteric coating designed to protect and release the pharmaceutical composition in a controlled manner in the lower gastrointestinal system of the subject and to avoid systemic side effects. In addition to the enteric coating, the peptide compound disclosed herein can be encapsulated, coated, joined or otherwise associated in any compatible oral drug delivery system or component. For example, in some embodiments, the peptide compound disclosed herein is provided in a lipid carrier system comprising at least one of a polymer hydrogel, nanoparticles, microspheres, micelles, and other lipid systems.

[0974] In order to overcome peptide degradation in the small intestine, some embodiments disclosed herein include a hydrogel polymer carrier system comprising the peptide compound disclosed herein, whereby the hydrogel polymer protects the peptide compound from proteolysis in the small intestine and / or colon. The peptide compound disclosed herein can be further formulated for compatible use with a carrier system designed to increase the dissolution kinetics of the peptide and enhance intestinal absorption of the peptide. These methods include using liposomes, micelles and nanoparticles to increase the GI tract penetration of the peptide.

[0975] Various bio-response systems can also be combined with one or more peptide compounds disclosed herein to provide pharmaceutical formulations for oral delivery. In some embodiments, the peptides disclosed herein are used in combination with bio-response systems, such as hydrogels and mucoadhesive polymers with hydrogen bonding groups (e.g., PEG, poly(methacrylic acid) acid [PMAA], cellulose, Chitosan and alginate). Other embodiments include methods for optimizing or extending the drug retention time of the peptide compounds disclosed herein, wherein the surface of the peptide compound surface is modified to contain mucoadhesive properties through hydrogen bonding, polymers with attached mucins, or / and hydrophobic interactions. According to the desired characteristics of the present disclosure, these modified peptide molecules can exhibit increased retention time of the drug in the subject. In addition, the targeted mucoadhesive system can specifically bind to receptors on the surface of intestinal cells and M cells, thereby further increasing the uptake of particles containing the peptide compound. Penetration Enhancers

[0976] Other embodiments include methods for oral delivery of peptide compounds disclosed herein, wherein the peptide compound is provided to a subject in combination with a penetration enhancer that facilitates transport of the peptide across the intestinal mucosa by increasing paracellular or transcellular permeation. Various penetration enhancers and methods for oral delivery of therapeutic agents are described in Bray den, DJ, Mrsny, RJ, 201 1. Oral peptide delivery: prioritizing the leading technologies. [Oral peptide delivery: Prioritizing leading technologies] Ther. Delivery [Therapeutic delivery] 2 (12), 1567-1573.

[0977] In certain embodiments, pharmaceutical compositions and preparations disclosed herein include peptide compounds disclosed herein and one or more penetration enhancers. Examples of absorption enhancers may include, for example, bile salts, fatty acids, surfactants (anions, cations and non-ionics) chelating agents, Zonular OT, esters, cyclodextrins, dextran sulfate, azones, crown ethers, EDTA, sucrose esters and phosphatidylcholine. Although absorption enhancers themselves are usually not carriers, they are also widely associated with other carriers to improve oral bioavailability by transporting peptides and proteins through the intestinal mucosa. Such a material can be added to the preparation as an excipient or incorporated to form non-specific interactions with the expected peptide compound.

[0978] Dietary ingredients and / or other naturally occurring substances that have been identified as promoting tight junction penetration and are generally recognized as safe (GRAS) include, for example, glycerides, acylcarnitines, bile salts, and medium-chain fatty acids. Sodium salts of medium-chain fatty acids (MCFAs) have also been proposed as permeation enhancers. The most widely studied MCFA is sodium caprate, a salt of capric acid, which comprises 2%-3% of the fatty acids in the milk fat fraction. To date, sodium caprate has been mainly used as an excipient in suppository formulations (Doktacillin TM ), for improving rectal ampicillin absorption. Compared with sodium caprate, the permeation properties of another dietary MCFA, sodium caprylate (8-carbon), have been shown to be lower in vitro. Sodium caprylate and a peptide drug were formulated together with other excipients in oil to produce an oil-based suspension (OS) with enhanced permeability (Tuvia, S. et al., Pharmaceutical Research, Vol. 31, No. 8, pp. 2010-2021 (2014)).

[0979] For example, in one embodiment, a permeation enhancer is combined with a peptide compound, wherein the permeation enhancer comprises at least one of a medium-chain fatty acid, a long-chain fatty acid, a bile salt, an amphiphilic surfactant, and a chelating agent. In certain embodiments, medium-chain fatty acid salts promote absorption by increasing the paracellular permeability of the intestinal epithelium. In one embodiment, a permeation enhancer comprising N-[(hydroxybenzoyl)amino]sodium caprate is used to form a weak non-covalent association with a peptide of the present disclosure, wherein the permeation enhancer facilitates membrane transport and further dissociates once it reaches the bloodstream. In another embodiment, a peptide compound of the present disclosure is conjugated to oligolysine, thereby increasing the cellular penetration of the peptide into various cell types. Additionally, in at least one embodiment, a non-covalent bond is provided between a peptide compound of the present disclosure and a permeation enhancer selected from the group consisting of cyclodextrin (CD) and dendrimer, wherein the permeation enhancer reduces peptide aggregation and increases the stability and solubility of peptide compound molecules.

[0980] In certain embodiments, a pharmaceutical composition or formulation comprises a peptide compound of the present disclosure and a transient permeability enhancer (TPE). The permeation enhancer and TPE can be used to increase the oral bioavailability of the peptide compound. An example of a TPE that can be used is an oil-based suspension formulation that disperses a powder containing sodium caprate and a therapeutic agent (Tuvia, S. et al., Pharmaceutical Research, Vol. 31, No. 8, pp. 2010-2021 (2014)).

[0981] In certain embodiments, a pharmaceutical composition and formulation can include a peptide compound of the present disclosure and one or more absorption enhancers, enzyme inhibitors, or mucoadhesive polymers.

[0982] In some embodiments, the peptide compounds disclosed herein are formulated in a formulation vehicle such as, for example, an emulsion, liposome, microsphere, or nanoparticle.

[0983] Other embodiments disclosed herein provide methods for treating subjects using peptide compounds disclosed herein with increased half-life. In one aspect, the disclosure provides peptide compounds having a half-life of at least several hours to one day in vitro or in vivo (e.g., when administered to human subjects), sufficient for once daily (qd) or twice daily (bid) administration of a therapeutically effective amount. In another embodiment, the peptide compound has a half-life of three days or longer, sufficient for once weekly (qw) administration of a therapeutically effective amount. In addition, in another embodiment, the peptide compound has a half-life of eight days or longer, sufficient for once every two weeks (biw) or once monthly administration of a therapeutically effective amount. In another embodiment, the peptide compound is derivatized or modified so that it has a longer half-life compared to an underivatized or unmodified peptide compound. In another embodiment, the peptide compound contains one or more chemical modifications to increase serum half-life.

[0984] When a peptide compound disclosed herein is used in at least one of the treatments or delivery systems described herein, the peptide compound can be used in pure form or, where such a form exists, in the form of a pharmaceutically acceptable salt.

[0985] The total daily dosage of the peptide compounds and compositions disclosed herein can be determined by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dosage level for any particular subject will depend on a variety of factors, including: a) the disorder being treated and the severity of the disorder; b) the activity of the specific compound being used; c) the specific composition being used; the patient's age, weight, general health, sex and diet; d) the administration time, route of administration and excretion rate of the specific peptide compound being used; e) the duration of treatment; f) drugs used in combination or concomitantly with the specific peptide compound being used, as well as similar factors well known in the medical field. Drug administration

[0986] The term "therapeutically effective amount" of a compound refers to a non-toxic amount of the compound that is sufficient to provide the desired effect. The amount of the compound of formula (I) or (Ia) required to achieve the desired biological effect depends on many factors, such as the specific compound selected, the intended use, the mode of administration, and the clinical condition of the patient. One of ordinary skill in the art can determine the appropriate "effective" amount in any individual case using routine experiments. For example, a "therapeutically effective amount" of a compound of formula (I) or (Ia) is about 0.01 to 50 mg / dose, or 0.02 to 1 mg / dose, or, for example, from 0.0001 to 300 mg / kg body weight per day, or from 1 to 300 mg / kg body weight per day.

[0987] In the case of parenteral application, it may be advantageous if corresponding formulations contain at least one antimicrobial preservative in order to inhibit the growth of microorganisms and bacteria between administrations. Administration units, packaging, pen devices and administration

[0988] One or more compounds disclosed herein can be prepared for use in a suitable pharmaceutical composition. Suitable pharmaceutical compositions can be in the form of one or more administration units.

[0989] The compositions may be prepared by any suitable pharmaceutical method which includes the step of contacting one or more compounds disclosed herein with a carrier (which may consist of one or more additional ingredients).

[0990] Administration units may be, for example, capsules, tablets, dragees, granules, sachets, drops, solutions, suspensions, lyophilisates, and powders, each containing a defined amount of one or more compounds disclosed herein.

[0991] The above-mentioned each administration unit (administration unit) of one or more compounds disclosed herein or pharmaceutical compositions disclosed herein can be provided in a package that is easy to transport and store. The administration unit is packaged in a standard single-dose or multi-dose package, and its form, material and shape depend on the type of unit prepared.

[0992] In some embodiments, the disclosure provides a kit comprising a compound of formula (I) or (Ia) or a physiologically acceptable salt or solvate thereof in any stereoisomeric form, and a set of instructions related to the use of the compound for the methods described herein. In some embodiments, the kit further comprises one or more inert carriers and / or diluents. In some embodiments, the kit further comprises one or more other pharmacologically active compounds, such as those described herein.

[0993] In certain embodiments, the administration unit may be provided together with an application device, such as a syringe, an injection pen or an auto-injector. Such a device may be provided separately from the pharmaceutical composition or pre-filled with the pharmaceutical composition.

[0994] A "pen-type injection device", often referred to simply as an "injection pen", is typically an injection device having an elongated shape similar to a fountain pen used for writing. Although such pens typically have a tubular cross-section, they can easily have different cross-sections, such as triangular, rectangular or square or any variation around these geometric shapes. In general, a pen-type injection device includes three main elements: a cartridge portion, including a cartridge typically contained within a housing or holder; a needle assembly connected to one end of the cartridge portion; and a dosing portion connected to the other end of the cartridge portion. The cartridge, also commonly referred to as an "ampule", typically includes a reservoir filled with a drug, a removable rubber-type stopper or plug located at one end of the cartridge reservoir, and a top with a pierceable rubber seal located at the other end of the cartridge reservoir (typically a retracted end). The rubber seal is typically secured in place using a curled annular metal band. Although the cartridge housing is typically made of plastic, the cartridge reservoir has historically been made of glass. Combination therapy

[0995] In some embodiments, the method disclosed herein includes providing a peptide compound disclosed herein (i.e., a first therapeutic agent) in combination with a second therapeutic agent to a subject in need. In certain embodiments, before and / or simultaneously with and / or after the peptide compound is administered to the subject, the second therapeutic agent is provided to the subject. In certain embodiments, the second therapeutic agent is an anti-inflammatory agent. In certain embodiments, the second therapeutic agent is a non-steroidal anti-inflammatory drug, a steroid, or an immunomodulator.

[0996] In another embodiment, the method comprises administering to the subject a third therapeutic agent.In certain embodiments, the second therapeutic agent is an antibody that binds IL-23 or IL-23R.

[0997] Combinations of active ingredients are particularly useful for synergistic improvement. They can be applied by administering the active ingredients separately to the patient or in the form of a combination product in which multiple active ingredients are present in one pharmaceutical preparation. The amount of the compound disclosed herein and one or more other pharmaceutically active ingredients and the relative administration time will be selected to achieve the desired combined therapeutic effect. The administration of the combination can be carried out simultaneously in the following forms: (1) a single pharmaceutical composition containing all pharmaceutically active ingredients; or (2) separate pharmaceutical compositions, each of which contains at least one pharmaceutically active ingredient. Alternatively, the combination can be administered separately in a sequential manner, wherein one therapeutic agent is administered first and then another therapeutic agent is administered, or vice versa. When the active ingredients are administered by separate administration of the active ingredients, this can be performed simultaneously or sequentially.

[0998] Other active substances suitable for such combinations include, for example, those which enhance the therapeutic effect of one or more active substances for one of the mentioned indications and / or allow a reduction in the dosage of one or more active substances.

[0999] In another aspect, the disclosure relates to the use of a compound according to the disclosure or a physiologically acceptable salt thereof in combination with at least one active substance as a combination partner for the preparation of a medicament suitable for the treatment or prevention of a disease or condition that can be influenced by binding to the receptor interleukin-23 and modulating the activity. This is, for example, a disease in the context of the immune system, such as one of the diseases or conditions listed above, such as irritable bowel syndrome, Crohn's disease, psoriasis and ulcerative colitis or its complications.

[1000] The combined use of a compound according to the present disclosure or a physiologically acceptable salt thereof and one or more active substances may be carried out simultaneously, separately or sequentially.

[1001] The combined use of a compound according to the present disclosure or a physiologically acceptable salt thereof with another active substance can be carried out simultaneously or staggered in time, but for example within a short time interval. If administered simultaneously, the two active substances are given to the patient together.

[1002] Therefore, in another aspect, the disclosure relates to a medicament comprising a compound according to the disclosure or a physiologically acceptable salt of the compound and at least one active substance as described above as a combination partner, optionally together with one or more inert carriers and / or diluents.

[1003] The compounds according to the present disclosure or their physiologically acceptable salts or solvates and the further active substances in combination therewith may be present together in one preparation, such as a tablet, capsule or solution, or separately in two identical or different preparations, such as a so-called kit of parts.

[1004] Another subject matter disclosed herein is a process for preparing compounds of formula (I) or (Ia) and their salts and solvates, by which these compounds can be obtained and which is exemplified below. [Example] method

[1005] The following abbreviations are used:

[1006] AA Amino Acid

[1007] ACN Acetonitrile

[1008] Aib α-amino-isobutyric acid

[1009] Boc tert-Butyloxycarbonyl

[1010] tBu tert-butyl

[1011] CV column volume

[1012] DCM Dichloromethane

[1013] DIC N,N'-Diisopropylcarbodiimide

[1014] DIPEA N,N-Diisopropylethylamine

[1015] DMF Dimethylformamide

[1016] DODT 3,6-dioxa-1,8-octanedithiol

[1017] DPBS Dulbecco's Phosphate Buffered Saline

[1018] EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide

[1019] EDT Ethylenedithiol

[1020] Fmoc Fluorenylmethoxycarbonyl

[1021] g

[1022] HATU O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate

[1023] HBTU 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyl-uronium hexafluorophosphate

[1024] HOAt 1-Hydroxy-7-azabenzotriazole

[1025] HOBt 1-Hydroxybenzotriazole

[1026] HPLC High Performance Liquid Chromatography

[1027] LC / MS Liquid chromatography / mass spectrometry

[1028] mM millimole

[1029] Mmt monomethoxy-trityl

[1030] na Not available

[1031] nd Undetermined

[1032] nM nanomolar

[1033] PBS Phosphate buffered saline

[1034] Pfp 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl

[1035] PyBOP Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate

[1036] tBu tert-butyl

[1037] TFA Trifluoroacetic acid

[1038] Trt Trityl / Triphenylmethyl

[1039] TSTU N,N,N′,N′-Tetramethyl-O-(N-succinimidyl)uronium tetrafluoroborate

[1040] UPLC Ultra-Performance Liquid Chromatography

[1041] UV Material

[1042] Different Rink-amide resins (e.g. 4-(2',4'-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-norleucylaminomethyl resin, Merck Biosciences; 4-[(2,4-dimethoxyphenyl)(Fmoc-amino)methyl]phenoxyacetamidomethyl resin, Agilent Technologies) were used to synthesize peptide amides with loadings in the range of 0.2-0.7 mmol / g.

[1043] Fmoc-protected natural amino acids were purchased from Protein Technologies Inc., Senn Chemicals, Merck Bioscience, Novabiochem, Iris Biotech, Bachem, Chem-Impex International, or MATRIX Innovation. The following standard amino acids were used throughout the synthesis: Fmoc-L-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-L-Asn(Trt)-OH, Fmoc-L-Asp(OtBu)-OH, OH, Fmoc-L-Gln(Trt)-OH, Fmoc-L-Glu(OtBu)-OH, Fmoc-L-Leu-OH, Fmoc-L-Lys(Boc)-OH, Fmoc-D-Lys(Boc)-OH, Fmoc-L-Phe-OH, Fmoc-L-Thr(tBu)-OH, Fmoc-L-Trp(Boc)-OH, Fmoc-L-Tyr(tBu)-OH, and Fmoc-Cys(Trt)-OH.

[1044] In addition, the following special amino acids were purchased from the same suppliers as above: Fmoc-L-1-Nal-OH, Fmoc-L-2-Nal-OH, Fmoc-L-Phe(2-Ae-Boc)-OH(Fmoc-L-Yae(Boc)-OH), Fmoc-L-Phe(Me)-OH(Fmoc-L-Yme-OH), Fmoc-Yde-OH, Fmoc-L-Orn(Boc), Fmoc-L-Trp(Me)-OH, Fmoc-L-Agb(Pbf)-OH, Fmoc-Ahx-OH, Fmoc-Aoa-OH, Fmoc-Apt-OH, Fmoc-Bal-OH, Fmoc-Hme-OH, Fmoc-Kme(Boc)-OH, Fmoc-L-Lys(Ac)-OH, ε-Fmoc-L-Lys(αAc)-OH, Fmoc-Mkdm-OH, Fmoc-Mle-OH, Fmoc-Mep-OH, Fmoc-Mly(Boc)-OH, ε-Fmoc-Ndmk-OH, Fmoc-Nmapt-OH, Fmoc-Nmc(Trt)- OH, Fmoc-Nmd(O-tBu)-OH, Fmoc-Nme(O-tBu)-OH, Fmoc-Nmha-OH, Fmoc-Nmn(Trt)-OH, Fmoc-Pal-OH, Fmoc-Pen(Trt)-OH, Fmoc-Pyal-OH, Fmoc-Sar-OH and Fmoc-Thp-OH.

[1045] In addition, the dicarboxylic acid Dad was purchased from the same supplier as mentioned for the amino acid in the form of the di-N-hydroxysuccinimide ester: Dad (di-O-Succ) and used. Synthesis of Mkdm

[1046] 470mg (2S) -6- (tert-butoxycarbonylamino) -2- (9H- fluorenes -9- ylmethoxycarbonylamino) caproic acid was treated with 5mL TFA for two hours. Then, 100mL water was added, and the solution was frozen and lyophilized. The residue was absorbed with 10mL methanol. Then, 129mg DIPEA, 126mg NaCNBH3 and 50mg formaldehyde were added, and the mixture was stirred for one hour. The product was purified by chromatography to obtain 230mg yield. Analytical UPLC / UV / MS Method

[1047] Method A: Detection at 214 nm

[1048] HPLC: Waters i-Class UPLC

[1049] Column: Waters ACQUITY CSH TM C18 1.7μm (75x 2.1mm), 50℃ Solvent: H2O+0.05% TFA: ACN+0.045% TFA (flow rate: 0.7ml / min)

[1050] Gradient: 95:5 (0 min) to 95:5 (1 min) to 20:80 (12 min) to 5:95 (12.5 min) to 5:95 (13.5 min) to 95:5 (14 min) to 95:5 (16 min)

[1051] With mass analyzer: Waters Xevo G2-XS QTof, electrospray cation mode, mass range: 300-3200 m / z, resolution mode

[1052] Method B: Detection at 214 nm

[1053] HPLC: Agilent 1290Infinity II UPLC

[1054] Column: Waters ACQUITY CSH TM C18 1.7μm (150x 2.1mm), 50℃ Solvent: H2O+0.05% TFA: ACN+0.035% TFA (flow rate: 0.5ml / min)

[1055] Gradient: 80:20 (0 min) to 80:20 (3 min) to 25:75 (23 min) to 2:98 (23.5 min) to 2:98 (30.5 min) to 80:20 (31 min) to 80:20 (37 min)

[1056] With mass analyzer: Agilent 6230 Accurate Mass TOF, Agilent Dual Jet Stream ESI+, mass range: 300-3200m / z, extended dynamic range mode (2Ghz)

[1057] Method C: Detection at 214 nm

[1058] HPLC: Agilent 1290Infinity II UPLC

[1059] Column: Waters ACQUITY CSH TM C18 1.7μm (150x 2.1mm), 50℃ Solvent: H2O+0.05% TFA: ACN+0.035% TFA (flow rate: 0.5ml / min)

[1060] Gradient: 95:5 (0 min) to 95:5 (3 min) to 40:60 (23 min) to 2:98 (23.5 min) to 2:98 (30.5 min) to 95:5 (31 min) to 95:5 (37 min)

[1061] With mass analyzer: Agilent 6230 Accurate Mass TOF, Agilent Dual Jet Stream ESI, mass range: 300-3200m / z, extended dynamic range mode (2Ghz)

[1062] Method D: Detection at 220 nm

[1063] HPLC: Shimadzu Nexera X2

[1064] Column: Waters ACQUITY BEH TM C18 1.7μm (100x 2.1mm), 40℃ Solvent: H2O+0.1%TFA: ACN+0.1%TFA (flow rate: 0.5ml / min)

[1065] Gradient: 95:5 (0 min) to 95:5 (3 min) to 40:60 (23 min) to 2:98 (23.5 min) to 2:98 (30.5 min) to 95:5 (31 min) to 95:5 (37 min)

[1066] With mass analyzer: LCMS2020, DL-temperature: 250C, nebulizer gas flow: 1.5L / min, detector voltage: 1.4KV

[1067] Method E: Detection at 214 nm

[1068] HPLC: Agilent 1290Infinity II UPLC

[1069] Column: Waters ACQUITY CSH TM C18 1.7μm (150x 2.1mm), 50℃ Solvent: H2O+0.05% TFA: ACN+0.035% TFA (flow rate: 0.5ml / min)

[1070] Gradient: 99:1 (0 min) to 99:1 (3 min) to 70:30 (18 min) to 2:98 (18.5 min) to 2:98 (25.5 min) to 99:1 (26 min) to 99:1 (32 min)

[1071] With mass analyzer: Agilent 6230 Accurate Mass TOF, Agilent Dual Jet Stream ESI, mass range: 300-3200m / z, extended dynamic range mode (2Ghz)

[1072] Method F: Detection at 214 nm

[1073] HPLC: Agilent 1290Infinity II UPLC

[1074] Column: Waters ACQUITY CSH TM C18 1.7μm (150x 2.1mm), 50℃ Solvent: H2O+0.05% TFA: ACN+0.045% TFA (flow rate: 0.5ml / min)

[1075] Gradient: 95:5 (0 min) to 95:5 (3 min) to 80:20 (25 min) to 2:98 (25.5 min) to 2:98 (30.5 min) to 95:5 (31 min) to 95:5 (35 min)

[1076] With mass analyzer: Agilent 6230 Accurate Mass TOF, Agilent Dual Jet Stream ESI, mass range: 300-3200m / z, extended dynamic range mode (2Ghz)

[1077] Method G: Detection at 214 nm

[1078] HPLC: Agilent 1290Infinity II UPLC

[1079] Column: Waters ACQUITY CSH TM C18 1.7μm (150x 2.1mm), 50℃ Solvent: H2O+0.05% TFA: ACN+0.045% TFA (flow rate: 0.5ml / min)

[1080] Gradient: 95:5 (0 min) to 95:5 (3 min) to 80:20 (30 min) to 2:98 (30.5 min) to 2:98 (34.5 min) to 95:5 (35 min) to 95:5 (40 min)

[1081] With mass analyzer: Agilent 6230 Accurate Mass TOF, Agilent Dual Jet Stream ESI, mass range: 300-3200m / z, extended dynamic range mode (2Ghz) General Preparative HPLC Purification Procedure

[1082] The crude peptide compound was Purification is carried out on a purifier system, Jasco semiprep HPLC system, Waters automatic purification system, Agilent 1100HPLC system or similar HPLC system. According to the amount of crude peptide to be purified, a preparative RP-C18-HPLC column of different sizes and different flow rates is used, for example, the following column is used: Waters XSelect CSH C18OBD Prep 5μm 30x250 mm, Waters SunFire C18 OBD Prep 5μm 30x250 mm, WatersSunFire C18 OBD Prep 5μm 50x150 mm, and Phenomenex Luna Prep C18 5μm 21.2x250mm. Acetonitrile (B) and water+0.1% TFA (A) or water+0.1% TFA (A) are used as eluents. The fractions containing the product are collected and lyophilized to obtain a purified product, usually a TFA salt.

[1083] Alternatively, the peptide compound can be separated as acetate via the following procedure: the peptide compound is dissolved in water and the solution is adjusted to pH 7.05 with NaHCO3. Then, the acetate salt is separated using RP Kinetex 21, 2x250 mm (column volume CV 88 ml, 5 μm, C18, 100A, Avant 25) Purify the dissolved compound: Equilibrate the column with solvent A (3x CV), inject the compound, and then wash with a mixture of solvent A (95%) and solvent B (5%) for 3CV. Then, run a gradient solvent A:B (95:5) to A:B (20:80) in 15CV. Collect the purified peptide and lyophilize. General Synthesis of Peptide Compounds Solid Phase Peptide Synthesis

[1084] Solid phase peptide synthesis was performed on a Prelude peptide synthesizer (Protein Technologies) or similar automated synthesizer using standard Fmoc chemistry and HBTU / DIPEA or HATU / DIPEA activation. DMF was used as solvent.

[1085] Deprotection: 20% piperidine / DMF for 2 x 2.5 min.

[1086] Wash: 7x DMF.

[1087] Coupling: 5 / 5 / 13 200 mM AA / 500 mM HBTU in DMF / 2M DIPEA in NMP 2x for 20 min. Wash: 5x DMF.

[1088] All standard couplings were activated using HBTU / DIPEA.

[1089] For N-terminally acetylated peptides, the N-terminal Fmoc protecting group was removed and the peptide was treated twice with 10% acetic anhydride and DIPEA solution for 20 minutes under shaking.

[1090] Peptide was cleaved from the resin using King's cleavage mixture consisting of 82.5% TFA, 5% phenol, 5% water, 5% thioanisole and 2.5% EDT or a modified cleavage mixture consisting of 82.5% TFA, 5% phenol, 5% water, 5% thioanisole and 2.5% DODT. The crude peptide was then precipitated in ether or diisopropyl ether, centrifuged and lyophilized. Peptide was analyzed by analytical HPLC and examined by ESI mass spectrometry. As described in the HPLC section, the crude peptide was purified by conventional preparative RP-HPLC purification procedures. Peptide synthesis of PyEA at position X13

[1091] In the case of PyEA at position X13, Wang resin was used. Solid phase synthesis started with the C-terminal attachment of the X12 amino acid to the resin, followed by construction of the sequence on the resin, cleavage of the peptide from the resin, and subsequent cyclization.

[1092] The free C-terminal carboxylic acid of the peptide was treated with TSTU (1 eq.), DIPEA (2 eq.) in DMF for 1 hour. PyEA (1 eq.) was then added to the solution to obtain the desired product. The mixture was purified by chromatography as described in the UPLC section. Peptide synthesis using dicarboxylic acid (Dad) at position X1

[1093] The purified peptide was dissolved in DMF. 10 eq. of DiPEA was added, followed by 0.95 eq. of di-OSu-ester in DMF, added dropwise, and mixed at room temperature for 5 min. The mixture was then purified by chromatography. Synthesis of peptides according to formula (Ia) Synthesis of compound SEQ ID NO:67

[1094] Synthesis of Fmoc-Mly-Palm-OH

[1095] 31 g of (2S)-6-(tert-butoxycarbonylamino)-2-(9H-fluorene-9-ylmethoxycarbonylamino)-2-methyl-hexanoic acid was dissolved in 50 mL of TFA (90%). Then, 1000 mL of water was added and the solution was freeze-dried. The residue was taken up in 150 mL of DMF and 10.5 g of DIPEA was added followed by 9.6 g of (2,5-dioxopyrrolidin-1-yl) hexadecanoate. After stirring at room temperature for one hour, the solution was concentrated in vacuo, 500 mL of water was added and the mixture was freeze-dried. The residue was purified by preparative HPLC to obtain the desired product (16 g).

[1096] This amino acid derivative was used at position X10 during SPPS in the same manner as conventional amino acids and the peptide was obtained as described for the general SPPS synthesis method. Synthesis of compound Seq ID No.71

[1097] The synthesis of Sema is described in WO 2011080102, which is incorporated by reference.

[1098] For the Sema side chain, Fmoc-protected lysine (1 eq.) and 1000 mg (1 eq.) of tert-butyl 18-oxo-18-[[rac-(1S)-1-tert-butoxycarbonyl-4-[2-[2-[2-[2-[2-[2-(2,5-dioxopyrrolidin-1-yl)oxy-2-oxo-ethoxy]ethoxy]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-4-oxo-butyl]amino]octadecenoate (i.e., succinyl) were used. 8-Oxo-18-[[(1S)-1-carboxy-4-[2-[2-[2-[2-[2-(carboxymethoxy)ethoxy]ethylamino]-2-oxo-ethoxy]ethoxy]ethylamino]-4-oxo-butyl]amino]octadecanoic acid activated with imide ester, wherein the glutamic acid carboxyl group and the terminal carboxyl group are protected as tert-butyl ester) was treated with TSTU (1.5 eq.) and DIPEA (4 eq.) in DMF (30 mL) and stirred for 15 min. The solution was concentrated in vacuo, water (100 mL) was added and lyophilized.

[1099] The derived amino acid was used in SPPS. The cysteine ​​at position X2 and X7 was used in the form of Fmoc-Cys(Mmt)-OH. The resin was rinsed with dichloromethane and then treated with a methanol solution of iodine (5 equivalents) (16 mg / mL). After 30 minutes, the iodine residue was removed with ascorbic acid to obtain the oxidation product. After rinsing with dichloromethane (100 mL), the Fmoc protecting group was cleaved by swelling the resin with DMF (50 mL) and adding piperidine (8 equivalents, 40 mL) for 10 minutes. This procedure was repeated once.

[1100] The peptide (0.1 mmol) was then cleaved from the resin with 100 mL of Kings mixture (85 mL of TFA / 5.355 g of phenol / 5 mL of H2O / 5 mL of thioanisole / 2.5 mL of ethanedithiol) at room temperature for 3 hours. The dissolved peptide was poured into cold ether (700 mL). The precipitated peptide was centrifuged and washed with ether (800 mL). The suspension was filtered and the solid peptide was dried under vacuum for 1 hour. The peptide was then dissolved in 600 mL of water / acetic acid 99 / 1 (1 hour) and lyophilized. The residue was purified by preparative HPLC.

[1101] 30 mg of dry peptide was dissolved in 10 mL of DMF and 10 equivalents of diisopropylethylamine were added. 0.95 equivalents of disuccinimidyl succinate were added and stirred at room temperature for 1 hour. The solution was concentrated and purified by preparative HPLC to give the desired product (16 mg). Peptide cyclization Disulfide cyclization

[1102] In the case of peptides with two sulfhydryl moieties, the compound was suspended (partially dissolved) in acetonitrile / water (2 mg / mL), and the mixture was treated dropwise with a solution of acetic acid / iodine (5 mL / 80 mg) until the solution had a bright yellow color. Then, ascorbic acid (1.7 g dissolved in 100 mL of water) was added until the yellow color disappeared.

[1103] The solution was diluted with water and lyophilized. The crude peptide was purified by conventional preparative RP-HPLC purification procedures as described in the HPLC methods section. The fractions containing the pure product were then freeze-dried on a freeze dryer. Lactam cyclization

[1104] Peptide cyclization was then performed under an argon atmosphere.The peptide was dissolved in DMF, then 10 equivalents of DIPEA, 3 equivalents of HOAT and 2 equivalents of EDC were added and the reaction was stirred at room temperature overnight.

[1105] Following the general Fmoc-SPPS procedure, peptides containing free thiols such as cysteine, homocysteine ​​(hCys), and homoserine (OTBDMS) were assembled on Rink Amide-MBHA resin. Cyclization via thioether formation (X2 is Abu and X7 is Cys)

[1106] In order to form thioether, mono-methoxy-trityl (Mmt) protected cysteine ​​was used. The MMT group was cut by using 2% TFA and 0.5% TIPS in dichloromethane (DCM) for 15 minutes. The procedure was repeated twice. The resin was washed three times with DCM. Chlorination was carried out at room temperature with triphenylphosphine dichloride (6 equivalents) together with pinene (6 equivalents) and thioanisole (4 equivalents) scavengers for 4 hours. By treating with cutting reagents 90% trifluoroacetic acid, 5% water, 2.5% 1,2-ethanedithiol, 2.5% triisopropylsilane, the peptide was cut from the resin. The cut peptide was precipitated in cold diethyl ether and then washed twice with ether. The filtrate was poured off and the cold ether of the second aliquot was added, and the procedure was repeated. The crude peptide was dissolved and filtered in a solution of acetonitrile: water (7:3, with 1% TFA) to obtain the desired uncyclized crude peptide. Crude peptides with free thiols (e.g., Cys, hCys, (D)Cys, or (D)hCys) and alkyl halides (hSer(Cl)) at positions X2 and X7 or X7 and X2 were dissolved in 0.1 M TRIS buffer (pH 8.5). Cyclization was performed overnight at room temperature. The solvent mixture was then purified by first diluting it twice with water and then loading it onto a reverse phase HPLC machine. The fractions containing the pure product were then freeze dried on a freeze dryer. Lactam cyclization

[1107] Alternatively, the peptide is dissolved in DMF, cooled to 0°C, and then 20 equivalents of NaHCO, 3 equivalents of HOAT, and 2.5 equivalents of EDC.HCl are added. The reaction is stirred and allowed to slowly equilibrate to room temperature overnight. The NaHCO is filtered under gravity, and the soluble fraction is dried under rotary evaporation. The crude cyclic peptide is dissolved in ACN: water and freeze-dried. The desired cyclic peptide product is isolated by conventional preparative RP-HPLC purification procedures.

[1108] In the case of Yae in the sequence, after cleavage from the resin with King cleavage mixture and (if applicable) disulfide ring closure under the above conditions, the N-terminus remained Fmoc-protected and the deprotected Yae portion was protected with BOC-OSu (2 equiv.) and diisopropyl-ethylamine in DMF. The N-terminal Fmoc group was then cleaved with piperidine (20 equiv.). After post-treatment and purification with RP-HPLC, the peptide was cyclized. Finally, the BOC protecting group was cleaved with TFA (50 equiv.). The desired cyclic peptide product was isolated by conventional preparative RP-HPLC purification procedures. Cyclization with succinaldehyde or 4-oxo-butyric acid (X1 is Buty or Butyl)

[1109] After cutting from the resin and purifying by HPLC, the freeze-dried peptide was dissolved in methanol. Sodium cyanoborohydride (1 equivalent) and DIPEA (1 equivalent) were added and the mixture was stirred for 16 hours. In the case of succinaldehyde, one equivalent of succinaldehyde was added together with DIPEA. The solvent was evaporated and the residue was purified by HPLC and freeze-dried to obtain the desired peptide. Peptides with Pen at X2 and Pen or Cys at X7

[1110] The following peptide compounds, wherein Cys in position X2 or in positions X2 and X7 is replaced by Pen (Pen peptide compounds), were prepared as described for the compounds of the present disclosure. Table 4: Peptide compounds with Pen at X2 and X7

[1111] (@) indicates the formation of an ester, thioether or disulfide bond between amino acid residues.

[1112] (§) indicates the formation of a lactam bond between amino acid residues.

[1113] By these methods, compounds with SEQ ID NOs: 1 to 74, 101 to 106, 115, 116, 122, 126, 127 and 149 to 158 were obtained, and compounds with SEQ ID NOs: 75 to 101, 107 to 121, 123 to 125, 127 to 148 were obtainable. Representative structures are shown in Table 5. Table 5: Representative structures of peptide compounds disclosed herein Table 6: List of synthetic peptides and comparison of calculated and measured molecular weights

[1114] na: not available Peptide solubility test at different pH

[1115] Prior to measuring the solubility of synthetic peptide batches, their purity was determined by UPLC / MS (Method BG).

[1116] For solubility testing, the target concentration was 1 mg pure compound / ml. Therefore, solutions of solid samples were prepared in the buffer system with a compound concentration of 1 mg / mL. Solid samples were obtained by drying aliquots of dimethyl sulfoxide stock solutions using a Thermo Speedvac vacuum centrifuge. The drying time was 3 hours.

[1117] Solubility buffer system A) 50 mM HCl pH 1.2

[1118] Solubility buffer system B) 50 mM phosphate buffer pH 6.5

[1119] Solubility buffer system C) 50 mM phosphate buffer pH 7.4

[1120] Solubility buffer system D) 50 mM phosphate buffer pH 9.0

[1121] UPLC-UV (method A) was performed after 2 hours of gentle stirring of the filtered (0.45 μm filter plate) solution obtained by centrifugal forced filtration at 1500 RCF (relative centrifugal acceleration) for 10 min.

[1122] Solubility was determined by comparing the UV peak area of ​​a 2 μL injection of a 1:5 diluted buffer sample to a standard curve of DMSO reference samples of known concentrations diluted in DMSO. The calculation took into account the different extinction coefficients.

[1123] The results are shown in Table 7. Table 7: Solubility of peptides in buffered formulations

[1124] na: not available Chemical stability assessment of peptides

[1125] Prior to chemical stability measurements, the purity of the peptide batches was determined by UPLC / MS (Method BG). The target concentration was 1 mg / ml pure compound. Based on the previously determined purity %, solutions of the solid samples were prepared in the following buffer systems with a compound concentration of approximately 1 mg / ml:

[1126] Solubility buffer system A) 50 mM HCl pH 1.2 + acetonitrile (1:1)

[1127] Solubility buffer system B) 50 mM phosphate buffer pH 6.5 + acetonitrile (1:1)

[1128] Solubility buffer system C) 50 mM phosphate buffer pH 7.4 + acetonitrile (1:1)

[1129] The prepared solutions were stored at 2°C and 37°C for 24 hours. After this time course, the samples were centrifuged at 2500 RCF for 15 min to produce a 1:5 diluted supernatant. 2 μl of the diluted solution was then analyzed by UHPLC-UV.

[1130] Chemical stability was assessed by relative purity loss calculated by the following formula:

[1131] [(Purity after 0 hours at 37°C) - (Purity after 24 hours at 37°C)] / (Purity after 0 hours at 37°C)] * 100%

[1132] Purity was calculated as follows: [(peak area peptide) / (total peak area)]*100%.

[1133] The results are shown in Table 8. Table 8: Chemical stability of peptides in buffered formulations (relative purity loss) Protease stability assessment of peptides

[1134] Studies were conducted in simulated intestinal fluid (SIF) and simulated gastric fluid (SGF) to evaluate the gastric stability of the peptide compounds disclosed herein.

[1135] For clarification, the term "pepsin-SGF" refers to a solution of simulated gastric fluid containing pepsin, while "SGF medium" refers to a solution of simulated gastric fluid without pepsin. Pepsin-SGF was prepared by dissolving 320 mg of pepsin (Merck Millipore) in 100 mL of SGF medium concentrate (ProSense).

[1136] Similarly, the term "pancreatic enzyme-SIF" refers to a solution of simulated intestinal fluid containing pancreatic enzymes, while "SIF medium" refers to a solution of simulated intestinal fluid without pancreatic enzymes.

[1137] Pancreatin-SIF was prepared by dissolving 1 mg of pancreatin (MP Biomedicals) in 10 mL of SIF medium concentrate (Persun).

[1138] The peptides were first dissolved in 0.01 HCl (+ / - 10% DMSO) at a stock concentration of 1 mM and then further diluted with water to a stock concentration of 20 μM. The final peptide concentration in the incubation was 1 μM.

[1139] 4 μL of 20 μM peptide stock solution was added to 76 μL of pepsin-SGF buffer and incubated at 37°C. At each time point (0, 60, 120 and 240 minutes), the reaction was quenched by adding 80 μL of ethanol (0.1% HCOOH). The sample was centrifuged for 20 minutes, and an aliquot of 100 μL of supernatant was transferred to a LoBind-MTP plate and analyzed by LCMS / MS. The peak area response of each test compound at each time point was calculated. As an internal reference, the peak area response of the same test compound at T0 was calculated. The remaining percentage at each time point was calculated based on the peak area response ratio of the test compound at T0. Time 0 was set to 100%, and all subsequent time points were calculated relative to time 0.

[1140] 4 μL of 20 μM peptide stock solution was added to 76 μL of pepsin-SGF buffer and incubated at 37°C. At each time point (0, 60, 120 and 240 minutes), the reaction was quenched by adding 80 μL of ethanol (0.1% HCOOH). The sample was centrifuged for 20 minutes, and an aliquot of 100 μL of supernatant was transferred to a LoBind-MTP plate and analyzed by LCMS / MS. The peak area response of each test compound at each time point was calculated. As an internal reference, the peak area response of the same test compound at T0 was calculated. The remaining percentage at each time point was calculated based on the peak area response ratio of the test compound at T0. Time 0 was set to 100%, and all subsequent time points were calculated relative to time 0. Table 9: Protease stability in simulated gastric fluid (FaSSGF) and simulated intestinal fluid (FaSSIF) expressed as the remaining percentage of peptide

[1141] na: not available Determination of human IL23R-specific antagonists

[1142] The antagonism of the compounds to human interleukin-23 receptor antagonist was determined by ELISA.

[1143] The 384-well plate was coated with 50 μl / well of human IL23 at a final concentration of 1 μg / ml and incubated overnight at 4°C. The wells were washed 3 times with 80 μl of wash buffer and blocked with 80 μl of blocking buffer at room temperature for 60 minutes and washed again. 20 μl of serially diluted test peptides were added to each well, followed by 20 μl of recombinant human IL-23R-Fc chimera at a final concentration of 0.1 μg / ml. The plate was incubated at room temperature for 60 minutes. After the wells were washed, the bound IL23R-Fc was detected with goat anti-human IgG1-HRP antibody. The signal was visualized with QuantaBlu fluorescent peroxidase substrate. Selectivity assay for IL23R-specific antagonists

[1144] For the selectivity of IL23R antagonist peptide binding to human IL12Rβ1, recombinant human IL-12Rβ1-Fc was used for ELISA assay.

[1145] For selectivity of IL23R antagonist peptide binding to mouse IL23R, recombinant mouse IL-23R-Fc chimera was used, and bound mouse IL23R-Fc was detected with goat anti-mouse IgG1-HRP antibody. HEKBLUE TM IL-23-induced STAT3 signaling in IL-23 cells

[1146] HEK-Blue TM IL-23 cells (Invivogen) were designed to detect bioactive human (hIL-23) and murine IL-23 (mIL-23) by monitoring activation of the STAT3 pathway. IL-23 and its receptor were expressed in HEK-Blue TM Binding of IL-23 on the cell surface triggers a signaling cascade leading to STAT3 activation and subsequent production of secreted embryonic alkaline phosphatase (SEAP). This can be done using QUANTI-Blue TM Solution (SEAP detection reagent) was easily evaluated.

[1147] HEK-Blue was cultured as described by Invitrogen TM IL-23 cells.

[1148] On the first day of the assay, 10 μL of HEK-Blue IL23 cell suspension (final concentration: 10,000 cells / well) and 10 μL of serially diluted peptide solution were dispensed into a 384-well assay plate. After pre-incubation of the reaction mixture at 37°C / 5% CO2 / 95% humidity for 60 minutes, 10 μL of human IL23 cytokine (final concentration: 0.25 ng / ml) was added to each well for STAT3 signaling activation. The plate was incubated overnight at 37°C / 5% CO2 / 95% humidity.

[1149] On the second day, 20 μl / well of Quanti-Blue detection solution (prepared according to the manufacturer's instructions) was dispensed into a new 384-well plate, and then 5 μl of the supernatant of the overnight incubated cell / sample mixture was transferred. After incubation at room temperature for 45 min, the signal at OD 620-655 nm was measured using PHERAstar (BMG). Dose response data were fitted using XLfit. Table 10: ELISA IC50 and pSTA3 values ​​of compounds of the present disclosure

[1150] na: not available Table 11: Comparison of ELISA IC50 between compounds of the present disclosure and Pen peptide compounds

[1151] As shown in Table 11, compared with the Pen peptide compound, the peptide compound disclosed in the present invention has a lower ELISA IC in inhibiting the binding of IL23 to its receptor. 50 , which indicates higher efficacy. [Disclosed items]

[1152] The disclosure is further described by the following items:

[1153] Item 1: A compound having formula (I):

[1154] in

[1155] -X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Pipa, Pipb, Pipp, Dab, Dad and Dap, and is linked to X11 via an amide bond,

[1156] or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond,

[1157] - R1 is absent or, if X1 is selected from the residues of Ahx, Aoa, Apt, Lys, Dab and Dap, R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[1158] -X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu and their corresponding d-form residues. In some embodiments, X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr and their corresponding d-form residues,

[1159] -X7 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Thr and Abu and their corresponding d-form residues,

[1160] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond,

[1161] -X3 is an amino acid residue selected from the group consisting of Sar, His, Lys, Ala, Ahx, Apt, Arg, Asn, Gab, Gln, Trp, Thr, Ndmk, Nmn, Ntmk and Lys(αAc),

[1162] - X4 is absent or is an amino acid residue selected from the group consisting of His, Lys, Ahx, Apt, Arg, Asn, Gab, Gln, Trp and Thr residues,

[1163] -X5 is an amino acid residue selected from the group consisting of Trp, Wme, Nak, Wcl, Wim, Wdm and Wfl,

[1164] -X6 is an amino acid residue selected from the group consisting of a residue of Gln, Aib, Glu, Phe, Ile, Iva, Lys, Lys(Ac), Leu, Mle, Mly, Mva, Thr, Val, Trp and Phe,

[1165] -X8 is an amino acid residue selected from the group consisting of: Yme, Tyr, Trp, Yde and Yae. In some embodiments, X8 is an amino acid residue selected from the group consisting of: Yme, Tyr, Trp and Yde,

[1166] -X9 is an amino acid residue selected from the group consisting of a residue of Nal, Nak and Trp,

[1167] -X10 is an amino acid residue selected from the group consisting of: Aib, Cba, Cit, d-Trp, d-Tza, Lys, Lys(Ac), Leu, Mle, Mly, Gln, Mkdm and Thp,

[1168] -X11 is an amino acid residue selected from the group consisting of Asp, Bal, Gab, Glu, Kme, Lys and Orn residues, and is linked to X1 via an amide bond,

[1169] -X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues,

[1170] -X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, Leu, Ile, Iva, Hol, Hph, Pal, Pyal, PyEA, His, Hme, Val and their corresponding d-form residues,

[1171] - X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile, Dnmy and Hme residues,

[1172] -X15 is absent or is a Lys amino acid residue,

[1173] -R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[1174] and

[1175] wherein the amide bonds between X1 and X2, X2 and X3, X3 and X4, X4 and X5, X11 and X1 are optionally methylated, wherein X2,

[1176] or a salt or solvate thereof,

[1177] and

[1178] The compound of formula (I) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[1179] Item 2: The compound as described in Item 1, wherein X2 is:

[1180] An amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu and their corresponding d-form amino acid residues, and X8 is an amino acid residue selected from the group consisting of Yme, Tyr, Trp and Yde,

[1181] Or an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr and their corresponding d-type amino acid residues, and X8 is an amino acid residue selected from the group consisting of Yme, Tyr, Trp, Yde and Yae.

[1182] Item 3: The compound as described in Item 1, wherein when X2 is Abu or its corresponding d-form, then X8 is not the amino acid residue of Yae.

[1183] Item 4: The compound as described in Item 1, wherein when X8 is Yae, then X2 is not Abu or its corresponding d-type amino acid residue.

[1184] Item 5: A compound having formula (I), wherein:

[1185] -X1 is the residue of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Pipa, Pipb, Pipp, Dab, Dad or Dap and is linked to X11 via an amide bond,

[1186] or is a Buty or Butyl residue and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond,

[1187] -R1 does not exist, or

[1188] If X1 is the residue of Ahx, Aoa, Apt, Lys, Dab or Dap, then R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[1189] -X2 is Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr or Abu and their corresponding d-type amino acid residues,

[1190] -X7 is Cys, Glu, Asp, Thr or Abu and their corresponding d-type amino acid residues,

[1191] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond,

[1192] -X3 is an amino acid residue of Sar, His, Lys, Ala, Ahx, Apt, Arg, Asn, Gab, Gln, Trp, Thr, Ndmk, Nmn, Ntmk or Lys(αAc),

[1193] -X4 is absent or is an amino acid residue of His, Lys, Ahx, Apt, Arg, Asn, Gab, Gln, Trp or Thr,

[1194] -X5 is an amino acid residue of Trp, Wme, Nak, Wcl, Wim, Wdm or Wfl,

[1195] -X6 is an amino acid residue of Gln, Aib, Glu, Phe, Ile, Iva, Lys, Lys(Ac), Leu, Mle, Mly, Mva, Thr, Val, Trp or Phe,

[1196] -X8 is an amino acid residue of Yme, Tyr, Trp or Yde,

[1197] -X9 is an amino acid residue of Nal, Nak or Trp,

[1198] -X10 is an amino acid residue of Aib, Cba, Cit, d-Trp, d-Tza, Lys, Lys(Ac), Leu, Mle, Mly, Gln, Mkdm or Thp,

[1199] -X11 is an amino acid residue of Asp, Bal, Gab, Glu, Kme, Lys or Orn, and is linked to X1 via an amide bond,

[1200] -X12 is absent or is an amino acid residue of Asn, Gly, Ser or Ala,

[1201] -X13 is absent or is Asn, Ala, Bal, Gly, Leu, Ile, Iva, Hol, Hph, Pal, Pyal, PyEA, His, Hme or Val and their corresponding d-type amino acid residues,

[1202] -X14 is absent or is an amino acid residue of Mep, Sar, Bal, Ile, Dnmy or Hme,

[1203] -X15 is absent or is a Lys amino acid residue,

[1204] -R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[1205] and

[1206] wherein the amide bonds between X1 and X2, X2 and X3, X3 and X4, X4 and X5, and X11 and X1 are optionally methylated,

[1207] or a salt or solvate thereof, and

[1208] The compound of formula (I) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[1209] Item 6: The compound as described in Item 5, wherein:

[1210] -X1 is a residue selected from the group consisting of Ahx, Apt, Nmha, Nmapt, Lys and Dad, and is linked to X11 via an amide bond,

[1211] or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond,

[1212] -R1 does not exist, or

[1213] If X1 is a residue selected from the group consisting of Ahx, Apt and Lys, then R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[1214] -X2 is an amino acid residue selected from the group consisting of a Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu residue,

[1215] -X7 is an amino acid residue selected from the group consisting of a Cys, Glu, Asp, Thr and Abu residue,

[1216] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond,

[1217] -X3 is an amino acid residue selected from the group consisting of Apt, Asn, Ndmk, Nmn and Lys(αAc),

[1218] -X4 does not exist or is a Thr amino acid residue,

[1219] -X5 is an amino acid residue selected from the group consisting of a residue of Trp, Wme and Wim,

[1220] -X6 is an amino acid residue selected from the group consisting of a Gln, Lys(Ac) and Leu residue,

[1221] -X8 is an amino acid residue selected from the group consisting of a residue of Yme, Trp and Yde,

[1222] -X9 is the amino acid residue of Nal,

[1223] - X10 is an amino acid residue selected from the group consisting of Aib, Lys, Lys(Ac), Mle, Mly, Mkdm and Thp,

[1224] -X11 is an amino acid residue selected from the group consisting of Asp, Glu, Kme, Lys and Orn residues, and is linked to X1 via an amide bond,

[1225] -X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues,

[1226] -X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, d-Leu, Ile, Pal, Pyal, PyEA, His and Hme residues,

[1227] - X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile and Hme residues,

[1228] -X15 is absent or is a Lys amino acid residue,

[1229] -R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[1230] or a salt or solvate thereof.

[1231] Item 7: A compound having formula (I), wherein:

[1232] -X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Pipa, Pipb, Pipp, Dab, Dad and Dap, and is linked to X11 via an amide bond,

[1233] or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond,

[1234] -R1 does not exist, or

[1235] If X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Lys, Dab and Dap, then R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[1236] -X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr and their corresponding d-form residues,

[1237] -X7 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Thr and Abu and their corresponding d-form residues,

[1238] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond,

[1239] -X3 is an amino acid residue selected from the group consisting of Sar, His, Lys, Ala, Ahx, Apt, Arg, Asn, Gab, Gln, Trp, Thr, Ndmk, Nmn, Ntmk and Lys(αAc),

[1240] -X4 is absent or is an amino acid residue selected from the group consisting of His, Lys, Ahx, Apt, Arg, Asn, Gab, Gln, Trp and Thr residues,

[1241] -X5 is an amino acid residue selected from the group consisting of Trp, Wme, Nak, Wcl, Wim, Wdm and Wfl,

[1242] -X6 is an amino acid residue selected from the group consisting of a residue of Gln, Aib, Glu, Phe, Ile, Iva, Lys, Lys(Ac), Leu, Mle, Mly, Mva, Thr, Val, Trp and Phe,

[1243] -X8 is an amino acid residue selected from the group consisting of a residue of Yme, Tyr, Trp, Yde and Yae,

[1244] -X9 is an amino acid residue selected from the group consisting of a residue of Nal, Nak and Trp,

[1245] -X10 is an amino acid residue selected from the group consisting of: Aib, Cba, Cit, d-Trp, d-Tza, Lys, Lys(Ac), Leu, Mle, Mly, Gln, Mkdm and Thp,

[1246] -X11 is an amino acid residue selected from the group consisting of Asp, Bal, Gab, Glu, Kme, Lys and Orn residues, and is linked to X1 via an amide bond,

[1247] -X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues,

[1248] -X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, Leu, Ile, Iva, Hol, Hph, Pal, Pyal, PyEA, His, Hme, Val and their corresponding d-form residues,

[1249] - X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile, Dnmy and Hme residues,

[1250] -X15 is absent or is a Lys amino acid residue,

[1251] -R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[1252] and

[1253] wherein the amide bonds between X1 and X2, X2 and X3, X3 and X4, X4 and X5, and X11 and X1 are optionally methylated,

[1254] or a salt or solvate thereof, and

[1255] Among them, the compound having formula (I) inhibits the binding of interleukin-23 to the interleukin-23 receptor.

[1256] Item 8: The compound as described in Item 7, wherein:

[1257] -X1 is a residue selected from the group consisting of Ahx, Apt, Nmha, Nmapt, Lys and Dad, and is linked to X11 via an amide bond,

[1258] or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond,

[1259] -R1 does not exist, or

[1260] If X1 is a residue selected from the group consisting of Ahx, Apt and Lys, then R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[1261] -X2 is an amino acid residue selected from the group consisting of a Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr residue,

[1262] -X7 is an amino acid residue selected from the group consisting of a Cys, Glu, Asp, Thr and Abu residue,

[1263] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond,

[1264] -X3 is an amino acid residue selected from the group consisting of Apt, Asn, Ndmk, Nmn and Lys(αAc),

[1265] -X4 does not exist or is a Thr amino acid residue,

[1266] -X5 is an amino acid residue selected from the group consisting of a residue of Trp, Wme and Wim,

[1267] -X6 is an amino acid residue selected from the group consisting of a Gln, Lys(Ac) and Leu residue,

[1268] -X8 is an amino acid residue selected from the group consisting of a residue of Yme, Trp, Yde and Yae,

[1269] -X9 is the amino acid residue of Nal,

[1270] - X10 is an amino acid residue selected from the group consisting of Aib, Lys, Lys(Ac), Mle, Mly, Mkdm and Thp,

[1271] -X11 is an amino acid residue selected from the group consisting of Asp, Glu, Kme, Lys and Orn residues, and is linked to X1 via an amide bond,

[1272] -X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues,

[1273] -X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, d-Leu, Ile, Pal, Pyal, PyEA, His and Hme residues,

[1274] - X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile and Hme residues,

[1275] -X15 does not exist or is a Lys amino acid residue,

[1276] -R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[1277] or a salt or solvate thereof.

[1278] Item 9: The compound as described in Items 1 to 8, wherein R1 does not exist.

[1279] Item 10: A compound as described in Items 1 to 8, wherein R1 is H.

[1280] Item 11: A compound as described in items 1 to 8, wherein R1 is C1-C4-alkyl.

[1281] Item 12: The compound as described in Items 1 to 8, wherein R1 is acetyl.

[1282] Item 13: A compound as described in Items 1 to 12, wherein R2 is absent.

[1283] Item 14: A compound as described in Items 1 to 12, wherein R2 is -NH2.

[1284] Item 15: A compound as described in Items 1 to 12, wherein R2 is -OH.

[1285] Item 16: The compound of Items 1 to 12, wherein R2 is -N(C2H5)2.

[1286] Item 17: The compound as described in Items 1 to 16, wherein

[1287] X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Pipa, Pipb, Pipp, Dab and Dap, and X11 is an amino acid residue selected from the group consisting of Asp and Glu,

[1288] or

[1289] X1 is a residue Dad and X11 is an amino acid residue selected from the group consisting of residues of Lys and Kme,

[1290] or

[1291] X1 is a residue selected from the group consisting of Buty or Butyl residues and X11 is an amino acid residue of Kme.

[1292] Item 18: The compound as described in Items 1 to 16, wherein

[1293] X1 is a residue of Ahx and X11 is an amino acid residue selected from the residue of Glu or Asp.

[1294] Item 19: The compound as described in Items 1 to 16, wherein

[1295] X1 is the residue of Apt and X11 is an amino acid residue selected from the residue of Glu or Asp.

[1296] Item 20: The compound as described in Items 1 to 16, wherein

[1297] X1 is the residue of Apt and X11 is the amino acid residue of Glu.

[1298] Item 21: The compound as described in Items 1 to 16, wherein

[1299] X1 is the residue of Nmapt and X11 is an amino acid residue selected from the residue of Glu or Asp.

[1300] Item 22: The compound as described in Items 1 to 16, wherein

[1301] X1 is the residue of Nmapt and X11 is the amino acid residue Glu.

[1302] Item 23: The compound as described in Items 1 to 16, wherein

[1303] X1 is the residue of Nmapt and X11 is the amino acid residue of Asp.

[1304] Item 24: The compound as described in Items 1 to 16, wherein

[1305] X1 is a residue of Nmha and X11 is an amino acid residue selected from the residue of Glu or Asp.

[1306] Item 25: The compound as described in Items 1 to 16, wherein

[1307] X1 is the residue of Nmha and X11 is the amino acid residue of Glu.

[1308] Item 26: The compound as described in Items 1 to 16, wherein

[1309] X1 is the residue of Nmha and X11 is the amino acid residue of Asp.

[1310] Item 27: The compound as described in Items 1 to 16, wherein

[1311] X1 is a Lys residue and X11 is an amino acid residue selected from the group consisting of a Glu residue and an Asp residue.

[1312] Item 28: The compound as described in Items 1 to 16, wherein

[1313] X1 is a Lys residue and X11 is a Glu amino acid residue.

[1314] Item 29: The compound as described in Items 1 to 16, wherein

[1315] X1 is a Lys residue and X11 is an Asp amino acid residue.

[1316] Item 30: The compound as described in Items 1 to 16, wherein

[1317] X1 is the residue of Dad and X11 is an amino acid residue selected from the residues of Lys or Kme.

[1318] Item 31: A compound as described in Items 1 to 16, wherein

[1319] X1 is the residue of Dada and X11 is the amino acid residue of Lys.

[1320] Item 32: The compound as described in Items 1 to 16, wherein

[1321] X1 is the residue of Dad and X11 is the amino acid residue of Kme.

[1322] Item 33: A compound as described in Items 1 to 16, wherein

[1323] X1 is a residue of Buty and X11 is an amino acid residue selected from the residues of Lys or Kme.

[1324] Item 34: The compound as described in Items 1 to 16, wherein

[1325] X1 is the residue of Buty and X11 is the amino acid residue of Lys.

[1326] Item 35: The compound as described in Items 1 to 16, wherein

[1327] X1 is the residue of Buty and X11 is the amino acid residue of Kme.

[1328] Item 36: The compound as described in Items 1 to 16, wherein

[1329] X1 is a residue of Butyl and X11 is an amino acid residue selected from the residues of Lys or Kme.

[1330] Item 37: The compound as described in Items 1 to 16, wherein

[1331] X1 is a Butyl residue and X11 is a Lys amino acid residue.

[1332] Item 38: The compound as described in Items 1 to 16, wherein

[1333] X1 is the residue of Butyl and X11 is the amino acid residue of Kme.

[1334] Item 39: A compound as described in Items 1 to 38, wherein X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu and their corresponding d-type residues.

[1335] Item 40: A compound as described in Items 1 to 38, wherein X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr and their corresponding d-type residues.

[1336] Item 41: A compound as described in Items 1 to 38, wherein

[1337] X2 is an amino acid residue selected from the group consisting of Cys and Nmc and their corresponding d-type residues,

[1338] X7 is an amino acid residue selected from Cys and its corresponding d-form residues,

[1339] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond,

[1340] or

[1341] X2 is an amino acid residue selected from the group consisting of Cys, Nmc, Thr and Abu and their corresponding d-form residues,

[1342] X7 is an amino acid residue selected from the group consisting of Cys, Thr and Abu and their corresponding d-form residues,

[1343] wherein X2 and X7 are linked to each other via Q, wherein Q is a thioether bond,

[1344] or

[1345] X2 is an amino acid residue selected from the group consisting of Glu, Asp, Nmd, Nme, Nmt and Thr and their corresponding d-type residues,

[1346] X7 is an amino acid residue selected from the group consisting of Glu, Asp, Thr and their corresponding d-type residues,

[1347] wherein X2 and X7 are linked to each other via Q, wherein Q is an ester bond.

[1348] Item 42: A compound as described in Items 1 to 38, wherein

[1349] X2 is an amino acid residue selected from Cys and its corresponding d-form residues,

[1350] X7 is an amino acid residue selected from Cys and its corresponding d-form residues,

[1351] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond,

[1352] or

[1353] X2 is an amino acid residue selected from the group consisting of Cys, Glu, Thr and Abu and their corresponding d-form residues,

[1354] X7 is an amino acid residue selected from the group consisting of Cys, Thr and Abu and their corresponding d-form residues,

[1355] wherein X2 and X7 are linked to each other via Q, wherein Q is a thioether bond,

[1356] or

[1357] X2 is an amino acid residue selected from the group consisting of Glu and Thr and their corresponding d-form residues,

[1358] X7 is an amino acid residue selected from the group consisting of Glu, Asp and Thr and their corresponding d-form residues,

[1359] wherein X2 and X7 are linked to each other via Q, wherein Q is an ester bond.

[1360] Item 43: A compound as described in Items 1 to 38, wherein

[1361] X2-Q-X7 is selected from the group consisting of:

[1362] Cys-Q-Cys, Nmc-Q-Cys and Cys-Q-Nmc, wherein Q is a disulfide bond, or

[1363] Abu-Q-Cys, Cys-Q-Abu, wherein Q is a thioether bond, or

[1364] Thr-Q-Asp, Thr-Q-Glu, Glu-Q-Thr, wherein Q is an ester bond.

[1365] Item 44: A compound as described in items 1 to 38, wherein X2-Q-X7 is selected from the group consisting of:

[1366] -Cys-Q-Cys, Nmc-Q-Cys and Cys-Q-Nmc, wherein Q is a disulfide bond, or

[1367] -Abu-Q-Cys, Cys-Q-Abu, wherein Q is a thioether bond, or

[1368] -Thr-Q-Asp, Thr-Q-Glu, Glu-Q-Thr, wherein Q is an ester bond.

[1369] Item 45: A compound as described in items 1 to 38, wherein X2-Q-X7 is selected from the group consisting of:

[1370] -Cys-Q-Cys, Nmc-Q-Cys and Cys-Q-Nmc, wherein Q is a disulfide bond, or

[1371] -Cys-Q-Abu, wherein Q is a thioether bond, or

[1372] -Thr-Q-Asp, Thr-Q-Glu, Glu-Q-Thr, wherein Q is an ester bond.

[1373] Item 46: A compound as described in Items 1 to 38, wherein

[1374] X2-Q-X7 is selected from the group consisting of Cys-Q-Cys and Nmc-Q-Cys, wherein Q is a disulfide bond, or Abu-Q-Cys, wherein Q is a thioether bond, or

[1375] Glu-Q-Thr, wherein Q is an ester bond.

[1376] Item 47: A compound as described in Items 1 to 38, wherein

[1377] X2-Q-X7 is selected from the group consisting of Cys-Q-Cys and Nmc-Q-Cys, wherein Q is a disulfide bond.

[1378] Item 48: A compound as described in Items 1 to 38, wherein

[1379] X2-Q-X7 is Abu-Q-Cys, wherein Q is a thioether bond.

[1380] Item 49: A compound as described in Items 1 to 38, wherein

[1381] X2-Q-X7 is Glu-Q-Thr, wherein Q is an ester bond.

[1382] Item 50: The compound as described in Items 1 to 49, wherein X3 is an amino acid residue selected from the group consisting of Apt, Ndmk, Nmn and Lys(αAc).

[1383] Item 51: The compound as described in Items 1 to 49, wherein X3 is an amino acid residue of Sar.

[1384] Item 52: The compound as described in Items 1 to 49, wherein X3 is an amino acid residue of His.

[1385] Item 53: The compound as described in Items 1 to 49, wherein X3 is an amino acid residue of Lys.

[1386] Item 54: The compound as described in Items 1 to 49, wherein X3 is an amino acid residue of Ala.

[1387] Item 55: The compound as described in Items 1 to 49, wherein X3 is an amino acid residue of Ahx.

[1388] Item 56: The compound as described in Items 1 to 49, wherein X3 is the amino acid residue of Apt.

[1389] Item 57: The compound as described in Items 1 to 49, wherein X3 is the amino acid residue of Arg.

[1390] Item 58: The compound as described in Items 1 to 49, wherein X3 is an amino acid residue of Asn.

[1391] Item 59: The compound as described in Items 1 to 49, wherein X3 is an amino acid residue of Gab.

[1392] Item 60: The compound as described in Items 1 to 49, wherein X3 is an amino acid residue of Gln.

[1393] Item 61: The compound as described in Items 1 to 49, wherein X3 is an amino acid residue of Trp.

[1394] Item 62: The compound as described in Items 1 to 49, wherein X3 is an amino acid residue of Thr.

[1395] Item 63: A compound as described in Items 1 to 49, wherein X3 is an amino acid residue of Ndmk,

[1396] Item 64: A compound as described in Items 1 to 49, wherein X3 is an amino acid residue of Nmn.

[1397] Item 65: The compound as described in Items 1 to 49, wherein X3 is an amino acid residue of Ntmk.

[1398] Item 66: The compound as described in Items 1 to 49, wherein X3 is an amino acid residue of Lys(αAc).

[1399] Item 67: A compound as described in Items 1 to 66, wherein X4 is absent.

[1400] Item 68: A compound as described in Items 1 to 49, wherein X3 is an amino acid residue selected from the group consisting of Lys, Ahx, Apt, Thr, Ndmk, Nmn, Ntmk and Lys(αAc), and X4 is absent.

[1401] Item 69: A compound as described in Items 1 to 49, wherein X3 is an amino acid residue selected from the group consisting of Apt, Ndmk, Nmn and Lys(αAc), and X4 is absent.

[1402] Item 70: A compound as described in Items 1 to 49, wherein X3 is an amino acid residue selected from the group consisting of Apt, Ndmk and Lys(αAc), and X4 is absent.

[1403] Item 71: The compound as described in Items 1 to 49, wherein X3 is an amino acid residue of Lys(αAc), and X4 is absent.

[1404] Item 72: A compound as described in Items 1 to 66, wherein X4 is an amino acid residue selected from the group consisting of His, Lys, Arg, Asn, Gab, Gln, Trp and Thr residues.

[1405] Item 73: A compound as described in Items 1 to 66, wherein X4 is an amino acid residue selected from the group consisting of His, Lys, Arg, Asn, Gln, Trp and Thr residues.

[1406] Item 74: The compound as described in Items 1 to 66, wherein X4 is an amino acid residue of His.

[1407] Item 75: The compound as described in Items 1 to 66, wherein X4 is an amino acid residue of Lys.

[1408] Item 76: The compound as described in Items 1 to 66, wherein X4 is an amino acid residue of Ahx.

[1409] Item 77: The compound as described in Items 1 to 66, wherein X4 is the amino acid residue of Apt.

[1410] Item 78: The compound as described in Items 1 to 66, wherein X4 is the amino acid residue of Arg.

[1411] Item 79: A compound as described in Items 1 to 66, wherein X4 is an amino acid residue of Asn.

[1412] Item 80: The compound as described in Items 1 to 66, wherein X4 is an amino acid residue of Gab.

[1413] Item 81: A compound as described in Items 1 to 66, wherein X4 is an amino acid residue of Gln.

[1414] Item 82: The compound as described in Items 1 to 66, wherein X4 is an amino acid residue of Trp.

[1415] Item 83: A compound as described in Items 1 to 66, wherein X4 is an amino acid residue of Thr.

[1416] Item 84: A compound as described in Items 1 to 83, wherein X5 is an amino acid residue selected from the group consisting of Trp, Wme, Nak, Wcl, Wim, Wdm and Wfl residues.

[1417] Item 85: A compound as described in Items 1 to 83, wherein X5 is a residue selected from the following amino acid residues: Trp, Wme, Wcl, Wim, Wdm and Wfl.

[1418] Item 86: A compound as described in Items 1 to 83, wherein X5 is an amino acid residue selected from the group consisting of Trp and Wim residues.

[1419] Item 87: The compound as described in Items 1 to 83, wherein X5 is an amino acid residue of Trp.

[1420] Item 88: A compound as described in Items 1 to 83, wherein X5 is an amino acid residue of Wme.

[1421] Item 89: The compound as described in Items 1 to 83, wherein X5 is an amino acid residue of Nak.

[1422] Item 90: A compound as described in Items 1 to 83, wherein X5 is an amino acid residue of Wcl.

[1423] Item 91: A compound as described in Items 1 to 83, wherein X5 is the amino acid residue of Wim.

[1424] Item 92: A compound as described in Items 1 to 83, wherein X5 is the amino acid residue of Wdm.

[1425] Item 93: A compound as described in Items 1 to 83, wherein X5 is the amino acid residue of Wfl.

[1426] Item 94: A compound as described in Items 1 to 93, wherein X6 is an amino acid residue selected from the group consisting of Gln, Aib, Glu, Phe, Ile, Iva, Lys, Lys(Ac), Leu, Mle, Mly, Mva, Thr, Val, Trp and Phe residues.

[1427] Item 94: A compound as described in Items 1 to 93, wherein X6 is an amino acid residue selected from the group consisting of Gln, Aib, Glu, Ile, Iva, Lys, Lys(Ac), Leu, Mle, Mly, Mva and Val residues.

[1428] Item 95: A compound as described in Items 1 to 93, wherein X6 is an amino acid residue selected from the group consisting of Gln, Lys(Ac) and Leu residues.

[1429] Item 96: A compound as described in Items 1 to 93, wherein X6 is an amino acid residue of Gln.

[1430] Item 97: A compound as described in Items 1 to 93, wherein X6 is an amino acid residue of Aib.

[1431] Item 98: The compound as described in Items 1 to 93, wherein X6 is an amino acid residue of Glu.

[1432] Item 99: The compound as described in Items 1 to 93, wherein X6 is an amino acid residue of Phe.

[1433] Item 100: The compound as described in Items 1 to 93, wherein X6 is the amino acid residue of Ile.

[1434] Item 101: A compound as described in Items 1 to 93, wherein X6 is the amino acid residue of Iva.

[1435] Item 91021: A compound as described in Items 1 to 93, wherein X6 is an amino acid residue of Lys.

[1436] Item 103: A compound as described in Items 1 to 93, wherein X6 is an amino acid residue of Lys(Ac).

[1437] Item 104: A compound as described in Items 1 to 93, wherein X6 is an amino acid residue of Leu.

[1438] Item 105: A compound as described in Items 1 to 93, wherein X6 is an amino acid residue of Mle.

[1439] Item 106: A compound as described in Items 1 to 93, wherein X6 is an amino acid residue of Mly.

[1440] Item 107: A compound as described in Items 1 to 93, wherein X6 is an amino acid residue of Mva.

[1441] Item 108: A compound as described in Items 1 to 93, wherein X6 is an amino acid residue of Thr.

[1442] Item 109: A compound as described in Items 1 to 93, wherein X6 is the amino acid residue of Val.

[1443] Item 110: A compound as described in Items 1 to 93, wherein X6 is an amino acid residue of Trp.

[1444] Item 111: A compound as described in Items 1 to 93, wherein X6 is an amino acid residue of Phe.

[1445] Item 112: A compound as described in Items 1 to 111, wherein X8 is an amino acid residue selected from the group consisting of Yme, Tyr, Trp, Yde and Yae residues.

[1446] Item 113: A compound as described in Items 1 to 111, wherein X8 is an amino acid residue selected from the group consisting of Yme, Tyr, Trp and Yde residues.

[1447] Item 114: A compound as described in Items 1 to 111, wherein X8 is an amino acid residue selected from the group consisting of Yme, Tyr, Trp, Yde and Yae residues.

[1448] Item 115: A compound as described in Items 1 to 111, wherein X8 is an amino acid residue selected from the group consisting of Yme, Yde and Yae residues,

[1449] Item 116: A compound as described in Items 1 to 111, wherein X8 is an amino acid residue of Yme.

[1450] Item 117: The compound as described in Items 1 to 111, wherein X8 is an amino acid residue of Tyr.

[1451] Item 118: A compound as described in Items 1 to 111, wherein X8 is an amino acid residue of Trp.

[1452] Item 119: A compound as described in Items 1 to 111, wherein X8 is the amino acid residue of Yde.

[1453] Item 120: A compound as described in Items 1 to 111, wherein X8 is the amino acid residue of Yae.

[1454] Item 121: A compound as described in Items 1 to 111, wherein X9 is the amino acid residue of Nal.

[1455] Item 122: A compound as described in Items 1 to 111, wherein X9 is an amino acid of Nak.

[1456] Item 123: A compound as described in Items 1 to 111, wherein X9 is an amino acid residue of Trp.

[1457] Item 124: A compound as described in Items 1 to 123, wherein X10 is an amino acid residue selected from the group consisting of Aib, Cba, Cit, d-Trp, d-Tza, Lys, Lys(Ac), Leu, Mle, Mly, Gln, Mkdm and Thp residues.

[1458] Item 125: A compound as described in Items 1 to 123, wherein X10 is an amino acid residue selected from the group consisting of Aib, Lys, Lys(Ac), Mle, Mly, Mkdm and Thp residues.

[1459] Item 126: A compound as described in Items 1 to 123, wherein X10 is an amino acid residue selected from the group consisting of Aib, Mle, Mly, Mkdm and Thp residues.

[1460] Item 127: A compound as described in Items 1 to 123, wherein X10 is an amino acid residue of Aib.

[1461] Item 128: A compound as described in Items 1 to 123, wherein X10 is an amino acid residue of Cba.

[1462] Item 129: A compound as described in Items 1 to 123, wherein X10 is an amino acid residue of Cit.

[1463] Item 130: The compound as described in Items 1 to 123, wherein X10 is an amino acid residue of d-Trp.

[1464] Item 131: A compound as described in Items 1 to 123, wherein X10 is an amino acid residue of d-Tza.

[1465] Item 132: The compound as described in Items 1 to 123, wherein X10 is an amino acid residue of Lys.

[1466] Item 133: The compound as described in Items 1 to 123, wherein X10 is an amino acid residue of Lys(Ac).

[1467] Item 134: A compound as described in Items 1 to 123, wherein X10 is an amino acid residue of Leu.

[1468] Item 135: A compound as described in Items 1 to 123, wherein X10 is an amino acid residue of Mle.

[1469] Item 136: A compound as described in Items 1 to 123, wherein X10 is an amino acid residue of Mly.

[1470] Item 137: A compound as described in Items 1 to 123, wherein X10 is an amino acid residue of Gln.

[1471] Item 138: A compound as described in Items 1 to 123, wherein X10 is the amino acid residue of Mkdm.

[1472] Item 139: A compound as described in Items 1 to 123, wherein X10 is an amino acid residue of Thp.

[1473] Item 140: A compound as described in Items 1 to 139, wherein X12 is absent or is an amino acid residue selected from the group consisting of Asn, Ser and Ala residues.

[1474] Item 141: A compound as described in Items 1 to 139, wherein X12 is absent.

[1475] Item 142: A compound as described in Items 1 to 139, wherein X12 is an amino acid residue of Asn.

[1476] Item 143: A compound as described in Items 1 to 139, wherein X12 is an amino acid residue of Ser.

[1477] Item 144: A compound as described in Items 1 to 139, wherein X12 is an amino acid residue of Ala.

[1478] Item 145: A compound as described in Items 1 to 144, wherein X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, Leu, d-Leu, Ile, Iva, Hol, Hph, Pal, Pyal, PyEA, His, Hme, Val and their corresponding d-type residues,

[1479] Item 146: A compound as described in Items 1 to 144, wherein X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, Leu, d-Leu, Ile, Iva, Hol, Hph, Pal, Pyal, PyEA, His, Hme and Val residues.

[1480] Item 147: A compound as described in Items 1 to 144, wherein X13 is absent.

[1481] Item 148: A compound as described in Items 1 to 144, wherein X13 is an amino acid residue of Asn.

[1482] Item 149: A compound as described in Items 1 to 144, wherein X13 is an amino acid residue of Ala.

[1483] Item 150: A compound as described in Items 1 to 144, wherein X13 is the amino acid residue of Bal.

[1484] Item 151: A compound as described in Items 1 to 144, wherein X13 is an amino acid residue of Gly.

[1485] Item 152: A compound as described in Items 1 to 144, wherein X13 is an amino acid residue of Leu.

[1486] Item 153: A compound as described in Items 1 to 144, wherein X13 is an amino acid residue of d-Leu.

[1487] Item 154: A compound as described in Items 1 to 144, wherein X13 is an amino acid residue of Ile.

[1488] Item 155: A compound as described in Items 1 to 144, wherein X13 is the amino acid residue of Iva.

[1489] Item 156: A compound as described in Items 1 to 144, wherein X13 is an amino acid residue of Hol.

[1490] Item 157: A compound as described in Items 1 to 144, wherein X13 is an amino acid residue of Hph.

[1491] Item 158: A compound as described in Items 1 to 144, wherein X13 is the amino acid residue of Pal.

[1492] Item 159: A compound as described in Items 1 to 144, wherein X13 is the amino acid residue of Pyal.

[1493] Item 160: A compound as described in Items 1 to 144, wherein X13 is an amino acid residue of PyEA.

[1494] Item 161: A compound as described in Items 1 to 144, wherein X13 is an amino acid residue of His.

[1495] Item 162: A compound as described in Items 1 to 144, wherein X13 is an amino acid residue of Hme.

[1496] Item 163: A compound as described in Items 1 to 144, wherein X13 is the amino acid residue of Val.

[1497] Item 164: A compound as described in Items 1 to 163, wherein X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile, Dnmy and Hme residues.

[1498] Item 165: A compound as described in Items 1 to 163, wherein X14 is absent.

[1499] Item 166: A compound as described in Items 1 to 163, wherein X14 is an amino acid residue of Mep,

[1500] Item 167: A compound as described in Items 1 to 163, wherein X14 is an amino acid residue of Sar.

[1501] Item 168: A compound as described in Items 1 to 163, wherein X14 is the amino acid residue of Bal.

[1502] Item 169: A compound as described in Items 1 to 163, wherein X14 is an amino acid residue of Ile.

[1503] Item 170: A compound as described in Items 1 to 163, wherein X14 is the amino acid residue of Dnmy.

[1504] Item 171: A compound as described in Items 1 to 163, wherein X14 is an amino acid residue of Hme.

[1505] Item 172: A compound as described in Items 1 to 171, wherein X15 is absent.

[1506] Item 172: A compound as described in Items 1 to 171, wherein X15 is Lys.

[1507] Item 173: A compound as described in Items 1 to 172, wherein X2-X3-X4-X5-X6-X7 is Cys-Asn-Thr-Trp-Gln-Cys,

[1508] Item 174: A compound of Items 1 to 172, wherein X2-X3-X4-X5-X6-X7 is Cys-Asn-Thr-Wim-Gln-Cys.

[1509] Item 175: A compound as described in Items 1 to 172, wherein X2-X3-X4-X5-X6-X7 is Cys-Asn-Thr-Trp-Lys(Ac)-Cys.

[1510] Item 176: A compound as described in Items 1 to 172, wherein X2-X3-X4-X5-X6-X7 is Cys-Asn-Thr-Wim-Lys(Ac)-Cys.

[1511] Item 177: A compound as described in Items 1 to 172, wherein X2-X3-X4-X5-X6-X7 is Cys-Nmn-Thr-Trp-Gln-Cys.

[1512] Item 178: A compound as described in Items 1 to 172, wherein X2-X3-X4-X5-X6-X7 is Abu-Asn-Thr-Trp-Lys(Ac)-Cys.

[1513] Item 179: A compound as described in Items 1 to 172, wherein X2-X3-X4-X5-X6-X7 is Abu-Asn-Thr-Wim-Lys(Ac)-Cys.

[1514] Item 180: A compound as described in Items 1 to 172, wherein X2-X3-X4-X5-X6-X7 is Abu-Asn-Thr-Wme-Leu-Cys.

[1515] Item 181: A compound as described in Items 1 to 180, wherein

[1516] X12-X13- is Gly-PyEA,

[1517] X14 does not exist,

[1518] X15 does not exist.

[1519] R2 does not exist.

[1520] Item 182: A compound as described in Items 1 to 181, wherein X8-X9-X10 is Yde-Nal-X10, wherein X10 is selected from the residue of Aib, Mle, Thp, Mkdm or Mly.

[1521] Item 183: A compound having formula (Ia)

[1522] in

[1523] R1, R2, X1, X2, X3, X4, X5, X6, X7, X8, X9, X11, X12, X13, X14, as defined in items 1 to 182 and

[1524] X10 is an amino acid residue selected from the group consisting of Aib, Cba, Cit, d-Trp, d-Tza, Lys, Lys(Ac), Leu, Mle, Mly, Gln, Mkdm and Thp,

[1525] X15 does not exist or is a Lys amino acid residue.

[1526] And among them

[1527] The amide bonds between X1 and X2, X2 and X3, X3 and X4, X4 and X5, and X11 and X1 are optionally methylated,

[1528] or a salt or solvate thereof,

[1529] and

[1530] At least one of X10 and X15

[1531] is an amino acid residue having a -NH2 group in the side chain, wherein the -NH2 side chain group is functionalized by -C(O)-R5, -C(O)O-R5, -C(O)NH-R5, -S(O)2-R5 or R5, for example by -C(O)-R5, wherein R5 can be a moiety containing up to 50 or up to 100 carbon atoms and optionally heteroatoms selected from halogen, N, O, S and P,

[1532] The compound of formula (Ia) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[1533] Item 184: A compound as described in Item 183, wherein the compound has the formula (Ia): X2 is:

[1534] An amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu and their corresponding d-form amino acid residues, and X8 is an amino acid residue selected from the group consisting of Yme, Tyr, Trp and Yde,

[1535] Or an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr and their corresponding d-type amino acid residues, and X8 is an amino acid residue selected from the group consisting of Yme, Tyr, Trp, Yde and Yae.

[1536] Item 185: The compound as described in Item 183, wherein the compound having formula (Ia) may be such a compound: when X2 is Abu or its corresponding d-form, then X8 is not the amino acid residue of Yae.

[1537] Item 186: The compound as described in Item 183, wherein the compound having formula (Ia) may be such a compound: when X8 is Yae, then X2 is not Abu or its corresponding d-type amino acid residue.

[1538] Item 187: The compound as described in Item 183, wherein the compound having formula (Ia) is:

[1539] -X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Pipa, Pipb, Pipp, Dab, Dad and Dap, and is linked to X11 via an amide bond,

[1540] or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond,

[1541] -R1 does not exist, or

[1542] If X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Lys, Dab and Dap, then R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[1543] -X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu and their corresponding d-form residues,

[1544] -X7 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Thr and Abu and their corresponding d-form residues,

[1545] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond,

[1546] -X3 is an amino acid residue selected from the group consisting of Sar, His, Lys, Ala, Ahx, Apt, Arg, Asn, Gab, Gln, Trp, Thr, Ndmk, Nmn, Ntmk and Lys(αAc),

[1547] - X4 is absent or is an amino acid residue selected from the group consisting of His, Lys, Ahx, Apt, Arg, Asn, Gab, Gln, Trp and Thr residues,

[1548] -X5 is an amino acid residue selected from the group consisting of Trp, Wme, Nak, Wcl, Wim, Wdm and Wfl,

[1549] -X6 is an amino acid residue selected from the group consisting of a residue of Gln, Aib, Glu, Phe, Ile, Iva, Lys, Lys(Ac), Leu, Mle, Mly, Mva, Thr, Val, Trp and Phe,

[1550] -X8 is an amino acid residue selected from the group consisting of a residue of Yme, Tyr, Trp and Yde,

[1551] -X9 is an amino acid residue selected from the group consisting of a residue of Nal, Nak and Trp,

[1552] -X10 is an amino acid residue selected from the group consisting of: Aib, Cba, Cit, d-Trp, d-Tza, Lys, Lys(Ac), Leu, Mle, Mly, Gln, Mkdm and Thp,

[1553] -X11 is an amino acid residue selected from the group consisting of Asp, Bal, Gab, Glu, Kme, Lys and Orn residues and is linked to X1 via an amide bond,

[1554] -X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues,

[1555] -X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, Leu, Ile, Iva, Hol, Hph, Pal, Pyal, PyEA, His, Hme, Val and their corresponding d-form residues,

[1556] - X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile, Dnmy and Hme residues,

[1557] -X15 is absent or is a Lys amino acid residue,

[1558] -R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[1559] and

[1560] wherein the amide bonds between X1 and X2, X2 and X3, X3 and X4, X4 and X5, and X11 and X1 are optionally methylated,

[1561] and

[1562] wherein at least one of X10 and X15 is an amino acid residue having a -NH2 group in the side chain, wherein the -NH2 side chain group is functionalized by -C(O)-R5, -C(O)O-R5, -C(O)NH-R5, -S(O)2-R5 or R5, wherein R5 can be a moiety comprising up to 50 or up to 100 carbon atoms and heteroatoms optionally selected from halogen, N, O, S and P,

[1563] or a salt or solvate thereof,

[1564] The compound of formula (Ia) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[1565] Item 189: The compound as described in Item 183, wherein the compound having formula (Ia) is:

[1566] -X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Pipa, Pipb, Pipp, Dab, Dad and Dap, and is linked to X11 via an amide bond,

[1567] or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond,

[1568] -R1 does not exist, or

[1569] If X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Lys, Dab and Dap, then R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1,

[1570] -X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr and their corresponding d-form residues,

[1571] -X7 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Thr and Abu and their corresponding d-form residues,

[1572] wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond,

[1573] -X3 is an amino acid residue selected from the group consisting of Sar, His, Lys, Ala, Ahx, Apt, Arg, Asn, Gab, Gln, Trp, Thr, Ndmk, Nmn, Ntmk and Lys(αAc),

[1574] - X4 is absent or is an amino acid residue selected from the group consisting of His, Lys, Ahx, Apt, Arg, Asn, Gab, Gln, Trp and Thr residues,

[1575] -X5 is an amino acid residue selected from the group consisting of Trp, Wme, Nak, Wcl, Wim, Wdm and Wfl,

[1576] -X6 is an amino acid residue selected from the group consisting of a residue of Gln, Aib, Glu, Phe, Ile, Iva, Lys, Lys(Ac), Leu, Mle, Mly, Mva, Thr, Val, Trp and Phe,

[1577] -X8 is an amino acid residue selected from the group consisting of a residue of Yme, Tyr, Trp, Yde and Yae,

[1578] -X9 is an amino acid residue selected from the group consisting of a residue of Nal, Nak and Trp,

[1579] -X10 is an amino acid residue selected from the group consisting of: Aib, Cba, Cit, d-Trp, d-Tza, Lys, Lys(Ac), Leu, Mle, Mly, Gln, Mkdm and Thp,

[1580] -X11 is an amino acid residue selected from the group consisting of Asp, Bal, Gab, Glu, Kme, Lys and Orn residues and is linked to -X1 via an amide bond,

[1581] -X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues,

[1582] -X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, Leu,

[1583] Ile, Iva, Hol, Hph, Pal, Pyal, PyEA, His, Hme, Val and their corresponding d-type residues,

[1584] - X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile, Dnmy and Hme residues,

[1585] -X15 is absent or is a Lys amino acid residue,

[1586] -R2 does not exist or is -NH2, -OH or -N(C2H5)2,

[1587] and

[1588] wherein the amide bonds between X1 and X2, X2 and X3, X3 and X4, X4 and X5, and X11 and X1 are optionally methylated,

[1589] and

[1590] wherein at least one of X10 and X15 is an amino acid residue having a -NH2 group in the side chain, wherein the -NH2 side chain group is functionalized by -C(O)-R5, -C(O)O-R5, -C(O)NH-R5, -S(O)2-R5 or R5, wherein R5 can be a moiety comprising up to 50 or up to 100 carbon atoms and heteroatoms optionally selected from halogen, N, O, S and P,

[1591] or a salt or solvate thereof,

[1592] The compound of formula (Ia) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[1593] Item 190: A compound as described in Items 183 to 189, wherein at least one of X10 and X15 is an amino acid residue having a -NH2 group in the side chain, wherein the -NH2 side chain group is functionalized by -C(O)-R5, wherein R5 can be a portion comprising up to 50 or up to 100 carbon atoms and optionally heteroatoms selected from halogen, N, O, S and P.

[1594] Item 191: A compound as described in Items 183 to 190, wherein

[1595] X10 is an amino acid residue selected from the group consisting of Lys and Mly residues,

[1596] X15 does not exist.

[1597] and wherein the -NH2 side chain group of X10 is functionalized by -C(O)-R5, -C(O)O-R5, -C(O)NH-R5, -S(O)2-R5 or R5, for example by -C(O)-R5, wherein R5 can be a moiety comprising up to 50 or up to 100 carbon atoms and heteroatoms optionally selected from halogen, N, O, S and P,

[1598] The compound of formula (Ia) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[1599] Item 192: A compound as described in Items 183 to 190, wherein

[1600] X10 is an amino acid residue selected from the group consisting of Lys and Mly residues,

[1601] X15 is Lys,

[1602] and wherein the -NH2 side chain group of X15 is functionalized by -C(O)-R5, -C(O)O-R5, -C(O)NH-R5, -S(O)2-R5 or R5, for example by -C(O)-R5, wherein R5 can be a moiety containing up to 50 or up to 100 carbon atoms and heteroatoms optionally selected from halogen, N, O, S and P,

[1603] The compound of formula (Ia) inhibits the binding of interleukin-23 to interleukin-23 receptor.

[1604] Item 193: A compound as described in Item 191 or 192, wherein the -NH2 side chain group of X10 or X15 is functionalized by -C(O)-R5.

[1605] Item 194: A compound as described in Item 193, wherein -C(O)-R5 is selected from the group consisting of: (S)-4-carboxy-4-hexadecanoylamino-butyryl-, (S)-4-carboxy-4-octadecanoylamino-butyryl-, 4-hexadecanoylamino-butyryl-, 4-{3-[(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino}-butyryl-, 4-octadecanoylamino-butyryl-, 4-((Z)-octadec-9-enoylamino)-butyryl-, 6-[(4,4-diphenyl-cyclohexyloxy)-hydroxy-phosphoryloxy]-hexanoyl-, hexadecanoyl- , (S)-4-carboxy-4-(15-carboxy-pentadecanoylamino)-butyryl-, (S)-4-carboxy-4-{3-[3-((2S,3R,4S,5R)-5-carboxy-2,3,4,5-tetrahydroxy-pentanoylamino)-propionylamino]-propionylamino}-butyryl-, (S)-4-carboxy-4-{3-[(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino}-butyryl-, (S)-4-carboxy-4-((9Z,12Z)-octadecane-9,12-dienoylamino)-butyryl-, (S)-4-carboxy-4-[6-((2S (S)-4-carboxy-4-((2S,3R,4S,5R)-5-carboxy-2,3,4,5-tetrahydroxy-pentanoylamino)-hexanoylamino]-butyryl-, (S)-4-carboxy-4-tetradecanoylamino-butyryl-, (S)-4-(11-benzyloxycarbonyl-undecanoylamino)-4-carboxy-butyryl-, (S)-4-carboxy-4-[11-((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxy-hexylcarbamoyl)-undecanoylamino]-butyryl-, (S)-4-carboxy-4-((Z)-octadec-9-enoylamino)-butyryl- (S)-4-carboxy-4-(4-p-dodecyloxy-benzoylamino)-butyryl-, (S)-4-carboxy-4-eicosylamino-butyryl-, (S)-4-carboxy-4-behenoylamino-butyryl-, (S)-4-carboxy-4-((Z)-19-10-enoylamino)-butyryl-, (S)-4-carboxy-4-(4-decyloxy-benzoylamino)-butyryl-, (S)-4-carboxy-4-[(4'-octyloxy-diphenyl-4-carbonyl)-amino]-butyryl-, (S)-4-carboxy-4-(12-phenyl-dodecylamino)-butyryl-, (S)-4-carboxy-4-eicosylamino-butyryl-,(S)-4-carboxy-4-((S)-4-carboxy-4-hexadecanoylamino-butyrylamino)-butyryl-, (S)-4-carboxy-4-((S)-4-carboxy-4-octadecanoylamino-butyrylamino)-butyryl-, 3-(3-octadecanoylamino-propionylamino)-propionyl-, 3-(3-hexadecanoylamino-propionylamino)-propionyl-, 3-hexadecanoylamino-propionyl-, (S)-4-carboxy-4-[(R)-4-((3R,5S,7R,8R,9R,10S,12S,13R,14R,17R)-3,7,12-trihydroxy-8,10,13-trimethyl-hexahydro-cyclopentyl] 17-phenanthren-17-yl)-pentanoylamino]-butyryl-, (S)-4-carboxy-4-[(R)-4-((3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-hexahydro-cyclopenta[a]phenanthren-17-yl)-pentanoylamino]-butyryl-, (S)-4-carboxy-4-((9S,10R)-9,10,16-trihydroxy-hexadecanoylamino)-butyryl-, tetradecanoyl-, 11-carboxy-undecanoyl-, 11-benzyloxycarbonyl-undecanoyl-, (S)-4-carboxy-4-((S)-4-carboxy-4-tetradecanoylamino- butyrylamino)-butyryl-, 6-[hydroxy-(naphthalen-2-yloxy)-phosphoryloxy]-hexanoyl-, 6-[hydroxy-(5-phenyl-pentyloxy)-phosphoryloxy]-hexanoyl-, 4-(naphthalene-2-sulfonylamino)-4-oxo-butyryl-, 4-(diphenyl-4-sulfonylamino)-4-oxo-butyryl-, (S)-4-carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyryl amino}-butyryl-, (S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyryl-, (S)-4-carboxy-2-{(S)-4-carboxy-2-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-,(S)-4-carboxy-2-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyryl-, (S)-4-carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-, (S)-4-carboxy-4-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl- -(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-butyryl-, (S)-4-carboxy-2-{(S)-4-carboxy-2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-, (S)-4-carboxy-2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-butyryl-, 2-(2-{2-[2-( 2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl-, 2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetyl, (S)-4-carboxy-4-((S)-4-carboxy-4-{(S)-4-carboxy-4-[(S)-4-carboxy-4-(19-carboxy-nonadecanoylamino)-butyrylamino]-butyrylamino}-butyrylamino)-butyryl, 2-(2-{2-[2-(2- {2-[(S)-4-carboxy-4-(16-1H-tetrazol-5-yl-hexadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl-, 2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(16-carboxy-hexadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl-, (S)-4-carboxy-4-{(S)-4-carboxy-4-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-butyrylamino}-butyryl-,(S)-4-carboxy-4-((S)-4-carboxy-4-{2-[2-(2-{2-[2-(2-{(S)-4-carboxy-4-[10-(4-carboxy-phenoxy)-decanoylamino]-butyrylamino}-ethoxy)-ethoxy]-acetylamino}-ethoxy)-ethoxy]-acetylamino}-butyryl-, (S)-4-carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-[7-carboxy-phenoxy)-decanoylamino]-butyrylamino}-ethoxy)-ethoxy]-acetylamino}-ethoxy)-acetylamino}-butyryl- butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-, (S)-4-carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(11-carboxy-undecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-, ( (S)-4-carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(13-carboxy-tridecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-, (S)-4-carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(15-carboxy-tridecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl- butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl- and (S)-4-carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(19-carboxy-nonadecaylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-. ,

[1606] Item 195. A compound as described in Items 1 to 194, which has a binding affinity for interleukin 23 receptor of 100 nM or less (ie, IC50≤100 nM).

[1607] Item 196. A compound as described in Items 1 to 194, which has a binding affinity for interleukin 23 receptor of 50 nM or less (ie, IC50≤50 nM).

[1608] Item 197. A compound as described in Items 1 to 194, which has a binding affinity for interleukin 23 receptor of 10 nM or less (ie, IC50≤10 nM).

[1609] Item 198. A compound as described in Items 1 to 194, which has a binding affinity for interleukin 23 receptor of 5 nM or less (ie, IC50≤5 nM).

[1610] Item 199. A compound as described in Items 1 to 194, which has chemical stability within 24 hours at 37°C in a solution with a relative purity loss of less than 30% at pH 1.2.

[1611] Item 200. A compound as described in Items 1 to 194, which has chemical stability within 24 hours at 37°C in a solution with a relative purity loss of less than 25% at pH 1.2.

[1612] Item 201. A compound as described in Items 1 to 194, which has chemical stability within 24 hours at 37°C in a solution with a relative purity loss of less than 5% at pH 6.5.

[1613] Item 202. A compound as described in Items 1 to 194, which has chemical stability within 24 hours at 37°C in a solution with a relative purity loss of less than 2% at pH 6.5.

[1614] Item 203. A compound as described in Items 1 to 194, which has chemical stability within 24 hours at 37°C in a solution with a relative purity loss of less than 5% at pH 7.4.

[1615] Item 204. A compound as described in Items 1 to 194, which has chemical stability within 24 hours at 37°C in a solution with a relative purity loss of less than 3% at pH 7.4.

Claims

1. A compound having formula (I): in -X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Pipa, Pipb, Pipp, Dab, Dad and Dap, and is linked to X11 via an amide bond, or is a residue selected from the group consisting of Buty and Butyl residues and is linked to X11 via an alkyl bond, and when X1 is a residue selected from the group consisting of Butyl residues, the residue selected from the group consisting of Butyl residues is linked to X2 via an alkyl bond, -R1 does not exist, or If X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Lys, Dab and Dap, then R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1, -X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu and their corresponding d-form residues, -X7 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Thr and Abu and their corresponding d-form residues, wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond, -X3 is an amino acid residue selected from the group consisting of Sar, His, Lys, Ala, Ahx, Apt, Arg, Asn, Gab, Gln, Trp, Thr, Ndmk, Nmn, Ntmk and Lys(αAc), - X4 is absent or is an amino acid residue selected from the group consisting of His, Lys, Ahx, Apt, Arg, Asn, Gab, Gln, Trp and Thr residues, -X5 is an amino acid residue selected from the group consisting of Trp, Wme, Nak, Wcl, Wim, Wdm and Wfl, -X6 is an amino acid residue selected from the group consisting of a residue of Gln, Aib, Glu, Phe, Ile, Iva, Lys, Lys(Ac), Leu, Mle, Mly, Mva, Thr, Val, Trp and Phe, -X8 is an amino acid residue selected from the group consisting of a residue of Yme, Tyr, Trp and Yde, -X9 is an amino acid residue selected from the group consisting of a residue of Nal, Nak and Trp, -X10 is an amino acid residue selected from the group consisting of Aib, Cba, Cit, d-Trp, d-Tza, Lys, Lys(Ac), Leu, Mle, Mly, Gln, Mkdm and Thp, -X11 is an amino acid residue selected from the group consisting of Asp, Bal, Gab, Glu, Kme, Lys and Orn residues, and is linked to X1 via an amide bond, -X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues, -X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, Leu, Ile, Iva, Hol, Hph, Pal, Pyal, PyEA, His, Hme and Val and their corresponding d-form residues, - X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile, Dnmy and Hme residues, - X15 is absent or is an amino acid residue selected from the group consisting of a Lys residue, -R2 does not exist or is -NH2, -OH or -N(C2H5)2, and wherein the amide bonds between X1 and X2, X2 and X3, X3 and X4, X4 and X5, and X11 and X1 are optionally methylated, or a salt or solvate thereof, and The compound of formula (I) inhibits the binding of interleukin-23 to interleukin-23 receptor.

2. The compound of claim 1 having formula (I), wherein: -X1 is a residue selected from the group consisting of Ahx, Apt, Nmha, Nmapt, Lys and Dad, and is linked to X11 via an amide bond, or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond, -R1 does not exist, or If X1 is a residue selected from the group consisting of Ahx, Apt and Lys, then R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1, -X2 is an amino acid residue selected from the group consisting of a Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu residue, -X7 is an amino acid residue selected from the group consisting of a Cys, Glu, Asp, Thr and Abu residue, wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond, -X3 is an amino acid residue selected from the group consisting of Apt, Asn, Ndmk, Nmn and Lys(αAc), -X4 does not exist or is a Thr amino acid residue, -X5 is an amino acid residue selected from the group consisting of a residue of Trp, Wme and Wim, -X6 is an amino acid residue selected from the group consisting of a residue of Gln, Lys(Ac) and Leu, -X8 is an amino acid residue selected from the group consisting of a residue of Yme, Trp and Yde, -X9 is the amino acid residue of Nal, - X10 is an amino acid residue selected from the group consisting of Aib, Lys, Lys(Ac), Mle, Mly, Mkdm and Thp, -X11 is an amino acid residue selected from the group consisting of Asp, Glu, Kme, Lys and Orn residues, and is linked to X1 via an amide bond, -X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues, -X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, d-Leu, Ile, Pal, Pyal, PyEA, His and Hme residues, - X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile and Hme residues, -X15 is absent or is a Lys amino acid residue, -R2 is absent or is -NH2, -OH or -N(C2H5)2.

3. A compound having formula (I): in -X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Pipa, Pipb, Pipp, Dab, Dad and Dap, and is linked to X11 via an amide bond, or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond, -R1 does not exist, or If X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Lys, Dab and Dap, then R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1, -X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr and their corresponding d-form residues, -X7 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Thr and Abu and their corresponding d-form residues, wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond, -X3 is an amino acid residue selected from the group consisting of Sar, His, Lys, Ala, Ahx, Apt, Arg, Asn, Gab, Gln, Trp, Thr, Ndmk, Nmn, Ntmk and Lys(αAc), - X4 is absent or is an amino acid residue selected from the group consisting of His, Lys, Ahx, Apt, Arg, Asn, Gab, Gln, Trp and Thr residues, -X5 is an amino acid residue selected from the group consisting of Trp, Wme, Nak, Wcl, Wim, Wdm and Wfl, -X6 is an amino acid residue selected from the group consisting of a residue of Gln, Aib, Glu, Phe, Ile, Iva, Lys, Lys(Ac), Leu, Mle, Mly, Mva, Thr, Val, Trp and Phe, -X8 is an amino acid residue selected from the group consisting of a residue of Yme, Tyr, Trp, Yde and Yae, -X9 is an amino acid residue selected from the group consisting of a residue of Nal, Nak and Trp, -X10 is an amino acid residue selected from the group consisting of Aib, Cba, Cit, d-Trp, d-Tza, Lys, Lys(Ac), Leu, Mle, Mly, Gln, Mkdm and Thp, -X11 is an amino acid residue selected from the group consisting of Asp, Bal, Gab, Glu, Kme, Lys and Orn residues, and is linked to X1 via an amide bond, -X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues, -X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, Leu, Ile, Iva, Hol, Hph, Pal, Pyal, PyEA, His, Hme, Val and their corresponding d-form residues, - X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile, Dnmy and Hme residues, -X15 is absent or is a Lys amino acid residue, -R2 does not exist or is -NH2, -OH or -N(C2H5)2, and wherein the amide bonds between X1 and X2, X2 and X3, X3 and X4, X4 and X5, and X11 and X1 are optionally methylated, or a salt or solvate thereof, and The compound of formula (I) inhibits the binding of interleukin-23 to interleukin-23 receptor.

4. The compound of claim 3 having formula (I), wherein: -X1 is a residue selected from the group consisting of Ahx, Apt, Nmha, Nmapt, Lys and Dad, and is linked to X11 via an amide bond, or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond, -R1 does not exist, or If X1 is a residue selected from the group consisting of Ahx, Apt and Lys, then R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1, -X2 is an amino acid residue selected from the group consisting of a Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr residue, -X7 is an amino acid residue selected from the group consisting of a Cys, Glu, Asp, Thr and Abu residue, wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond, -X3 is an amino acid residue selected from the group consisting of Apt, Asn, Ndmk, Nmn and Lys(αAc), -X4 does not exist or is a Thr amino acid residue, -X5 is an amino acid residue selected from the group consisting of a residue of Trp, Wme and Wim, -X6 is an amino acid residue selected from the group consisting of a residue of Gln, Lys(Ac) and Leu, -X8 is an amino acid residue selected from the group consisting of a residue of Yme, Trp, Yde and Yae, -X9 is the amino acid residue of Nal, - X10 is an amino acid residue selected from the group consisting of Aib, Lys, Lys(Ac), Mle, Mly, Mkdm and Thp, -X11 is an amino acid residue selected from the group consisting of Asp, Glu, Kme, Lys and Orn residues, and is linked to X1 via an amide bond, -X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues, -X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, d-Leu, Ile, Pal, Pyal, PyEA, His and Hme residues, - X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile and Hme residues, -X15 does not exist or is a Lys amino acid residue, -R2 is absent or is -NH2, -OH or -N(C2H5)2.

5. A compound of formula (I) according to any one of claims 1 to 4, wherein: -X3 is an amino acid residue selected from the group consisting of Asn and Nmn residues, -X4 is an amino acid residue of Thr.

6. A compound of formula (I) according to any one of claims 1 to 4, wherein: -X3 is an amino acid residue selected from the group consisting of Ndmk and Lys(αAc), -X4 does not exist.

7. A compound of formula (I) according to claim 1 or 3, wherein: - X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Pipa, Pipb, Pipp, Dab and Dap, and X11 is an amino acid residue selected from the group consisting of Asp and Glu, or - X1 is a residue of Dad and X11 is an amino acid residue selected from the group consisting of residues of Lys and Kme, or -X1 is a residue selected from the group consisting of Buty and Butyl residues and X11 is an amino acid residue of Kme.

8. The compound of claim 1 having formula (I), wherein X2-Q-X7 is a group consisting of: -Cys-Q-Cys, Nmc-Q-Cys and Cys-Q-Nmc, wherein Q is a disulfide bond, or -Abu-Q-Cys, Cys-Q-Abu, wherein Q is a thioether bond, or -Thr-Q-Asp, Thr-Q-Glu, Glu-Q-Thr, wherein Q is an ester bond.

9. The compound of claim 3 having formula (I), wherein X2-Q-X7 is a group consisting of: -Cys-Q-Cys, Nmc-Q-Cys and Cys-Q-Nmc, wherein Q is a disulfide bond, or -Cys-Q-Abu, wherein Q is a thioether bond, or -Thr-Q-Asp, Thr-Q-Glu, Glu-Q-Thr, wherein Q is an ester bond.

10. A compound of formula (I) according to claim 1 or 3, wherein: -R1 is absent or is H, C1-C4-alkyl or acetyl and is linked to the amino function of X1, -X1 is the residue of Apt and is linked to X11 via an amide bond, -X2 is an amino acid residue of Cys, -X7 is an amino acid residue of Cys, wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, -X3 is an amino acid residue selected from the group consisting of Asn and Lys(αAc), -X4 does not exist or is a Thr amino acid residue, -X5 is the amino acid residue of Wim, -X6 is an amino acid residue of Lys(Ac), -X8 is the amino acid residue of Yde, -X9 is the amino acid residue of Nal, -X10 is an amino acid residue selected from the group consisting of the residues of Mkdm and Thp, -X11 is an amino acid residue of Glu and is linked to -X1 via an amide bond, -X12 is an amino acid residue of Asn, -X13 is the amino acid residue of Pal, -X14 is the amino acid residue of Sar, -X15 does not exist, -R2 is -NH2, and The compound of formula (I) inhibits the binding of interleukin-23 to interleukin-23 receptor.

11. A compound of formula (I) according to any one of claims 1, 2 and 6, wherein: -X1 is a residue selected from the group consisting of Ahx, Apt, Nmha, Nmapt, Lys and Dad, and is linked to -X11 via an amide bond, or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond, -R1 does not exist or If -X1 is a residue selected from the group consisting of Ahx, Apt and Lys, then R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of -X1, -X2 is an amino acid residue selected from the group consisting of a Cys, Nmc and Abu residue, -X7 is an amino acid residue selected from the group consisting of a Cys, Glu, Asp and Thr residue, wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond, -X3 is an amino acid residue of Lys(αAc), -X4 does not exist, -X5 is an amino acid residue selected from the group consisting of Trp and Wim residues, -X6 is an amino acid residue of Lys(Ac), -X8 is the amino acid residue of Yde, -X9 is the amino acid residue of Nal, -X10 is an amino acid residue selected from the group consisting of the residues of Mkdm and Thp, -X11 is an amino acid residue selected from the group consisting of Asp, Glu, Kme and Lys residues, and is linked to X1 via an amide bond, -X12 is an amino acid residue of Gly, -X13 is the amino acid residue of PyEA, -X14 does not exist, -X15 does not exist, -R2 does not exist.

12. The compound of formula (I) according to claim 1, wherein the compound is selected from the group consisting of SEQ ID NOs: 1-66, 68-70, 72-74, 76-82, 84-95, 98, 102-106, 108-158.

13. A compound having formula (Ia): in -X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Pipa, Pipb, Pipp, Dab, Dad and Dap, and is linked to X11 via an amide bond, or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond, -R1 does not exist, or If X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Lys, Dab and Dap, then R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1, -X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt, Thr and Abu and their corresponding d-form residues, -X7 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Thr and Abu and their corresponding d-form residues, wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond, -X3 is an amino acid residue selected from the group consisting of Sar, His, Lys, Ala, Ahx, Apt, Arg, Asn, Gab, Gln, Trp, Thr, Ndmk, Nmn, Ntmk and Lys(αAc), - X4 is absent or is an amino acid residue selected from the group consisting of His, Lys, Ahx, Apt, Arg, Asn, Gab, Gln, Trp and Thr residues, -X5 is an amino acid residue selected from the group consisting of Trp, Wme, Nak, Wcl, Wim, Wdm and Wfl, -X6 is an amino acid residue selected from the group consisting of a residue of Gln, Aib, Glu, Phe, Ile, Iva, Lys, Lys(Ac), Leu, Mle, Mly, Mva, Thr, Val, Trp and Phe, -X8 is an amino acid residue selected from the group consisting of a residue of Yme, Tyr, Trp and Yde, -X9 is an amino acid residue selected from the group consisting of a residue of Nal, Nak and Trp, -X10 is an amino acid residue selected from the group consisting of Aib, Cba, Cit, d-Trp, d-Tza, Lys, Lys(Ac), Leu, Mle, Mly, Gln, Mkdm and Thp, -X11 is an amino acid residue selected from the group consisting of Asp, Bal, Gab, Glu, Kme, Lys and Orn residues and is linked to X1 via an amide bond, -X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues, -X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, Leu, Ile, Iva, Hol, Hph, Pal, Pyal, PyEA, His, Hme, Val and their corresponding d-form residues, - X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile, Dnmy and Hme residues, -X15 is absent or is a Lys amino acid residue, -R2 does not exist or is -NH2, -OH or -N(C2H5)2, and wherein the amide bonds between X1 and X2, X2 and X3, X3 and X4, X4 and X5, and X11 and X1 are optionally methylated, and wherein at least one of X10 and X15 is an amino acid residue having a -NH2 group in the side chain, wherein the -NH2 side chain group is functionalized by -C(O)-R5, -C(O)O-R5, -C(O)NH-R5, -S(O)2-R5 or R5, wherein R5 can be a moiety comprising up to 50 or up to 100 carbon atoms and heteroatoms optionally selected from halogen, N, O, S and P, or a salt or solvate thereof, The compound of formula (Ia) inhibits the binding of interleukin-23 to interleukin-23 receptor.

14. A compound having formula (Ia): in -X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Nmha, Nmapt, Lys, Pipa, Pipb, Pipp, Dab, Dad and Dap, and is linked to X11 via an amide bond, or is a residue selected from the group consisting of Buty and Butyl residues, and is linked to X11 via an alkyl bond, and when X1 is a Butyl residue, the Butyl residue is linked to X2 via an alkyl bond, -R1 does not exist, or If X1 is a residue selected from the group consisting of Ahx, Aoa, Apt, Lys, Dab and Dap, then R1 is H, C1-C4-alkyl or acetyl and is attached to the amino function of X1, -X2 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Nmc, Nmd, Nme, Nmt and Thr and their corresponding d-form residues, -X7 is an amino acid residue selected from the group consisting of Cys, Glu, Asp, Thr and Abu and their corresponding d-form residues, wherein X2 and X7 are linked to each other via Q, wherein Q is a disulfide bond, a thioether bond or an ester bond, -X3 is an amino acid residue selected from the group consisting of Sar, His, Lys, Ala, Ahx, Apt, Arg, Asn, Gab, Gln, Trp, Thr, Ndmk, Nmn, Ntmk and Lys(αAc), - X4 is absent or is an amino acid residue selected from the group consisting of His, Lys, Ahx, Apt, Arg, Asn, Gab, Gln, Trp and Thr residues, -X5 is an amino acid residue selected from the group consisting of Trp, Wme, Nak, Wcl, Wim, Wdm and Wfl, -X6 is an amino acid residue selected from the group consisting of a residue of Gln, Aib, Glu, Phe, Ile, Iva, Lys, Lys(Ac), Leu, Mle, Mly, Mva, Thr, Val, Trp and Phe, -X8 is an amino acid residue selected from the group consisting of a residue of Yme, Tyr, Trp, Yde and Yae, -X9 is an amino acid residue selected from the group consisting of a residue of Nal, Nak and Trp, -X10 is an amino acid residue selected from the group consisting of Aib, Cba, Cit, d-Trp, d-Tza, Lys, Lys(Ac), Leu, Mle, Mly, Gln, Mkdm and Thp, -X11 is an amino acid residue selected from the group consisting of Asp, Bal, Gab, Glu, Kme, Lys and Orn residues and is linked to -X1 via an amide bond, -X12 is absent or is an amino acid residue selected from the group consisting of Asn, Gly, Ser and Ala residues, -X13 is absent or is an amino acid residue selected from the group consisting of Asn, Ala, Bal, Gly, Leu, Ile, Iva, Hol, Hph, Pal, Pyal, PyEA, His, Hme, Val and their corresponding d-form residues, - X14 is absent or is an amino acid residue selected from the group consisting of Mep, Sar, Bal, Ile, Dnmy and Hme residues, -X15 is absent or is a Lys amino acid residue, -R2 does not exist or is -NH2, -OH or -N(C2H5)2, and wherein the amide bonds between X1 and X2, X2 and X3, X3 and X4, X4 and X5, and X11 and X1 are optionally methylated, and wherein at least one of X10 and X15 is an amino acid residue having a -NH2 group in the side chain, wherein the -NH2 side chain group is functionalized by -C(O)-R5, -C(O)O-R5, -C(O)NH-R5, -S(O)2-R5 or R5, wherein R5 can be a moiety comprising up to 50 or up to 100 carbon atoms and heteroatoms optionally selected from halogen, N, O, S and P, or a salt or solvate thereof, The compound of formula (Ia) inhibits the binding of interleukin-23 to interleukin-23 receptor.

15. A compound of formula (Ia) according to claim 13 or 14, wherein: -X10 is a residue selected from the group consisting of Lys and Mly residues, wherein the -NH2 side chain group is functionalized by -C(O)-R5, and -X15 is absent, or -X15 is Lys, wherein the -NH2 side chain group is functionalized by -C(O)-R5, and -C(O)-R5 is selected from the group consisting of: (S)-4-carboxy-4-hexadecanoylamino-butyryl -, (S)-4-carboxy-4-octadecanoylamino-butyryl-, 4-hexadecanoylamino-butyryl-, 4-{3-[(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino}-butyryl-, 4-octadecanoylamino-butyryl-, 4-((Z)-octadec-9-enoylamino)-butyryl-, 6-[(4,4-diphenyl-cyclohexyloxy)-hydroxy-phosphoryloxy]-hexanoyl-, hexadecanoyl-, (S)-4-carboxy-4-(15-carboxy-pentadecanoylamino)-butyryl-, (S)-4-carboxy -4-{3-[3-((2S,3R,4S,5R)-5-carboxy-2,3,4,5-tetrahydroxy-pentanoylamino)-propionylamino]-propionylamino}-butyryl-, (S)-4-carboxy-4-{3-[(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino}-butyryl-, (S)-4-carboxy -4-((9Z,12Z)-octadecadienylamino)-butyryl-, (S)-4-carboxy -4-[6-((2S,3R,4S,5R)-5-carboxy-2,3,4,5-tetrahydroxy-pentanoylamino)-hexanoylamino]-butyryl -, (S)-4-carboxy-4-((2S,3R,4S,5R)-5-carboxy-2,3,4,5-tetrahydroxy-pentanoylamino)-butyryl-, (S)-4-carboxy-4-tetradecanoylamino-butyryl-, (S)-4-(11-benzyloxycarbonyl-undecanoylamino)-4-carboxy-butyryl-, (S)-4-carboxy-4-[11-((2S,3R,4R,5R)-2,3,4,5-tetrahydroxy-pentanoylamino)-butyryl- 5,6-pentahydroxy-hexylcarbamoyl)-undecanoylamino]-butyryl-, (S)-4-carboxy-4-((Z)-octadec-9-enoylamino)-butyryl-, (S)-4-carboxy-4-(4-p-dodecyloxy-benzoylamino)-butyryl-, (S)-4-carboxy-4-eicosanoylamino-butyryl-, (S)-4-carboxy-4-behenoylamino-butyryl-, (S)-4-carboxy -4-((Z)-19-10-enoylamino)-butyryl-, (S)-4-carboxy-4-(4-decyloxy-benzoylamino)-butyryl-, (S)-4-carboxy-4-[(4'-octyloxy-diphenyl-4-carbonyl)-amino]-butyryl-, (S)-4-carboxy-4-(12-phenyl-dodecanoylamino)-butyryl-, (S)-4-carboxy-4-eicosanoylamino-butyryl -, (S)-4-carboxy-4-((S)-4-carboxy-4-hexadecanoylamino-butyrylamino)-butyryl-, (S)-4-carboxy-4-((S)-4-carboxy-4-octadecanoylamino-butyrylamino)-butyryl-, 3-(3-octadecanoylamino-propionylamino)-propionyl-, 3-(3-hexadecanoylamino-propionylamino)-propionyl-, 3-hexadecanoylamino-propionyl-, (S)-4-carboxy -4-[(R)-4-((3R,5S,7R,8R,9R,10S,12S,13R,14R,17R)-3,7,12-trihydroxy-8,10,13-trimethyl-hexahydro-cyclopenta[a]phenanthrene-17-yl)-pentanoylamino]-butyryl-, (S)-4-carboxy -4-[(R)-4-((3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-hexahydro-cyclopenta[a]phenanthrene-17-yl)-pentanoylamino]-butyryl-, (S)-4-carboxy-4-((9S,10R)-9,10,16-trihydroxy-hexadecanoylamino)-butyryl-, tetradecanoyl-, 11-carboxy-undecanoyl-, 11-benzyloxycarbonyl-undecanoyl-, ( S)-4-carboxy-4-((S)-4-carboxy-4-tetradecanoylamino-butyrylamino)-butyryl-, 6-[hydroxy-(naphthalen-2-yloxy)-phosphoryloxy]-hexanoyl-, 6-[hydroxy-(5-phenyl-pentyloxy)-phosphoryloxy]-hexanoyl-, 4-(naphthalene-2-sulfonylamino)-4-oxo-butyryl-, 4-(diphenyl-4-sulfonylamino)-4-oxo-butyryl-, (S)-4-carboxy-4-{(S)-4-carboxy -4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-, (S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyryl-, (S)-4-carboxy-2-{(S)-4-carboxy -2-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-, (S)-4-carboxy-2-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyryl-, (S)-4-carboxy-4-{(S)-4-carboxy -4-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-, (S)-4-carboxy-4-[2-(2-{2-[(S)-4-carboxy -4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-butyryl-, (S)-4-carboxy-2-{(S)-4-carboxy-2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-, (S)-4-carboxy-2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy} -ethoxy)-acetylamino]-butyryl-, 2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl-, 2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetyl, (S)-4-carboxy-4-((S)-4-carboxy-4-{(S)-4-carboxy-4-[(S)-4-carboxy -4-(19-carboxy-nonadecaylamino)-butyrylamino]-butyrylamino}-butyrylamino)-butyryl, 2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(16-1H-tetrazol-5-yl-hexadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl-, 2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(16-carboxy-hexadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl -, (S)-4-carboxy-4-{(S)-4-carboxy-4-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-butyrylamino}-butyryl-, (S)-4-carboxy-4-((S)-4-carboxy-4-{2-[2-(2-{2-[2-(2-{(S)-4-carboxy-4-[10-(4-carboxy-phenoxy)-decanoylamino]-butyrylamino}-ethoxy)-ethoxy]-acetylamino}-ethoxy)-ethoxy]-acetylamino}-butyryl-, (S)-4-carboxy-4-{(S)-4-carboxy -4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(7-carboxy-heptanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-, (S)-4-carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(11-carboxy-undecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-, (S)-4-carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(11-carboxy-undecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-, -4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(13-carboxy-tridecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-, (S)-4-carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(15-carboxy-pentadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl- and (S)-4-carboxy-4-{(S)-4-carboxy -4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(19-carboxy-nonadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-.

16. A compound of formula (Ia) according to claim 13 or 15, wherein -C(O)-R5 is selected from tetradecanoyl, hexadecanoyl and 2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl-.

17. The compound according to any one of claims 1 to 17, wherein the compound is represented by SEQ ID NO: 1 to 158.

18. The compound according to claim 13 or 15, wherein the compound is represented by SEQ ID NO: 67, 71, 75, 83, 96, 97, 99, 100, 101 and 108.

19. The compound according to claim 1 or 3, wherein the compound is represented by SEQ ID NO: 35, 66, 113, 128, 144, 146, 147, 147, 148 and 149.

20. A compound for use according to any one of claims 1 to 20 for the treatment of an autoimmune disease or an inflammatory disease.

21. The compound for use according to claim 21, wherein the autoimmune or inflammatory disease is selected from inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, psoriasis, psoriatic arthritis and hidradenitis suppurativa.

22. A compound for use according to any one of claims 1 to 20, as an active agent, in a pharmaceutical composition together with at least one pharmaceutically acceptable carrier.

23. A pharmaceutical composition for use as a medicament, comprising at least one compound according to any one of claims 1 to 20, or a physiologically acceptable salt or solvate thereof, and at least a pharmaceutically acceptable carrier.

Images